EVALUATION OF UHRF1 AND THE ANTIOXIDANT RESPONSE PATHWAY IN PANCREATIC CANCER AND THE PREDICTION OF RESPONSE TO TREATMENT by Gana, T
 
 
 
 
Institute of Translational Medicine 
Department of Molecular and Clinical Cancer Medicine 
 
 
EVALUATION OF UHRF1 AND THE 
ANTIOXIDANT RESPONSE PATHWAY IN 
PANCREATIC CANCER AND THE 
PREDICTION OF RESPONSE TO 
TREATMENT  
 
 
Thesis submitted in accordance with the requirements of the University of Liverpool for the 
degree of Doctor in Philosophy by 
 
 
Thompson GANA 
 
October 2017 
 
Supervisors: Prof. Eithne Costello, Dr William Greenhalf and       
Dr Lakis Liloglou 
 
 
DECLARATION 
I certify that this is an original piece of work undertaken at the University of Liverpool. 
Except where stated otherwise, all work included in this thesis was undertaken by 
myself. This work has not been submitted or used at any other University. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my parents and siblings 
and 
To the company of my unseen and very special friends that have kept me hale and hearty 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, 
characterised by very poor survival. The cellular defence protein Nrf2 is a mediator 
of oncogenesis in pancreatic cancer, although its role in this cancer type is not fully 
understood. UHRF1 is a nuclear protein involved in epigenetic regulation. Our 
laboratory recently established that UHRF1 suppresses Keap1, an important negative 
regulator of the Nrf2 pathway.  
The aim of this study was to explore how UHRF1 contributes to Nrf2 function in 
pancreatic cancer cells and in pancreatic stellate cells, and to determine whether 
UHRF1 or NQO1, a downstream marker of Nrf2 activity could be predictive of PDAC 
treatment response. Depletion of UHRF1 from PDAC cells was associated with 
transcriptional upregulation of KEAP1, decreased levels of Nrf2 and Nrf2-regulated 
downstream proteins (NQO1 and AKR1C1), increased oxidative stress in the form of 
lower glutathione levels and increased reactive oxygen species. UHRF1 depletion 
enhanced cell cycle arrest, and concomitant depletion of UHRF1 and Keap1 reversed 
this effect, restored Nrf2 levels and reversed the increase in reactive oxygen species.  
The expression of UHRF1 in human pancreatic stellate cells (hPSCs) was limited to a 
small subset of cells. Analysis in Nrf2-null mouse pancreatic stellate cells was 
precluded by the fact that these cells, unlike their wild-type counterparts could not 
be maintained in culture. Histological analysis of the pancreata of Nrf2-null mice 
revealed early signs of pancreatitis.  
 
 
Germline single nucleotide polymorphisms (SNPs) were analysed in patients with 
advanced PDAC (n=140) from TeloVac and ViP clinical trials. The NQO1 rs1800566 CC 
homozygous major genotype was associated with poor survival (p=0.01) and the 
combined NQO1 rs1800566 and SRXN1 rs6053666 SNPs were prognostic of survival 
in these patients (p=0.039). No SNP–related differences in survival for NRF2 
rs2886162 and SRXN1 rs6053666 variants were observed (p=0.405 and p=0.634 
respectively). 
To determine whether UHRF1 or NQO1 expression are predictive of PDAC patient 
response to treatment, tissue microarrays from 349 patients randomized to 
chemotherapy in the ESPAC-3 trial (plus controls from ESPAC-1) were analysed by 
immunohistochemistry for these proteins. Patients were dichotomized into low and 
high expression for nuclear UHRF1 and cytoplasmic NQO1 levels respectively and 
groups compared using Kaplan-Meier curves, log-rank tests, and Cox proportional 
hazards models.  
UHRF1 was expressed in 181 of 199 (90.9%) PDAC tumours. Its levels were not 
associated with survival in the observation only group, or in either 5FU/folinic acid or 
gemcitabine treated groups (p=0.882, p=0.34 and p=0.92 respectively). Interestingly, 
an inverse relationship between UHRF1 and diabetes was apparent (p=0.005).  
NQO1 was expressed in the cytoplasm of 197 (95.2%) PDAC tumours. NQO1 levels 
were not associated with survival for the patents in the observation only group 
(p=0.301). However, median survival for patients treated with gemcitabine was 13.7 
(95% CI 10.2 to 16.8) months for those with low NQO1 expression versus 24.2 (95% 
 
 
CI 16.3 to 29.5) months for those with high NQO1 expression (p=0.01). For the 
5FU/folinic acid group, median survival was 13.4 (95% CI 10.9 to 19.6) and 21.8 (95 % 
CI 16.9 to 25.7) months for those with low and high NQO1 levels respectively 
(p=0.08). Multivariable Cox proportional hazard analysis in gemcitabine treated 
patients, revealed that NQO1 expression was not an independent predictive factor in 
gemcitabine-treated (p=0.19) patients.  
In summary, UHRF1 regulates Nrf2 in PDAC. UHRF1 levels are not prognostic, nor are 
they predictive of response to treatment in this disease. Interestingly, UHRF1 levels 
are inversely associated with diabetes, a finding that merits further study. By 
contrast, the NQO1 SNP rs1800566 is prognostic in advanced PDAC patients and 
NQO1 protein expression is not an independent predictive marker of response to 
adjuvant gemcitabine treatment in PDAC patients.  
 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGEMENTS 
Looking back in time through this mentally inspiring and physically challenging 
academic journey, I find myself indebted to all of those with whom I have had the 
pleasure of working with during these years. 
Foremost, I would like to express my heartfelt gratitude to my supervisor, Professor 
Eithne Costello for her guidance, motivation and patience; she inspired me to think 
and work independently from which I have gained a wealth of experience. I would 
like to also thank other members of my supervisory team, Dr William Greenhalf and 
Dr Lakis Liloglou for their constructive criticism and insightful comments. My sincere 
thanks also goes to Professor Fiona Campbell with whom I spent many hours over 
several days scoring the tissue microarray immunohistochemistry slides. 
Special thanks to Dr Anthony Evans for introducing me to several statistical softwares 
and together with Dr Karen Aughton both proof read my thesis draft; I cannot thank 
you both well enough for all your support. Other research staffs have been wonderful 
and deserve special mention too: Dr Lawrence B. Barrera, Dr Claire Jenkinson, Dr 
Wafa Abu-Alainin, Dr Adedamola O. Olayanju, Dr Paul Sykes, Dr Li Yan, Dr Taha 
Elmitwalli, Dr Lucy Oldfield, Dr Elinor Chapman, Dr Asmaa Salman, Dr Peppy Emeagi, 
Dr Victoria Shaw, Mr Tom Hanna; you have introduced me to new research skills and 
I owe my gratitude to you all.   
I also want to acknowledge the friendship of fellow research colleagues: Mr Kulbir 
Mann, Mr Rohith R. Gopala, Ms Andrea Sheel, Mr Eyas Mohammed, Dylan Williams, 
Ms Frances Oldfield, Mr Summit Nandi, the companionship in short and long time 
 
 
was worthwhile. I am also grateful to Dr Elizabeth Garner, Katie Bullock, Leigh 
Shannon, Natalie Coplin, Patricia Gerard, Timothy Dickson and Dr John Stanbury for 
their technical and logistic support. 
I would also like to thank CRUK Liverpool Cancer Trials Unit for permission to use and 
include clinical trial data in this thesis. I am grateful to Institute of Translational 
Medicine (ITM), University of Liverpool and Hospitals Management Board, Niger 
State, Government of Nigeria for funding my research. I am also indebted to ITM 
postgraduate research team for giving me a memorable student experience here at 
the University of Liverpool.  
Finally, I would like to thank my parents Mr and Mrs E.K. Gana and my siblings Henry, 
Patience, Moses and Solomon for their loving support while I have been away from 
them for many years. Last but not the least, I am grateful to my Uncle and his family 
Dr and Dr (Mrs) H.B. Gana for accommodating and supporting me during my 
programme here and to Dr and Mrs P. Gana and Dr and Mrs S. Yisa for their kind 
gestures during my stay in the UK. 
 
 
  
 
 
 
 
 
PUBLICATIONS AND POSTERS: 
Findings of the first result chapter (chapter 3) have been published in a peer 
reviewed journal: 
Abu-Alainin, W., Gana, T., Liloglou, T., Olayanju, A., Barrera, L. N., Ferguson, R., 
Campbell, F., Andrews, T., Goldring, C., Kitteringham, N., Park, B. K., Nedjadi, T., 
Schmid, M. C., Slupsky, J. R., Greenhalf, W., Neoptolemos, J. P. and Costello, E. (2016), 
UHRF1 regulation of the Keap1–Nrf2 pathway in pancreatic cancer contributes to 
oncogenesis. J. Pathol., 238: 423–433. doi: 10.1002/path.4665 
 
 
The findings of the first result chapter (chapter 3) have been presented at the 
following research meeting: 
Oral Presentation 
UHRF1 regulates the Keap1-Nrf2 cellular defence pathway in pancreatic cancer, 
European Pancreatic Club Conference, Toledo, Spain, 23 -26 June 2015. 
 
 
 
The findings of the third result chapter (chapter 5) have been presented at the 
following research meeting: 
Poster Presentation 
Correlation of protein abundance and Single Nucleotide Polymorphism of NRF2, 
NQO1 and SRXN1 with patient survival in pancreatic cancer, Annual University of 
Liverpool Postgraduate Poster day, University of Liverpool, United Kingdom, June 
2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIST OF ABBREVIATIONS 
5FU   5-fluorouracil  
AKR   Aldo-keto reductases     
APSCs   Activated pancreatic stellate cells 
ARE   Antioxidant response elements 
BCA   Bicinchoninic acid 
BIO   Biotinylated 
BSA   Bovine serum albumin 
CAF   Cancer associated fibroblast 
CDKN2A  Cyclin dependent kinase inhibitor 2A 
CI    Confidence interval 
CKIs   Cyclin dependent kinase inhibitors 
CpG   Cytosine-phosphate guanine 
DAB   Diamidino-2-phenylindole 
dFdC    2’, 2’ –difluorodeoxycytidine (Gemcitabine) 
dFdCDP  Gemcitabine diphosphate  
dFdCTP  Gemcitabine  triphosphate  
DMSO   Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
DNMT1  DNA methyl transferase 1 
DTT   Dithiothreitol 
ECL   Enhanced chemiluminescence 
ECM   Extra cellular matrix 
EDTA   Ethylene diamine tetraacetic acid 
EGFR   Epidermal growth factor receptor 
EMT   Epithelial to mesenchymal transition  
ESPAC   European Study Group for Pancreatic Cancer 
 
 
FACS   Fluorescence-activated cell sorting 
FBS   Fetal bovine serum 
FAP  Fibroblast activation protein 
FSP-1   Fibroblast specific protein-1  
FAF   Fibrosis associated fibroblasts  
FOLFIRINOX   Folinic acid, 5-FU, Irinotecan and Oxaliplatin 
GCLc   Glutamate cysteine ligase catalytic subunit  
GCLm   Glutamate cysteine ligase modulatory subunit  
GS   Gluthathione synthetase  
GSH   Reduced glutathione 
GSR   Glutathione reductase  
GSSG   Oxidized glutathione  
HDAC   Histone deacetylase 
HSCs   Hepatic stellate cells  
HR   Hazard ratio 
HRP   Horseradish peroxidase  
ICBP 90  Inverted CCAAT box binding protein of 90 kDa 
ICC   Immunocytochemistry 
IHC   Immunohistochemistry 
IPMN   Intraductal papillary mucinous neoplasm 
JASPAC-1   Japan Adjuvant Study Group of Pancreatic Cancer 1 
KM   Kaplan-Meier  
Keap1   Kelch-like ECH-associated protein  
KRAS   Kirsten rat sarcoma viral oncogene homolog 
Maf   Masculoaponeurotic fibrosarcoma 
MCN   Mucinous cyst neoplasm 
NAF   Normal activated fibroblast 
NQO1   NAD(P)H:quinone oxidoreductase 1  
 
 
Nrf2    Nuclear factor erythroid 2-related factor 2  
PAGE   Polyacrylamide gel electrophoresis 
PanIN   Pancreatic intraepithelial neoplasia 
PBS   Phosphate buffered saline 
PC   Pancreatic cancer 
PCR   Polymerase chain reaction 
PCSs   Pancreatic stellate cells 
PDAC   Pancreatic ductal adenocarcinoma 
PHD   Plant homeo domain 
PI   Propidium iodide 
qPSCs   Quiescent pancreatic stellate cells 
RING   Really interesting new gene 
RNA   Ribonucleic acid 
RNS   Reactive nitrogen species 
ROS   Reactive oxygen species  
RT   Reverse transcriptase 
SDS   Sodium dodecyl sulphate 
siRNA   Small interfering RNA 
SRA   Set and ring associated domain 
TeloVac  Telomerase vaccine 
TMA   Tissue microarray 
TTD   Tandem tudor domain 
USP7   Ubiquitin specific peptidase 7   
UBL   Ubiquitin-like domain 
UHRF1  Ubiquitin-like with PHD and RING finger domains 1 
VEGFR   Vascular endothelial factor receptor 
ViP   Vandetanib in Pancreatic cancer  
α-SMA  Alpha-smooth muscle actin  
 
 
TABLE OF CONTENTS 
 
1 GENERAL INTRODUCTION ........................................................................... 18 
1.1 Introduction ................................................................................................. 19 
1.2 Pancreatic cancer ........................................................................................ 20 
1.2.1 Epidemiological Trend .......................................................................... 20 
1.2.2 Treatment trials for pancreatic cancer ................................................ 21 
1.2.3 Pancreatic cancer biology .................................................................... 26 
1.2.4 Ubiquitin-like with PHD and RING finger domains (UHRF) .................. 33 
1.2.5 UHRF1 ................................................................................................... 34 
1.2.6 UHRF1 regulation ................................................................................. 36 
1.2.7 UHRF1 in cancers ................................................................................. 36 
1.2.8 Keap1-Nrf2 defence pathway .............................................................. 38 
1.3 Desmoplastic stroma in pancreatic cancer ................................................. 46 
1.3.1 Cancer Associated Fibroblast ............................................................... 48 
1.3.2 Origin of CAFs ....................................................................................... 49 
1.3.3 Pancreatic stellate cells ........................................................................ 49 
1.3.4 Prognostic value of stromal activity ..................................................... 54 
1.3.5 CAF polarization ................................................................................... 55 
1.3.6 Epigenetic regulation of fibroblast activation ...................................... 56 
1.4 Predictive biomarkers in pancreatic cancer ................................................ 57 
1.4.1 NADP(H):quinone oxidoreductase 1 .................................................... 57 
1.4.2 Single nucleotide polymorphisms ........................................................ 60 
1.4.3 Gemcitabine metabolizing enzymes .................................................... 62 
1.4.4 DNA synthesis and repair enzymes ...................................................... 63 
1.4.5 MicroRNAs ............................................................................................ 63 
1.5 Hypotheses .................................................................................................. 65 
1.6 Aims and objectives ..................................................................................... 65 
 
 
 
 
2 MATERIALS AND METHODS ....................................................................... 66 
2.1 Materials and Reagents ............................................................................... 67 
2.1.1 Sigma Aldrich ........................................................................................ 67 
2.1.2 Thermo Fisher Scientific ....................................................................... 68 
2.2 Cell line maintenance .................................................................................. 68 
2.2.1 Human pancreatic cancer cell lines ..................................................... 68 
2.2.2 Primary mouse pancreatic cancer cells................................................ 69 
2.2.3 Pancreatic cancer associated primary fibroblast - R2875.................... 69 
2.3 Cell counting ................................................................................................ 71 
2.4 Freezing of cell stocks .................................................................................. 71 
2.5 Culturing cells from frozen stocks ............................................................... 71 
2.6 siRNA transfection ....................................................................................... 72 
2.6.1 siRNA stock preparation ....................................................................... 72 
2.6.2 Optimization of siRNA transfection for UHRF1 Knockdown ................ 72 
2.6.3 siRNA transfection ................................................................................ 73 
2.7 Harvesting cells ............................................................................................ 75 
2.8 Western blot analysis .................................................................................. 75 
2.8.1 Preparation of protein lysate ............................................................... 75 
2.8.2 Protein quantification .......................................................................... 76 
2.8.3 Protein sample preparation for SDS-PAGE .......................................... 76 
2.8.4 Gel electrophoresis and protein transfer ............................................ 76 
2.8.5 Blocking and protein detection ............................................................ 77 
2.9 Cell viability and proliferation assay ........................................................... 79 
2.10 Cytotoxicity test ........................................................................................... 79 
2.11 Cell cycle analysis ........................................................................................ 80 
2.12 Analysis of oxidative stress .......................................................................... 80 
2.12.1 Reactive oxygen species assay ............................................................. 80 
2.12.2 Glutathione assay ................................................................................. 81 
2.13 Dual-Glo Luciferase assay ............................................................................ 82 
2.14 Culturing cancer associated fibroblast with conditioned media from cancer 
cells 83 
2.15 RNA isolation ............................................................................................... 84 
 
 
2.16 cDNA synthesis ............................................................................................ 85 
2.17 Quantitative real-time PCR .......................................................................... 86 
2.18 Method development for investigating DNA methylation in pancreatic 
cancer tissues ......................................................................................................... 88 
2.18.1 Laser capture microdissection ............................................................. 88 
2.18.2 Isolation of genomic DNA from pancreatic cancer tissues .................. 88 
2.18.3 CT conversion ....................................................................................... 90 
2.18.4 KEAP1 pyrosequencing primer design ................................................. 91 
2.18.5 PCR amplifications ................................................................................ 92 
2.18.6 Pyrosequencing .................................................................................... 94 
2.19 Animals ........................................................................................................ 95 
2.20 Haematoxylin and Eosin stain ..................................................................... 96 
2.21 Isolating quiescent pancreatic stellate cells ................................................ 97 
2.22 Rescue of pancreatic stellate cells .............................................................. 98 
2.23 Antibody validation ..................................................................................... 98 
2.24 Processing and paraffin embedding of MiaPaCa-2 cell pellet..................... 99 
2.25 Immunocytochemistry for UHRF1 detection in MiaPaCa-2 and pancreatic 
fibroblast cell pellets ............................................................................................ 100 
2.26 Statistical Analysis ..................................................................................... 101 
2.27 Samples and Methods for single nucleotide polymorphism and tumour 
tissue protein expression ..................................................................................... 101 
2.27.1 Single nucleotide polymorphism - study population ......................... 101 
2.27.2 Gene and single nuclueotide polymorphism selection ...................... 102 
2.27.3 DNA isolation for single nucleotide polymorphism study ................. 102 
2.27.4 Tissue microarray construction .......................................................... 104 
2.27.5 Immunohistochemical staining of TMA sections for NQO1 and UHRF1
 105 
2.27.6 Scoring ................................................................................................ 105 
2.27.7 Statistical analysis .............................................................................. 106 
 
 
 
 
 
3 INVESTIGATING THE FUNCTION OF UHRF1 ON THE KEAP1-NRF2 
PATHWAY IN PANCREATIC CANCER CELLS .................................................. 108 
3.1 Introduction ............................................................................................... 109 
3.2 Results ....................................................................................................... 111 
3.2.1 Optimization for transfection ............................................................ 111 
3.2.2 UHRF1 depletion is associated with Keap1-Nrf2 pathway deactivation
 114 
3.2.3 Suppression of Keap1 by UHRF1 is required for the maintenance of 
low oxidative states .......................................................................................... 116 
3.2.4 UHRF1 depletion causes G2-M cell cycle arrest ................................. 119 
3.2.5 UHRF1 depletion does not confer increased sensitivity to gemcitabine
 122 
3.2.6 Method development for KEAP1 gene promoter analysis ................ 124 
3.3 Discussion .................................................................................................. 128 
 
4 INVESTIGATING THE FUNCTION OF UHRF1 ON THE NRF2 PATHWAY 
IN PANCREATIC STELLATE CELLS ..................................................................... 134 
4.1 Introduction ............................................................................................... 135 
4.2 Results ....................................................................................................... 137 
4.2.1 Isolated stellate cells from the pancreas of both Nrf2 wild-type and 
Nrf2 null mice exhibit a quiescent phenotype ................................................. 137 
4.2.2 Pancreatic stellate cell rescue ............................................................ 137 
4.2.3 Differential expression of UHRF1 and α-SMA in PDAC cell lines and 
primary pancreatic stellate cell lines ................................................................ 140 
4.2.4 Differential expression of UHRF1 and α-SMA in PDAC tissues .......... 144 
4.2.5 UHRF1 stromal expression in normal gastrointestinal tissues .......... 146 
4.2.6 Conditioned media from cancer cells induces Nrf2 in pancreatic 
stellate cells ...................................................................................................... 151 
4.2.7 Nrf2 null mice show differential weight gain and develop early signs of 
pancreatitis ....................................................................................................... 152 
4.3 Discussion .................................................................................................. 154 
 
 
 
 
 
5 EXAMINATION FOR POTENTIAL PREDICTIVE BIOMARKERS FOR 
PANCREATIC CANCER ........................................................................................ 163 
5.1 Introduction ............................................................................................... 164 
5.2 Results ....................................................................................................... 166 
5.2.1 SNP genotyping .................................................................................. 166 
5.2.2 Patient dataset ................................................................................... 167 
5.2.3 Analyses of ViP patients ..................................................................... 167 
5.2.4 Analyses of TeloVac patients ............................................................. 168 
5.2.5 Overall survival analysis for ViP and TeloVac patients combined ..... 168 
5.2.6 Evaluating the predictive effect of SNP on treatment ....................... 173 
5.2.7 Antibody validation for immunohistochemistry in resected pancreatic 
cancer patients (ESPAC-1 and ESPAC-3) ........................................................... 174 
5.2.8 UHRF1 and NQO1 immunohistochemistry staining in normal 
pancreatic tissues ............................................................................................. 177 
5.2.9 UHRF1 and NQO1 immunohistochemistry staining in adjacent normal 
pancreatic tissues and ducts ............................................................................. 178 
5.2.10 UHRF1 and NQO1 immunohistochemistry staining in normal colon and 
duodenum ......................................................................................................... 181 
5.2.11 UHRF1 and NQO1 immunohistochemistry staining and manual scoring 
in PDAC 183 
5.2.12 UHRF1 and NQO1 immunohistochemistry staining and Definiens 
(software) scoring in PDAC ............................................................................... 185 
5.2.13 UHRF1 and NQO1 immunohistochemistry data analysis .................. 190 
5.2.14 UHRF1 and NQO1 are overexpressed in pancreatic cancer .............. 190 
5.2.15 Clinicopathological correlation of UHRF1 and NQO1 in pancreatic 
cancer 191 
5.2.16 Overall survival analysis ..................................................................... 197 
5.3 Discussion .................................................................................................. 207 
 
6 OVERALL DISCUSSION ................................................................................ 214 
6.1 Future directions ....................................................................................... 218 
 
7 APPENDICES .................................................................................................. 220 
 
8 REFERENCES .................................................................................................. 237 
 
 
 
 
 
 
 
 
 
1 GENERAL INTRODUCTION 
 
 
 
 
 
 
 
  
19 
 
1.1 Introduction  
 
The pancreas is a vital organ that forms part of the gastrointestinal system and has 
digestive and hormonal functions. The digestive function of the pancreas is defined 
by the exocrine pancreas which makes up more than 95% of the pancreas and 
comprises acinar cells that secrete the digestive enzymes, the pancreatic ducts that 
deliver secreted enzymes to the small intestine, and the associated nerves, vessels 
and connective tissues. The endocrine pancreas (the islets) constitute 1-2% of the 
pancreatic mass and are responsible for hormonal synthesis and secretion of several 
hormones including insulin and glucagon1. Disturbances to the function of the 
pancreas can have severe consequences. 
The term ‘cancer’ refers to the development of abnormal cell(s) that can arise from 
any tissue or organ characterized by uncontrolled cellular proliferation2. The 
transformation of normal cells into cancer cells which permits their proliferation, 
survival and spread is characterized by the acquisition of several biological traits2. 
Hanahan and Weinberg have described 10 hallmarks and facilitating characteristics 
commonly observed in cancers: enabling replicative immortality, sustaining 
proliferative signalling, resisting cell death, evading growth suppressors, inducing 
angiogenesis, activating invasion and metastasis, reprogramming cellular metabolism 
and evading immune destruction, all facilitated by tumour promoting inflammation 
and genome instability and mutation2. These properties although complex, are 
acquired by different cancers at various times during the multistep process leading 
to carcinogenesis.  
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Cancer is a major public health challenge worldwide; in 2012, an estimated 14.1 
million new cancer cases and 8.2 million deaths from cancer occurred globally and 
this burden is expected to grow3. In Europe, an estimated 3.45 million new cancer 
cases and 1.75 million cancer related deaths were recorded in 20124. In the United 
States, cancer is the second leading cause of death5. 
 
1.2 Pancreatic cancer  
 
Pancreatic cancer is a leading cause of cancer related deaths in Europe and United 
States and the most lethal of gastrointestinal cancers3-5 with an overall five-year 
survival of less than 7 %6. Surgical resection is potentially curative in patients that 
have cancers limited to the pancreas but despite surgical resection, the five-year 
survival in this group is still low though it has gradually improved from <18 %7 to 
almost 29 %8.  
1.2.1 Epidemiological Trend 
 
Sadly, there are currently no established screening tools for early detection of 
pancreatic cancer with an estimated 80 - 85 % of patients being diagnosed when the 
disease is advanced and no longer amenable to surgical resection6,9. In the early 
stages of PDAC patients have vague symptoms and present later with symptoms such 
as weight loss, jaundice, anorexia, fatigue and abdominal pain when the disease is 
advanced10. Both environmental (cigarette smoking, chronic pancreatitis, heavy 
alcohol consumption and long standing diabetes) and genetic factors (hereditary 
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pancreatitis and Peutz-Jeghers syndrome amongst others) have been implicated in 
pancreatic cancer development11. A 40-year trend in 5-year survival for pancreatic 
cancer in England from 1971 – 2011 showed a 1 % increase in survival from 2.3 – 3.3 
%12. This is a very dismal prognosis. In Europe, an estimated pancreatic cancer 
incidence of 103,800 and mortality of 104,500 was recorded in 20124. In the United 
States, pancreatic cancer is the fourth leading cause of cancer-associated death and 
is projected to be the second cause of cancer-related death by 20305,13. The dismal 
prognosis associated with pancreatic cancer is attributable to late diagnosis and/or 
presentation and the blunted response to currently available therapeutics6,14. The 
intense stromal reaction and cancer heterogeneity have potentially contributed to 
this poor response15,16. Understanding these complexities will be beneficial towards 
defining therapies, diagnostic and therapeutic biomarkers that will improve 
pancreatic cancer management. 
 
1.2.2 Treatment trials for pancreatic cancer 
 
Gemcitabine and 5-fluorouracil (5-FU) have been for many years the two 
chemotherapeutic agents predominantly used in the treatment of pancreatic cancer 
in both adjuvant (after surgical resection) and advanced and metastatic 
(nonresectable) settings7,17-20. Gemcitabine (2’, 2’ –difluorodeoxycytidine – dFdC) is a 
prodrug that requires intracellular activation (phosphorylation) by deoxycytidine 
kinase to the active metabolites gemcitabine diphosphate (dFdCDP) and triphosphate 
(dFdCTP)21,22. 5-FU is a fluoropyrimidine that is an active antimetabolite23. Although 
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gemcitabine and 5-FU differ in their mechanisms of action, they both interfere with 
DNA synthesis22,23.  
The European Study Group for Pancreatic Cancer (ESPAC) have undertaken clinical 
trials to assess the benefit of adjuvant therapy in pancreatic cancer patients7,8,18,19. 
ESPAC-1 trial demonstrated a need for adjuvant chemotherapy with a statistically 
significant survival benefit18; the estimated 5-year survival rate for patients who had 
adjuvant chemotherapy with 5-FU versus resection and no chemotherapy 
(observation only) was 21.1% (95% CI 14.6–28.5) and 8% (95% CI 3.8–14.1) 
respectively while patients receiving adjuvant chemoradiotherapy did not fare any 
better to the observation arm with an estimated 5-year survival of 10% (95% CI 6.1–
17.0). Following on from ESPAC-1, ESPAC-3 clinical trial was undertaken to determine 
the superiority of either 5-FU plus folinic acid to gemcitabine in terms of overall 
patient survival, progression-free survival and quality of life in the adjuvant setting7; 
in comparison to gemcitabine, 5-FU did not show any significant survival benefit with 
a medium survival of 23 months in both treatment arms. The estimated 5-year 
survival was 17.5% (95% CI 14.0–21.2) and 15.9% (95% CI 12.7–19.4) in gemcitabine 
and 5-FU plus folinic acid group respectively. Similarly, the progression-free survival 
and global quality of life scores was not significantly different between both 
treatment arms. On the toxicity profile however, gemcitabine had a better safety 
profile with fewer treatment related serious adverse events than 5-FU plus folinic 
acid. Continued efforts to improve overall survival for patients in adjuvant setting led 
to ESPAC-4 trial which examined the efficacy and safety of gemcitabine plus 
capecitabine combination therapy with gemcitabine monotherapy8. Capecitabine is 
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a 5-FU prodrug. This results of the trial were recently reported and showed a 
statistically significant difference in median overall survival of 28 months (95% CI 
23.5–31.5) for gemcitabine plus capecitabine group compared with 25.5 (95% CI 
22.7–27.9) months in the gemcitabine only group [hazard ratio (HR) 0.82; 95% CI 
0.68–0.98, p=0.032]. The estimated 5-year survival rate was 28.8% (95% CI 22.9–35.2) 
for patients in the gemcitabine plus capecitabine group and 16.3% (95% CI 12.7–19.4) 
for gemcitabine group. Although more adverse events were recorded for the 
gemcitabine plus capecitabine group, they were within an acceptable level of 
toxicity8. The findings from ESPAC-4 are encouraging and come with the 
recommendation that chemotherapy with gemcitabine plus capecitabine should be 
the standard of care following surgery for pancreatic ductal adenocarcinoma (PDAC). 
The Japan Adjuvant Study Group of Pancreatic Cancer 1 (JASPAC-1) was undertaken 
to assess the efficacy of S-1 (an orally acting prodrug of fluorouracil) to gemcitabine24. 
This study showed that S-1 had a superior survival advantage with an estimated 
overall 5-year survival of 44.1% (95% CI 36.9–51.1) in the S-1 group compared with 
24.4% (95% CI 18.6–30.8) in the gemcitabine group. While this result is interesting, 
several factors need to be considered when attempting to translate this finding to an 
European population. These include differences in race and the performance status 
(a quantification of general well-being in cancer patients with a 0 status denoting 
perfect health and 5 death) of patients enrolled into the study as 69% of patients in 
the JASPAC-1 trial had a low performance status of 0 compared with 42% in ESPAC-
48,24. 
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In patients with advanced or metastatic pancreatic cancer, combination 
chemotherapy has also shown benefits25-28. An open label randomized phase III trial 
demonstrated a better performance for gemcitabine plus capecitabine than 
gemcitabine alone with an improved response rate (19.1% versus 12.4%) and 
progression-free survival (HR 0.78; CI 0.66–0.93)25. Another phase III trial compared 
the efficacy and safety of folinic acid, 5-FU, irinotecan and Oxaliplatin (FOLFIRINOX) 
with gemcitabine in metastatic pancreatic cancer in patients with good performance 
scores of 0 or 1 on a scale of 0–5 with higher scores indicative of disease severity26. 
This study demonstrated FOLFIRINOX therapy was superior to gemcitabine only 
therapy: the median overall survival of 11.1 months in the FOLFIRNOX arm compared 
with 6.8 months for gemcitabine therapy (HR 0.57; 95% CI 0.45–0.73); median 
progression-free survival was 6.4 months in the FOLFIRINOX group and 3.3 months in 
the gemcitabine group (HR 0.47; 95% CI 0.37–0.59); the objective response rate was 
also higher in the FOLFIRINOX group at 31.6% versus 9.4% in the gemcitabine group 
and the 1-year survival in the FOLFIRINOX group was approximately 50% compared 
with 9.4% in the gemcitabine group. FOLFIRINOX was however associated with 
increased toxicity. A phase 3 clinical trial assessing the efficacy and safety of the 
combination albumin bound paclitaxel (nab-paclitaxel) plus gemcitabine 
demonstrated a better performance than gemcitabine monotherapy in patients with 
advanced pancreatic cancer27: here the median overall survival was 8.5 months in 
nab-paclitaxel-gemcitabine group compared with 6.7 months in the gemcitabine 
group (HR 0.72; 95% CI 0.62–0.83); the median progression free survival was 5.5 
months in nab-paclitaxel-gemcitabine group versus 3.7 months in the gemcitabine 
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group (HR 0.69; 95% CI 0.58–0.82) and the response rate was 23% versus 7% in nab-
paclitaxel-gemcitabine group and gemcitabine group respectively but more adverse 
events were recorded in the nab-paclitaxel-gemcitabine group. In a separate phase 2 
clinical Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR) trial, the 
efficacy and safety of combination chemotherapy involving Nab-paclitaxel plus either 
gemcitabine or simplified leucovorin with fluorouracil in metastatic pancreatic cancer 
was undertaken28. In this study the primary endpoint was progression free survival at 
4 months with a target of 50% to qualify for future phase 3 trial. At 4 months greater 
than 50% of patients in both treatment arms were progression free with tolerable 
toxicities recorded. Emerging vaccine therapies have been tried in pancreatic cancer. 
A telomerase vaccine (TeloVac) trial assessing the efficacy and safety of sequential 
and simultaneous telomerase vaccination (GV1001) in combination with 
chemotherapy (gemcitabine plus capecitabine) was undertaken in patients with 
locally advanced or metastatic cancer29; this study randomized patients 1:1:1 into 3 
groups: chemotherapy alone (gemcitabine plus capecitabine), chemotherapy plus 
sequential GV1001 (sequential chemoimmunotherapy) or chemotherapy plus 
concurrent GV1001 (concurrent chemoimmunotherapy); the reported median 
overall survival was not significantly different between chemotherapy group (7.9 
months, 95% CI 7.1–8.8) and sequential chemoimmunotherapy (6.9 months, 95% CI 
6.4–7.6), HR 1.19; 98.25% CI 0.97–1.48) or concurrent chemoimmunotherapy group 
(8.4 months, 95% CI 7.3 – 9.7), HR 1.05; 98.25% CI 0.85 – 1.29. More recently, a phase 
2 double blind Vandetanib in Pancreatic cancer (ViP) trial was undertaken30. 
Vandetanib is a rearranged during transfection (RET) tyrosine kinase inhibitor with 
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marked vascular endothelial factor receptor (VEGFR) and epidermal growth factor 
receptor (EGFR) inhibitory signalling activity all involved in the pathogenesis of 
pancreatic cancer30,31. Vandetanib has also shown improvement in overall survival in 
patients with medullary carcinoma of the thyroid32. The ViP trial compared the clinical 
efficacy of vandetanib plus gemcitabine (vandetanib group) and placebo plus 
gemcitabine (placebo group) with overall survival as the primary outcome30. This 
study did not show an improvement in overall survival with a median survival of 8.83 
months and 8.95 months in the vandetanib and placebo group respectively (HR 1.21; 
80.8 % CI 0.95–1.53). Moreover, more adverse events were recorded for vandetanib 
group. Taken together, the studies outlined above demonstrate a superior advantage 
for combination-based chemotherapy over monotherapy.  
 
1.2.3 Pancreatic cancer biology 
 
Uncontrolled proliferation of cells, one of the hallmarks of cancer2, is the result of 
abrogated cell cycle check points or disruption in growth signalling pathways33. 
Normal cell cycle check points and/or signalling pathways are physiologically 
regulated by activation or repression of relevant genes and/or proteins but 
dysfunctional modifications to either the DNA nucleotide sequence (genetic changes) 
or modifications to the genome without changes to the nucleotide sequence 
(epigenetic changes) can contribute to cancer formation34,35. 
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1.2.3.1 Pancreatic cancer genetics 
 
Pancreatic cancer is a heterogeneous disease characterized by several molecular and 
histological changes; both primary and metastatic tumours have distinct clonal 
subpopulations contributing to the heterogeneity in pancreatic cancer15,36-39. Global 
genomic analyses of 24 pancreatic cancers identified an average of 63 genetic 
alterations and most were due to point mutations15; these mutations altogether 
defined a set of 12 core signalling pathways that were altered although not every 
pancreatic cancer has an alteration in all 12 pathways. The 12 pathways include: KRAS 
signalling, DNA damage control, apoptosis, integrin signalling, hedgehog signalling, 
regulation of invasion, homophilic cell adhesion, G1/S phase transition regulation, c-
Jun N-terminal kinase signalling, small GTPase-dependent signalling, TGF-β signalling 
and Wnt/Notch signalling. Genomic analyses of 99 pancreatic cancer patient tumours 
identified 2,016 non-silent mutations while another study analysed 100 pancreatic 
cancer tissues and reported 7,888 non-silent mutations in 5,424 genes38,39. These 
variations in pancreatic cancer genomes highlight the complexity of this disease.  
PDAC is the most common (approximately 85%) of all pancreatic cancers arising from 
ductal epithelium; other pancreatic cancers include neuroendocrine carcinoma and 
intraductal papillary mucinous neoplasm (IPMN) with invasive cancer40. PDAC has 
also been hypothesized to arise from acinar cells in a process called acinar-to-ductal 
metaplasia (ADM)41. The established model for the development of PDAC begins with 
a normal ductal epithelium progressing to precancerous (pancreatic intraepithelial 
neoplasia – PanIN) lesions and finally to established primary invasive carcinomas42; 
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the PanIN grades 1-3 are histologically distinct and genetic mutations seen in invasive 
PDAC can be seen in these precancerous lesions. Low grade PanIN-1 through 
intermediate grade PanIN-2 to high grade PanIN-3 lesions are associated with 
accumulating genetic alterations 42 PanIN-1 are associated with Kirsten rat sarcoma 
viral oncogene homolog (KRAS) mutation; PanIN-2 in addition shows mutations in the 
p16 gene while PanIN-3 lesions demonstrate accumulated mutations including the 
p53 gene. This progression model is well supported by the findings that 
approximately two-thirds of genetic mutations are shared between PanINs and 
invasive carcinomas43. Other precancerous lesions thought to precede PDAC 
development include IPMN and MCN (mucinous cyst neoplasm) which also have 
shared and distinct mutations from PDAC44.  
Frequently mutated genes that characterize PDAC include oncogene the KRAS and 
tumour suppressor genes cyclin-dependent kinase inhibitor 2A (CDKN2A/p16INK4a), 
tumour protein p53 (TP53) and deleted in pancreatic cancer-4 (DPC-4)11,15,38,44; KRAS 
is the most commonly activated oncogene with more than 90% of pancreatic 
adenocarcinomas harbouring oncogenic KRAS mutation KRas, a small GTPase protein 
involved in signal transduction from growth factors and cell surface receptors; KRAS 
encodes 2 splice variants KRAS1, a pseudogene and KRAS2, a protooncogene. The 
commonly encountered KRAS mutation involves the KRAS2 oncogene and typically 
occurs at codon 12 resulting in a gain-of-function mutation that constitutively yields 
active KRas even in the absence of cell surface receptor activation or other 
signals45,46. The result is continued activation of its target signalling pathways such as 
RAF-mitogen activated kinase (MAPK) pathway and phosphoinositide 3-kinase (PI3K) 
29 
 
pathway which regulates cell division, proliferation, gene expression and survival44. 
Of note is that KRAS mutations are also observed in chronic pancreatitis and healthy 
individuals 47 which underscores the fact that additional genetic and/or epigenetic 
events are needed to ultimately transform cells.  
To understand the significance of oncogenic activating mutations of KRAS in 
pancreatic cancer, Collins et al.48 used genetically modified mice that allowed for 
pancreas-specific inducible and reversible expression of KRas oncoprotein. 
Doxycycline in drinking water induced KRas while doxycycline-free drinking water 
switched off KRas activity. Using this model, the effect of KRas activity under different 
experimental conditions such as in caerulein-induced pancreatitis and p53 mutations 
could be examined. After caerulein-induced pancreatitis, KRas induction for 3 weeks 
led to the development of PanIN and fibrotic stroma while KRas inactivation following 
the 3 week period resulted in full pancreatic tissue recovery. When KRas was 
switched on for a longer duration of 5 weeks, the pancreatic tissue was composed 
mostly of PanIN lesions and fibrotic response and KRas inactivation resulted in 
apoptosis of the PanIN lesions and persistence of fibrosis. In p53 mutant mice that 
had developed pancreatic cancer, inactivation of KRas caused apoptosis and tumour 
regression with residual fibrosis. Taken together, these findings indicate that KRAS is 
required for both initiation and maintenance of pancreatic cancer in mice. Cyclin 
dependent kinase inhibitor 2A or inhibitor of CDK4 (CDKN2A/p16INK4a)is the most 
commonly inactivated tumour suppressor gene in pancreatic cancer which encodes 
CDKN2A/p16INK4a; CDKN2A protein plays a role in cell cycle regulation by preventing 
the phosphorylation of retinoblastoma protein44. The genetic alterations mentioned 
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above and others such as telomere shortening, breast cancer type 2 (BRCA2) or 
ataxia-telangiectasia mutated (ATM) mutations contribute to PDAC progression15,44. 
 
1.2.3.2 Epigenetics 
 
Epigenetic changes modify the genome by suppressing or inducing gene expression 
without changes in the DNA nucleotide sequence; well recognized epigenetic 
mechanisms include DNA methylation, histone modifications and microRNAs49. 
Notably, epigenetic modifications have been observed in both normal cells and 
diseased cells such as cancer50-53. Aberrant DNA methylation patterns are one of the 
epigenetic landscapes of cancer. DNA hypomethylation is often associated with a gain 
in functional activation of transcription of a particular gene while hypermethylation 
leads to gene silencing. Both hypomethylation and hypermethylation of several 
genes including oncogenes and tumour suppressor genes respectively have been 
reported in several cancers54. 
The best studied epigenetic modification in pancreatic cancer is DNA methylation 
which is the addition of a methyl group at carbon 5 position of the cytosine ring 
resulting in 5-methyl cytosine49,55. The addition of a methyl group occurs on cytosines 
preceding a guanosine in the DNA sequence (CpG dinucleotide). More often, these 
CpGs are found in clusters (CpG islands) within the proximal promoter regulatory 
regions of genes. DNA methyltransferases (DNMTs), in particular DNMT1 is 
responsible for the addition and maintenance of the methylation pattern from parent 
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strand to newly synthesized daughter strand56. Methylation of these CpG islands 
within the promoter region of genes is generally correlated with gene silencing 
(Figure 1.1) mediated by disrupting the binding of transcription factors and most 
importantly, by attracting methyl-CpG binding domain (MBD) proteins to activate 
heterochromatin formation57,58. The 3 members of the MBD suppressive proteins are 
MBD, UHRF and zinc finger proteins55. UHRF1 is the focus of this thesis and is 
discussed further. 
 
 
Figure 1.1. Gene silencing in association with promoter hypermethylation. (A) The unmethylated promoter of a 
hypothetical gene at exon 1 is actively transcribed. (B) Transcriptional repression of gene; gene silencing 
correlates with methylation of CpG within the promoter regions. The methylation of the CpGs and subsequent 
gene repression requires the cooperation of UHRF1, Dnmt1, proliferating cell nuclear antigen (PCNA) and histone 
deacetylase inhibitor 1 (HDAC1). 
 
A
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In order to identify gene targets and understand the functional relevance of aberrant 
methylation in pancreatic cancer, Sato et al. used methylation-specific (MSP) PCR to 
determine the methylation status of genes in 4 pancreatic cancer cell lines after 
treatment with 5 - aza - 2’- deoxycytidine (5 Aza-dC) a demethylating agent. They 
found greater than 5 fold induction of 475 genes in cancer cell lines compared with 
nonneoplastic normal human ductal epithelial (HPDE) cell lines50. They further 
examined the methylation status of 11 genes in a panel of 42 pancreatic cancers 
(laser microdissected) and reported aberrant methylation of all 11 genes with no 
methylation in a panel of 10 normal pancreatic duct epithelia (laser microdissected). 
Some genes hypermethylated in most (85%) of the 42 pancreatic cancers examined 
include UCHL1, NPTX2, SARP2, CLDN5 and Reprimo50. In another study, Sato et al. 
examined the relevance of DNA hypomethylation in pancreatic cancer and reported 
methylation of 19 genes in normal pancreatic duct epithelia (laser microdissected)51. 
When examined in primary pancreatic cancerous tissue, 7 (claudin 4, lipocalin 2, 14-
3-3 sigma, S100A4, mesothelin, trefoil factor 2 and prostate stem cell antigen) of the 
19 genes were hypomethylated and overexpressed. These studies indicate 
hypomethylation and hypermethylation are frequent events in pancreatic cancer 
with functional relevance in affected genes. 
In support of the studies by Sato et al. above50,51, p16 tumour suppressor gene 
inactivation by promoter hypermethylation is well established in pancreatic cancer 
and studies by Schutte et al. have demonstrated p16 inactivation by genetic and 
epigenetic mechanisms occurring in more than 95% of pancreatic cancer53. 
Progression through G1 phase of the cell cycle in normal cells requires the 
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inactivation of Rb (retinoblastoma) protein through phosphorylation by cyclin D1 and 
Cdk4 (cyclin dependent kinase 4) complex. p16 protein competitively binds to Cdk4 
disrupting Cdk4-cyclin D1 complex. Inactivation of p16 leads to loss of cell cycle check 
and uninhibited progression of cells through G1 that can perpetuate 
tumourigenesis53. 
To determine if epigenetic changes occurs early in tumourigenesis, Sato et al. 
investigated methylation patterns in 65 laser microdissected PanIN lesions using 
methylation specific PCR (MSP); they reported aberrant methylation involving 8 
genes in 68% of PanIN lesions52. This finding shows that early PanIN lesions also 
harbour epigenetic changes; these and many other genetic and epigenetic 
modifications can culminate in the initiation and progression of PDAC. 
1.2.4 Ubiquitin-like with PHD and RING finger domains (UHRF) 
 
As mentioned above, UHRF is one of the 3 members of the MBD suppressive proteins 
that play a role in DNA methylation. Four members of the UHRF family of proteins 
UHRF1, UHRF2, UHRF3 and UHRF4 have been described but most of the published 
data relate to UHRF1 with some limited data available for UHRF259. UHRF2 is 
structurally similar to UHRF1 but the two proteins differ in expression patterns60; 
UHRF2 is widely expressed in differentiated human tissues and poorly expressed in 
human cancers whereas UHRF1 is expressed in proliferating embryonic stem cells and 
several cancers . It is suggested that UHRF2 might function as a tumour suppressor 
given that its overexpression led to growth inhibition and its levels were 
downregulated during partial hepatectomy59. UHRF1 is the focus of this thesis. 
34 
 
1.2.5 UHRF1 
 
UHRF1 is a 793 amino acid multi-domain nuclear protein, also known as inverted 
CCAAT box-binding protein of 90 kDa (ICBP90) that binds to one of the several 
topoisomerase II alpha gene promoters61. It is important in cell cycle progression and 
growth62-64 and in maintaining epigenetic modifications such as DNA methylation65, 
histone methylation66, histone ubiquitination67 and histone deacetylation68. UHRF1 
plays a vital role in linking epigenetic markers – histone post-translational 
modifications and DNA methylation which are required for normal gene expression 
and cellular processes66,69.  
Five domain structures have been described for UHRF1 (Figure 1.2)70. Through its SET 
and RING associated (SRA) domains, it maintains inherited epigenetic methylation 
patterns by binding to hemi-methylated DNA during replication subsequently 
recruiting DNMT1 to copy the methylation pattern to newly synthesized daughter 
strand65,68. A proposed mechanism for the UHRF1 and DNMT1 interaction has been 
described by Arita et al. as a base-flipping mechanism71; here, the SRA domain of 
UHRF1 recognising and binding to hemi-methylated cytosine in the CpG, leads to the 
formation of SRA-DNA complex which flips 5-methyl cytosine out of the parent strand 
of the DNA helix permitting DNA binding to UHRF1. This is followed by flipping out of 
the unmethylated cytosine on the newly synthesized daughter strand into the 
catalytic domain of DNMT1 to become methylated (Figure 1.2)71.  
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Figure 1.2. Schematic diagram of the cooperation between UHRF1 and Dnmt1 in DNA methylation 
maintenance. (A) Recognition of hemi-methylated cytosine on parent strand by the SRA domain of UHRF1. (B) 
Methylated cytosine flipped out into the SRA domain. (C) Recruitment of Dnmt1 by UHRF1. (D) Unmethylated 
cytosine on daughter strand is flipped out of the DNA helix after transfer of hemi-methylated DNA to Dnmt1. 
UHRF1 domains: UBL – Ubiquitin-like; TTD - Tandem tudor domain; PHD - Plant homeodomain; SRA - Set and ring 
associated domain and RING – Really interesting new gene domain. Dnmt1 – DNA methyl transferase 1. Adapted 
from Hashimoto et al. 200970 and Arita et al. 200871 
 
Further studies have demonstrated that in addition to the SRA domain of UHRF1, the 
tandem tudor domain (TTD) and/or plant homeodomain (PHD) of UHRF1 are able to 
target DNMT1 for DNA maintenance methylation68. 
In addition, UHRF1 interacts with and binds to histone deacetylase 1 (HDAC1) through 
its SRA domain66,68. The SRA domain has also been shown to participate in histone 3 
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(H3) methylation. The Really Interesting New Gene (RING) domain has E3 ubiquitin 
ligase activity responsible for histone ubiquitination72. These UHRF1 domain 
interactions enhance heterochromatin formation that structurally silences gene 
transcription66. It is not yet known whether these domains act in unison or 
independently70. 
1.2.6 UHRF1 regulation  
 
In response to DNA damage, p53 up regulates p21 which down regulates UHRF1 by 
deactivating E2F1 transcription factor that directs UHRF1 transcription63. UHRF1 is 
also able to silence p21 by recruiting histone methyl transferase, DNMT1 and HDAC1 
to the promoter site of p2166. UHRF1 has binding sites for retinoblastoma protein 
(pRB) which functions as a tumour suppressor by inhibiting cell cycle progression at 
G1/S transition73; overexpression of UHRF1 has led to pRB downregulation and 
increased the S and G2/M phase cell fractions of serum-starved lung fibroblasts74. 
UHRF1 through its RING domain ubiquitinates itself (autoubiquitination) and DNMT1 
but ubiquitin specific peptidase 7 (USP7), also known as herpes virus associated 
ubiquitin specific protease (HAUSP) is able to deubiquitinate both UHRF1 and DNMT1 
which stabilizes both proteins by preventing their proteasomal degradation72,75. 
 
1.2.7 UHRF1 in cancers 
 
In a study to demonstrate the role of UHRF1 in oncogenesis, Unoki et al. 
demonstrated that in cancer cells, UHRF1 was found bound to the methylated 
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promoter regions of tumour suppressor genes such as p16INK4A and p14ARF genes68. 
The expression of UHRF1 occurs in proliferating cells but not in dormancy and its level 
has been shown to peak in late G1 and G2M phases of the cell cycle in proliferating 
non-cancer cells whereas, cancer cells show increased and sustained UHRF1 
expression throughout the cell cycle61,62. UHRF1 has been reported to be 
overexpressed in many cancers including lung cancer76, bladder cancer77, breast62, 
colon cancer78 and pancreatic79,80 and has been suggested as such to be a potential 
target for treatment as functional studies demonstrate increased cell death with 
UHRF1 knockdown64 and its expression is associated with poorer prognosis in some 
cancers76,77.  
Previous work by Crnogorac-Jurcevic et al., undertaken in collaboration with our 
research group reported overexpression of UHRF1 in pancreatic cancer compared to 
chronic pancreatitis and normal pancreas79. Subsequent work by Abu-Alainin et al. 
from within our research group showed that 86% (114 of 132) of PDAC tissues 
overexpressed UHRF1; when UHRF1 expression was grouped as negative (score 0) or 
positive (score 1,2 or 3), a statistically significant association was found between 
positive UHRF1 tumours and larger tumour size but no association was found with 
patient outcome80. In recent reports, KRas has been shown to lie upstream of UHRF1 
where it drives UHRF1 expression80,81.  
In summary, UHRF1 is involved in the maintenance of epigenetic changes and 
aberrant changes to these normal epigenetic processes can lead to cancer.  
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1.2.8 Keap1-Nrf2 defence pathway 
 
Cells have developed defence mechanisms to defend themselves and overcome 
perturbations arising from chemical or oxidative stress82. A prominent defence 
mechanisms that maintains and reinstates cellular homeostasis is the Kelch-like ECH-
associated protein (Keap1) and nuclear factor-erythroid 2-related factor 2 (Nrf2) 
pathway82,83. Nrf2 is a transcription factor and it functions to activate the 
transcription of several antioxidant proteins, detoxifications enzymes and xenobiotic 
transporters in addition to other functions in lipid synthesis, proliferation and 
inflammation84. Examples of such cytoprotective proteins include but are not limited 
to aldo-keto reductases (AKR), glutamate cysteine ligase catalytic subunit (GCLc), 
glutamate cysteine ligase modulatory subunit (GCLm), glutathione reductase (GSR), 
gluthathione synthetase (GS) and NAD(P)H:quinone oxidoreductases (NQO)82. A 
generally accepted mechanism for Nrf2 mediated cytoprotection is well described in 
the literature, and illustrated in Figure 1.3. Keap1 functions as a negative regulator of 
Nrf2 by serving as an adapter for cullin3/ring box1 (Cul3/Rbx1) E3 ubiquitin ligase 
complex; under basal physiological conditions, Keap1 continuously drives Nrf2 
degradation via ubiquitin dependent proteasome degradation in the cytoplasm; in 
response to oxidative or chemical stress, modifications to the cysteine residues in 
Keap1 and/or modifications to Nrf2 protein liberates Nrf2 from Keap1 and prevents 
continued Nrf2 degradation; Nrf2 stabilization and accumulation in the cytoplasm 
leads to its translocation to the nucleus where it heterodimerizes with small 
masculoaponeurotic fibrosarcoma (Maf) protein that enhances the binding of Nrf2 to 
antioxidant response elements (ARE) in the promoter region of Nrf2-regulated 
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cytoprotective genes; Nrf2 also has ARE sequences within its own promoter and 
autoactivates its own transcription furthering the antioxidant defence response82,84-
86.  
 
Figure 1.3. Keap1-dependent regulation of Nrf2. (A) Under basal and unstressed conditions, Keap1 anchors Nrf2 
for ubiquitination and subsequent degradation by the proteasome. (B) When the cell is stressed from endogenous 
or exogenous factors the interaction between Keap1 and Nrf2 is partial and in this state, Keap1 is no longer able 
to fully anchor Nrf2 for ubiquitination and subsequent degradation by proteasome. As a result Nrf2 accumulates 
in the cytoplasm and then in the nucleus where with the cooperation of masculoaponeurotic fibrosarcoma (Maf) 
protein binds antioxidant response elements (ARE) present in the promoter region of Nrf2 target genes where it 
drives their transcription. 
 
Another level to Keap1-Nrf2 regulation has been shown to be mediated by p62 also 
known as sequestosome 1 (SQSTM1)87. p62/SQSTM1 functions as a scaffold protein 
by directing polyubiquinated proteins for autophagy88. In a study by Copple et al., 
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ectopic expression of p62 in several cell lines resulted in downregulation of Keap1 
protein while p62 depletion led to an upregulation in Keap1 protein and a 
concomitant downregulation of Nrf2 proteins as well as a decrease in mRNA and 
protein levels of Nrf2-regulated genes but without changes to Keap1 or Nrf2 mRNA 
levels; in addition, in the absence of p62, the half-life of Keap1 almost doubled87. 
Other Keap1-independent Nrf2 regulatory mechanisms have been reported84. 
Oxidative stress is exerted by reactive oxygen species (ROS – such as hydroxyl, .OH; 
superoxide, .O2–; are free radical ROS while hydrogen peroxide H2O2 is a non-radical 
ROS) which are continuously produced by enzymatic and non-enzymatic reactions89. 
Oxidative stress can contribute to the process of tumour development caused by 
oxidative damage to macromolecules such as DNA, protein and lipids from ROS 
overproduction and/or defective antioxidant and/or DNA repair mechanisms Figure 
1.490,91. Nrf2 is a master regulator of proteins with antioxidant function. Glutathione 
(GSH) is the most abundant non-enzymatic antioxidant cofactor in cells and Nrf2 
contributes to the regulation of enzymes involved in the synthesis of GSH; Nrf2 also 
plays a major role in GSH regeneration through its action on increasing the synthesis 
of NADPH-generating enzymes; NADPH serves as a reducing agent for the 
regeneration of reduced glutathione (GSH) from oxidized glutathione (GSSG)89. Nrf2 
can be activated by stressors such as ROS, RNS (reactive nitrogen species) as well as 
small molecules of endogenous and exogenous origin90.  
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Figure 1.4. Role of reactive oxygen species (ROS) in tumour initiation. Functional single nucleotide polymorphism 
(SNP) involving antioxidant genes can also contribute to increased ROS levels.  
 
Maintaining low intracellular ROS levels is important for normal homeostasis and 
protective against cancer as studies have demonstrated a role for ROS in 
degenerative disease and tumour development92,93. Nrf2 studies in mice showed that 
all aged Nrf2 null mice developed vacuolar leukoencephalopathy92 while Nrf2-null 
mice chronically exposed to carcinogenic agents had a significantly higher incidence 
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of hepatocellular carcinomas compared to their wild-type counterparts93. In addition, 
chronic oxidative stress from chronic inflammatory conditions such as ulcerative 
colitis94 and chronic pancreatitis95 have also been associated with increased incidence 
of tumour development. ROS, initially considered detrimental to cells, are now being 
appreciated as contributing to the regulation of redox signalling and may therefore 
play a role in both normal homeostasis and disease development90,96,97. While high 
ROS levels may induce apoptosis and severe cell damage, low to moderate levels may 
activate proliferation, differentiation and survival97. It therefore appears that the 
cellular levels of ROS may determine cell fate for either proliferation or death.  
Once regarded as primarily beneficial to maintaining normal cellular homeostasis, 
Nrf2 is increasingly being appreciated as promoting tumourigenesis by protecting 
cancer cells from oxidative stress as well as chemotherapy and radiotherapy98,99. The 
increase in basal Nrf2 activation seen in cancers may be due to different mechanisms 
acting alone or in combination to disrupt Keap1-Nrf2 interaction or by other Keap1 
independent dysregulation of Nrf2. Some emerging mechanisms for the perturbation 
leading to increased Nrf2 activity in cancers include KEAP1 gene promoter 
methylation80,100-102, hyper-phosphorylation of SQSTM1103, somatic mutations in 
KEAP1 and NRF2 genes104 and oncogene induced Nrf2 transcription independent of 
Keap198. In pancreatic cancer, two independent research studies have shown that 
Nrf2 is elevated and promotes cancer cell proliferation98,99.  
In investigating the integrity of Keap1/Nrf2 system in pancreatic cancer, Lister et al.99 
examined a panel of pancreatic cancer lines and pancreatic cancer tissue and found 
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no mutation in Nrf2 exon 2 and only synonymous mutations in Keap1 exons 2 – 6 
which in other cancer types have been shown to harbour functionally relevant SNP 
(single nucleotide polymorphism). In addition, while correlations between basal 
Keap1 and Nrf2 protein levels were observed in all cell lines (high Keap1 protein levels 
associated with lower Nrf2 levels or low Keap1 with higher Nrf2 protein levels), there 
was no uniform correlation between basal Keap1 mRNA and Keap1 protein in the 
cells relative to each other (FAMPAC cells had high Keap1 mRNA and protein; Suit-2 
cells had low Keap1 mRNA and protein and MiaPaCa-2 cells had low Keap1 mRNA and 
high Keap1 protein) but the classical mechanism of Nrf2 degradation via the 
proteasome appeared to be in existence as all cell lines showed Nrf2 stabilization 
following treatment with the proteasome inhibitor, MG132. These observations 
suggest posttranslational mechanisms play a role in the dysregulation of Keap1/Nrf2 
pathway in some pancreatic cancer cell lines. Functional studies in two of the cell 
lines examined (FAMPAC and MiaPaCa-2) showed that siRNA mediated depletion of 
Keap1 was accompanied by increased Nrf2 and Nrf2 target proteins suggesting that 
despite perturbations to the Keap1/Nrf2 pathway, some functional integrity of the 
pathway is still preserved. Nrf2 siRNA depletion impaired the proliferation of 
pancreatic cancer cells while depletion of Keap1 reversed and increase proliferation 
in these cells. Furthermore, Nrf2 depletion in combination with chemotherapy or 
radiotherapy increased treatment response by decreasing cell viability although the 
response to different chemotherapeutic agents varied between cells. In summary, 
Nrf2 appears to play a role in resistance to chemotherapy and radiotherapy. Most 
44 
 
importantly, Lister et al. reported a significantly higher Nrf2 immunoreactivity in the 
cytoplasm of PDAC tumours than in benign duct99.  
In a seminal study by Denicola et al., it was demonstrated that oncogenes can induce 
Nrf2 activity to maintain low ROS levels and reduced intracellular environment in 
KRasG12D/+ MEFs98. In that study, Denicola et al. first showed that endogenous 
oncogenes KRas and Myc could both decrease intracellular ROS, 7,8-dihydro-8-oxo-
2’ –deoxyguanosine (8-oxo-dGuo, a marker of DNA oxidation product) and increase 
total GSH and GSH/GSSG ratio. They next demonstrated that the increased 
antioxidant effect observed from endogenous oncogene activation was driven by 
Nrf2 induction and showed an approximately two-fold increase in Nrf2 protein, Nrf2 
mRNA, Nrf2 downstream target proteins and increased binding to Nrf2 downstream 
target promoters upon endogenous oncogene KRasG12D/+ expression. More 
importantly, at this level of Nrf2 induction, they demonstrated two points: firstly, the 
induction of Nrf2 activity was independent of Keap1 and secondly in Nrf2 deficient 
MEFs, KRasG12D/+ could not elevate both total GSH and the GSH/GSSG ratio.  
In defining the pathway of KRasG12D/+ mediated Nrf2 activation, they used a potent 
and specific inhibitor of MEK, AZD6244 (ARRY – 142886) and this restored the ROS 
levels almost to that of control KRasLSL/+ MEF cells and this treatment was also 
accompanied by downregulation of Nrf2 downstream target genes. Translating their 
in vitro findings to in vivo, they examined the pancreas of KRas mutant mice, human 
PanINs and PDAC tumours and reported an increased Nrf2 downstream target 
(NQO1) and decreased 8-oxo-dGuo in cancer cells compared to adjacent normal 
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ducts. While investigating the involvement of somatic KEAP1 and NRF2 mutations in 
PDAC, Denicola et al. sequenced over 100 pancreatic cancers and found only 1 
concomitant case of KEAP1 and KRAS mutation. These findings further support an 
oncogenic KRas mediated Nrf2 activation in effect in human PDAC. To further 
establish the activity of Nrf2 in promoting KRasG12D/+ –initiated cancers, the effect of 
Nrf2 knockout was examined in mouse models of PDAC. Interestingly, the pancreas 
of Nrf2 knockout mice demonstrated fewer PanINs and lower proliferative activity 
than Nrf2 wild-type PDAC mouse models98. The work by Denicola et al. demonstrates 
an oncogene-mediated Nrf2 signalling in pancreatic cancer that is independent of 
Keap1 that maintains a reduced intracellular environment. The implication is that 
high ROS levels could be lethal to cancer cells while low ROS levels may in fact be 
driving proliferative and survival signalling pathways89,90. 
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1.3 Desmoplastic stroma in pancreatic cancer 
 
The importance of cancer-stromal interaction has been of scientific interest for many 
decades105,106, and recently research into the stromal content, function and interplay 
with tumour has gained significant attention. The increasing awareness of this 
tumour-stromal cross-talk has increased our understanding of the biologic behaviour 
of solid tumours. However, despite the growing knowledge of stromal interaction, 
more research is needed to explain the precise cooperation between tumour and 
stromal elements and to solve ongoing debates9,107-109. 
In solid tumours, there are two distinct yet interdependent compartments; the 
tumour cells and the surrounding stroma110. The tumour microenvironment tumour 
stroma or desmoplastic reaction is “all components of the tumour other than cancer 
cells”111 and includes a complex network of non-neoplastic cells present within a 
tumour and the proteins and molecules produced including but not limited to 
extracellular matrix (ECM) components, soluble factors and signalling molecules 
which influence tumour behaviour112,113.  
Fibroblasts are a resilient group of cells that can withstand extreme stress that will 
normally be detrimental to other cells; they have been isolated and established in 
cultures from post-mortem tissue111,114-116. Fibroblasts play a crucial role in tissue 
homeostasis, wound healing, fibrosis and tumour desmoplasia111,117,118. Earlier 
studies investigating the contractile properties of granulation tissue in wound 
healing, found that fibroblast where responsible for the wound contraction and this 
was achieved by trans-differentiation into cells with structural and functional 
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similarities to smooth muscle cells (characterized by extensive cytoplasmic fibrillar 
system, nuclei indentations and selective cytoplasmic localization of smooth muscle 
serum-a cytoskeletal protein associated with smooth muscle cells) and the name 
myofibroblast was proposed by Gabbiani et al. to describe such cells117. This 
description of myofibroblast cells in normal wound healing was followed in 
subsequent years by the observation that myofibroblast cells inhabit tumour stroma. 
Tremblay et al. demonstrated using electron microscopy the ultrastructural features 
of the stromal aspects of breast cancer and ductal carcinoma of the pancreas and 
found that a large population of stromal cells in both cancers displayed features that 
were intermediate between fibroblasts and smooth muscle cells (myofibroblasts); in 
addition, collagen fibrils were found in the extracellular space110. Because of the 
evidence in support of the similarities between normal wound healing and tumour 
stroma, Dvorak in 1986 hypothesized that “a tumour is a wound that never heals 
completely”105.  
An understanding of the physiological role of fibroblasts is important in order to 
appreciate the wider contribution of fibroblasts in tumours. Fibroblasts are fusiform 
or spindle like elongated cells of mesodermal origin found in the extracellular matrix 
(ECM). They are considered to be the primary producers of the ECM and the 
predominant cells in the connective tissue. The fibrillary collagen, fibronectins, 
proteoglycans and hyaluronic acid make up the ECM and provide the structural 
support for tissue homeostasis and serve as a reservoir for growth factors, cytokines 
and soluble factors 108,111. Following tissue injury, an initial provisional stroma of clot 
forms which is later replaced by new blood capillaries and proliferating and 
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differentiated fibroblasts (myofibroblasts) characterized by α-smooth muscle actin 
(α-SMA) expression105. These myofibroblasts increase their synthesis of ECM 
production which results in a richly vascular and oedematous tissue called 
granulation tissue117. The myofibroblasts contract to bring the wound edges together 
and the granulation tissue is subsequently and finally remodelled into a scar tissue 
characterized by dense collagen and sparse blood vessels and fibrocytes105. Once the 
tissue damage has been restored, the myofibroblast undergo apoptosis119 or 
programmed necrosis120. 
1.3.1 Cancer Associated Fibroblast  
 
In much of the published literature, the phrase cancer associated fibroblast (CAF) is 
often used to refer to fibroblasts in tumours. More importantly, CAFs and the 
accompanying desmoplastic stroma have been shown to impact on the biological 
behaviour of tumours2,108,109,111. CAFs are one of the most predominant stromal cell 
types in solid tumours including pancreatic and breast cancers. A cellular definition 
of CAFs is that “they are all the fibroblastic, nonneoplastic, nonvascular, nonepithelial 
and noninflammatory cells found in the stroma”108. A consensus has not been 
reached regarding the molecular definition of CAFs108. CAFs are activated fibroblasts 
and in many ways share similarities with fibroblast induced during wound healing and 
in inflammatory conditions. In their activated states, CAFs produce a host of factors 
such as α-smooth muscle actin (α-SMA, a typical CAF marker), fibroblast specific 
protein-1 (FSP-1, also called S100A), fibroblast activation protein (FAP) and vimentin. 
Others factors include cytokines, chemokines and growth factors107. Some of these 
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molecular markers have been proposed to define CAFs but it is now being 
acknowledged that these markers are not entirely unique to CAFs107,108. Numerous 
cellular origins of CAF, the tumour-stroma derived factors and tissue type from which 
the tumour developed are believed to underlie CAF heterogeneity and hence their 
molecular characteristics. It is important to mention that other than CAFs in the 
tumour stroma, there are other non-neoplastic cells that also contribute to 
influencing tumour behaviour such as the immune cells, neural cells and endothelial 
cells9.  
1.3.2 Origin of CAFs 
 
CAFS are derived from several local and distant cellular sources and include resident 
fibroblasts, stellate cells and mesenchymal cells; bone marrow derived cells, 
epithelial to mesenchymal transition (EMT) and endothelial to mesenchymal 
transition (EndMT) are additional sources that have been proposed9,108.  
1.3.3 Pancreatic stellate cells 
 
Pancreatic stellate cells (PSCs) are the key players responsible for the stromal 
reaction (desmoplasia) observed in chronic pancreatitis and pancreatic cancer (the 
two common pancreatic diseases)121. They share similarities with hepatic stellate 
cells (HSCs) in their stellate cell morphology and vitamin A storing lipid droplets. PSC 
research came into the lime light when they were isolated and cultured by Apte et al. 
and Bachem et al. in 1998122,123. In a healthy pancreas, PSCs exist in a quiescent 
phenotype (qPSCs) located in the periacinar spaces and characterized by abundant 
50 
 
vitamin A containing lipid cytoplasmic droplets. qPSCs constitute about 4 – 7 % of all 
parenchymal tissue in a normal rat pancreas122,123. 
 
Figure 1.5. The architectural stroma in pancreatic ductal adenocarcinoma (PDAC). (A) The normal exocrine 
pancreas is largely populated by acini with acinar cells. The normal cuboidal ductal epithelial cells are uniformly 
arranged and surrounded by intact basement membrane; the normal ductal epithelial cells have their nuclei 
basally located. Few quiescent pancreatic stellate cells (qPSCs) with perinuclear lipid droplets (white) and resident 
fibroblast are present and located in the periacinar space. The extracellular matrix (ECM) is thin and limited to 
periductal areas. Very few immune/inflammatory cells (lymphocyte, neutrophil, macrophage) are seen. (B) In 
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PDAC the normal architecture is distorted and cancer cells breach the basement membrane to invade adjacent 
stroma. Preceding the PDAC stage are precursor lesions (pancreatic intraepithelial neoplasia – PanIN) which have 
not breached the basement membrane but have a more elongated ductal epithelial cells and non-basal location 
of nuclei. A stromal reaction (desmoplasia) is characterized largely by ECM, increased inflammatory/immune cell 
infiltration and diminished acini tissue. Increase vessel infiltration is also seen in PDAC.  
 
 
Similar to fibroblasts, qPSCs are activated during tissue injury or carcinogenesis and 
acquire an activated phenotype (aPSCs or pancreatic CAFs) characterized by α-SMA 
production122. In addition, aPSCs develop a myofibroblast-like morphology, lose their 
vitamin A lipid containing cytoplasmic droplets and secrete excessive amounts of 
ECM proteins and other soluble factors (Figure 1.5)122. When found in cancer tissue, 
PSCs are categorized as CAFs108,111. 
Pancreatic cancer is characterized by an intense stromal/ desmoplastic reaction that 
surrounds cancer cells and comprises 50 – 80 % of the tumour volume 124. PSCs are 
the major source of CAFs in pancreatic cancer and are largely responsible for the 
deposition of collagenous stroma109. PSCs have for the most part been shown to have 
a tumour promoting function but recent studies have suggested a tumour inhibitory 
role125,126. Several in vitro and in vivo studies have demonstrated a role for PSCs in 
pancreatic carcinogenesis. In vitro conditioned media or co-culture experiments 
between pancreatic cancer cells and PSCs have demonstrated that pancreatic cancer 
cell proliferation, survival and migration are enhanced in response to PSCs, while PSC 
proliferation and ECM synthesis are stimulated upon exposure to pancreatic cancer 
cells127-129.  
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Using mouse xenograft models, Bachem et al. demonstrated that co-injection of 
pancreatic cancer cells and PSCs led to increased cell proliferation, larger tumour, 
increased stromal content128. Orthotopic mouse models have also shown that co-
injection of human PSCs and human pancreatic cancer cells directly into mouse 
pancreas resulted in higher local pancreatic tumour growth and distant metastases 
with histological evidence of these tumours also showing greater tumour cell density, 
increased fibrotic content and increased aPSC numbers than tumours formed by 
pancreatic cancer alone127,129.  
Additional xenograft studies by Xu et al. also showed evidence in support of the 
concept that pancreatic cancer can recruit neighbouring PSCs to favour their survival, 
growth and distant metastasis130. The authors further demonstrated using gender 
mismatch approach to show that PSCs from primary pancreatic cancer sites were able 
to establish themselves at distant metastatic sites together with cancer cells. This 
latter observation was supported by in vitro studies demonstrating that the migration 
of PSCs through a single layer of endothelial cells was in response to platelet derived 
growth factor (PDGF) secreted by pancreatic cancer cells130.  
Most therapies for treating pancreatic cancer have only targeted cancer cells. In view 
of the observations that the pancreatic tumour microenvironment influences and 
promotes cancer growth and metastasis, attempts have been made at targeting 
different aspects of the tumour stroma with the ultimate aim of improving clinical 
outcomes. The hedgehog (Hh) signalling pathway mediates cross-talk between PSCs 
and pancreatic cancer cells131. Inhibition of Hh signalling by IPI-926, a smoothened 
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(Smo) inhibitor in a genetically engineered mouse model (GEMM) of pancreatic 
cancer, depleted the stroma, increased intratumoural vascular perfusion, vascular 
density and improved survival when used in combination with gemcitabine 
chemotherapy132. Similarly, hyaluronic acid (HA) targeted degradation of the tumour 
stroma in a KPC mouse model of pancreatic cancer demonstrated increased vascular 
perfusion associated with an increase in intratumoural concentration of 
chemotherapeutic agents and increased survival133,134. These above observations 
were encouraging but a randomized phase II clinical trial of IPI-926 + gemcitabine had 
to be aborted due to poor survival of patients on this treatment arm.  
In a recent study by Rhim et al., genetic ablation of Hh in GEMM of pancreatic cancer 
resulted in a decrease in intratumoural stroma, increase vascularity, increase over all 
cancer aggressiveness and decreased survival125. In a separate study using drug 
inducible α-SMA deletion of α-SMA positive myofibroblasts in a transgenic mouse 
model of pancreatic cancer, similar results were observed characterized by immune 
suppression (increased infiltrating Tregs), more aggressive and invasive tumours with 
associated reduced survival126. These observations suggest the possible role of the 
stroma in restricting carcinogenesis contrary to earlier observations suggesting a 
tumour promoting function and therefore emphasize the need for further 
understanding of the functions of the stromal elements.  
Stromal modulation rather than depletion is another therapeutic approach at 
targeting the stroma. Sherman et al. demonstrated using an orthotopic model of 
pancreatic cancer that targeting vitamin D receptor on human cancer associated PSCs 
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with vitamin D receptor ligand, calcipotriol, induced a quiescent PSC phenotype 
(characterized by increased lipid droplet and decreased α-SMA expression) resulting 
in stromal remodelling and improved survival135. Chemokine ligand 12- chemokine 
receptor 4 (CXCL12-CXCR4) ligand-receptor pathway has been shown to be active in 
pancreatic cancer136. A study by Ene-Obong et al., demonstrated that in pancreatic 
cancer, CD 8 positive T cells were sequestered by chemokine CXCL12 secreted by PSCs 
137. In a mouse model of pancreatic cancer, Feig et al. showed that CXCR4 inhibition 
together with immune checkpoint antagonist α-programmed cell death–ligand 1 (α-
PD-L1) enhanced tumoural T-cell accumulation and increased cancer cell death136. 
1.3.4 Prognostic value of stromal activity 
 
The precise role of the stroma in pancreatic cancer is still an issue of ongoing concern. 
Erkan et al. investigated the expression of α-SMA and collagen from 233 pancreatic 
cancer resected specimens and found that patients with higher collagen had a 
modest survival benefit but no significant association between α-SMA expression and 
overall survival138. When these patients were further classified by stromal activity 
index (ratio of α-SMA expression to collagen density), a higher stromal activity index 
was associated with poorer prognosis138. In a recent study, Özdemir et al. reported a 
poorer survival in patients with low α-SMA expression126. Similarly, Bever et al. 
examined the stromal density (ratio of collagen positive stroma to area of tumour 
mass) and found a positive association with overall survival in patients with high 
stromal density139. These varied conclusions on the prognostic value of stromal 
activity may be due to differences in methods of measuring stromal activity but 
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importantly, brings to light the possible protective role of the desmoplastic stroma in 
pancreatic cancer. One clear message is that the stroma is not just a bystander but 
either works in favour of or against pancreatic cancer probably in a context defined 
manner and more understanding is required to develop effective strategies of 
targeting both tumour cells and the accompanying stromal elements. 
1.3.5 CAF polarization 
 
Recently, the concept of CAF polarization was proposed to reflect functional 
heterogeneity of CAFs107,111. F1 CAFs are suggested to have tumour inhibitory 
properties, F2 as exhibiting tumour promoting properties, F3 subtypes are proposed 
to influence tumour immunity and angiogenesis and F4 subtypes are proposed to 
define ECM production and remodelling. In a study by Sugimoto et al., two CAF 
subtypes were described using pancreatic and breast cancer mouse models140. One 
subtype was characterized by FSP-1 expression and the other subtype was defined 
by co-expression of α-SMA, PDBFRβ and NG2. In another study Ikenaga et al. using 
human pancreatic cancer specimen, CD10-positive subpopulation of PSCs were 
identified and patients with CD10-positive PSCs had significantly poorer survival141. 
These findings call for more investigations to identify, understand and characterize 
the functions of different subtypes of CAFs in pancreatic cancer in order to 
understand how to therapeutically intervene. 
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1.3.6 Epigenetic regulation of fibroblast activation 
 
Several factors activate qPSCs and resting fibroblasts into aPSCs and myofibroblasts 
respectively9,142. Fibroblast activation in the setting of a transient physiological tissue 
repair process or from an overwhelming/sustained abnormal tissue injury is 
characterized by increased proliferation, ECM deposition and α-SMA expression143. 
Emerging data indicate a reversible and irreversible fibroblast activation mechanism 
mediated in part by epigenetic processes55,143,144. Bechtel et al. demonstrated using 
in vivo and in vitro techniques that hypermethylation of RAS protein activator like 1 
(RASAL1), encoding an inhibitor of RAS oncoprotein, led to downregulation of RASAL1 
protein and activation of RAS in kidney fibrosis associated fibroblasts (FAF) but this 
was not the case in fibroblasts isolated form normal kidney or acute injury associated 
kidneys; RAS activation was associated with fibroblast activation143. Moreover, 
treatment of FAFs with the demethylating agaent 5-azacytidine, reduced 
proliferation, α-SMA expression and collagen I synthesis. Bechtel et al. furthermore, 
showed that TGFβ1, which is known to activate fibroblasts, caused the transcriptional 
silencing of Rasal1 mRNA in a time dependent manner via two distinct mechanisms; 
mechanism 1 – short term exposure of normal mouse fibroblasts with TGFβ1 led to a 
reversible suppression of Rasal1 without RASAL1 methylation and mechanism 2 – a 
long term exposure with TGFβ1 caused RASAL1 promoter methylation accompanied 
by irreversible transcriptional silencing143. Their findings suggest a role for 
methylation in FAFs in fibrotic kidney lesions and could also be a mechanism in CAFs 
from different cancer tissues including pancreatic cancer. Interestingly, RASAL1 
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hypermethylation has been reported in hepatic stellate cells in experimental liver 
fibrosis55.  
1.4 Predictive biomarkers in pancreatic cancer 
  
A biomarker, as defined by the National Institutes of Health Biomarkers Definitions 
Working Group “is a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention”145. An emerging area of research that could 
potentially improve outcome and overall survival in pancreatic cancer patients is 
predicting the likelihood of a patients response to chemotherapy based on putative 
biomarkers such as the levels of cellular defence and/or drug metabolising enzymes 
and genetic variations (germline or tumour biology)146.  
1.4.1 NADP(H):quinone oxidoreductase 1 
 
NADP(H):quinone oxidoreductase 1 (NQO1) is a protein that protects cells against 
oxidative stress and carcinogenesis (cytoprotective) and also functions to detoxify 
and bioactivate quinones or xenobiotics; NQO1 transcription is regulated by Nrf2 via 
ARE present its promoter147,148. NQO1 is a cytosolic enzyme that catalyses the two-
electron reduction of quinone compounds to less toxic hydroquinone, preventing the 
generation of semiquinones (1 electron reduction of quinone) free radicals, ROS and 
depletion of sulfhydryl groups thereby protecting cells against free radical ROS 
induced mutagenesis and carcinogens147,149. Quinones are abundant in nature and 
are considered to be cytotoxic because unstable quinone derivatives can undergo 
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rapid redox cycling by interacting with molecular oxygen to generate ROS; 
furthermore, quinones are electrophilic and dependent on their reactive states, can 
alkylate DNA149. Quinone based polycyclic aromatic hydrocarbons abound in burnt 
organic materials such as cigarette smoke, automobile exhaust and industrial air 
pollutants. Quinones naturally exist in foods and are used as chemical compounds in 
quinone based anticancer drugs149.  
In addition to its role in quinone reduction and in preventing ROS generation, NQO1 
directly scavenges superoxides150. NQO1 has been reported to play a role in p53 
stabilization. Asher et al.151 reported that NQO1 stabilized p53 by inhibiting the 
proteasomal degradation of p53 in human colon cancer cell line (HCT116). They 
demonstrated that treatment of HCT116 cells with NQO1 inhibitor dicumarol led to 
reduced levels of both endogenous and gamma-irradiation-induced p53. Similarly, in 
normal thymocytes and myeloid leukemic cells that overexpress wild-type p53, NQO1 
inhibition increased p53 degradation and caused a reduction in p53 dependent 
apoptosis. Conversely, this effect was rescued by proteasome inhibitors lactacystin 
and MG132151. Interestingly, transfection with wild type NQO1 but not C609T NQO1 
minor allele led to p53 stabilization152.  
Despite these reports, the modulation of p53 by NQO1 is still controversial153. A study 
by Zeekpudsa et al.153 reported that cholangiocarcinoma cells were more susceptible 
to chemotherapeutic agents (gemcitabine, 5-FU, and doxorubicin) when NQO1 was 
depleted from the cells, an effect that was accompanied by increase p53, p21 and 
Bax protein expression. Furthermore, the increased sensitivity of cholangiocarcinoma 
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cells to chemotherapy following NQO1 silencing was abrogated by p53 
knockdown153. This study suggests that NQO1 protects cholangiocarcinoma cells 
from chemotherapy and that NQO1 may not contribute to the stabilization of p53.  
Studies have been undertaken to investigate the effects of differential expression of 
NQO1 in the bioactivation of anticancer drugs. Siegel et al. and Siegel et al.154,155 have 
demonstrated that in colon cancer cells with high NQO1 expression compared with 
low protein expressing cells, the two electron bioreductive activation of quinone 
based anticancer drugs (diaziquone and mitomycin C) by NQO1 may be responsible 
for mitomycin C and diaziquone induced genotoxicity and cytotoxicity. Conversely, 
other researchers have reported a lack of correlation between NQO1 levels with 
sensitivity to mitomycin C156,157.  
NQO1 protein levels have been reported to be overexpressed in several cancers 
including pancreatic cancer158-160. In pancreatic cancer, both the cytoprotective and 
bioactivation properties of NQO1 are being investigated with regard to optimizing 
response to chemotherapy. A study by Cullen et al. 161 showed that NQO1 inhibition 
in MiaPaCa-2 cells with a selective NQO1 inhibitor dicumarol increased ROS and 
inhibited cell growth whereas in the presence of manganese superoxide dismutase, 
these effects were reversed. Taking advantage of the fact that NQO1 is overexpressed 
in pancreatic cancer several fold above normal tissue levels and that NQO1 can 
bioactivate quinone based anticancer drugs, strategies are being undertaken to 
exploit these tumour specific therapeutic potentials. β-Lapachone (3,4-dihydro-2,2-
dimethyl-2H-naphtho[1,2-b] pyan-5-6-dione) is a quinone based anticancer drug that 
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is activated by NQO1 in a 2 electron redox process leading to futile redox cycling and 
production of massive ROS effectively killing cancer cells overexpressing NQO1 while 
sparing normal cells that lack or have minimal levels of the enzyme148,162,163.  
Clinical trials in pancreatic cancer are currently underway to evaluate the 
combination of β-Lapachone (ARQ761) and chemotherapy (gemcitabine plus nab-
paclitaxel) in predicting response to treatment based on a cut off histo-score (H-
score) level of NQO1 in tumours163. The levels of NQO1 in tumours could potentially 
become an integral biomarker to inform patient stratification for treatment options. 
1.4.2 Single nucleotide polymorphisms  
 
The majority of the genetic variation in humans are due to single nucleotide 
polymorphisms (SNPs) which are defined as variation at a single nucleotide position 
in a DNA sequence which exists in at least 1 % of the population164,165. An estimated 
10 million SNPs exist in the human genome166 and most of the SNPs are synonymous 
(silent) but a small proportion of SNPs occurring in the coding or regulatory regions 
of genes may cause functional differences164.  
NQO1 has a characteristic SNP, C to T substitution at nucleotide position 609 (C609T, 
rs1800566) on exon 6 that results in a proline to serine amino acid change at codon 
187 (Pro187Ser)167,168. The homozygous TT genotype is essentially an inactive 
enzyme169 with a half-life of 1.2 h while the heterozygous CT has an intermediate 
activity in comparison with the homozygous CC genotype with a half-life of > 18 h170. 
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In breast cancer, NQO1 polymorphism has been shown to be predictive of response 
to treatment. In a study involving two independent cohort of women with breast 
cancer, the NQO1 minor allele TT was shown to be correlate with poor overall survival 
compared with CT, CC genotypes combined (p=0.0017, n=1,005; p=0.005, 
n=1,162)171. Furthermore, in patients who had received adjuvant anthracycline based 
chemotherapy with epirubicin, NQO1 TT genotype was independently predictive of 
poor overall survival (p=7.52 x 10 – 6, n=178; hazard ratio [HR]=6.55, 95% confidence 
interval [CI]=2.54-16.90)171. Similarly, in another study, the TT genotype was 
associated with a poorer outcome (overall survival p=0.003, progression free survival 
p=0.001) in breast cancer patients who had received chemotherapy172. In lung 
cancer, the TT genotype was associated with increased risk for development of non-
small cell lung cancer (NSCLC) (p=0.001) and poor response to chemotherapy 
(p=0.003)173. An European study was undertaken to investigate the risk of pancreatic 
cancer and functional antioxidant SNPs but no association between C609T rs1800566 
NQO1 SNP and the risk for pancreatic cancer development was found174.  
Single nucleotide polymorphisms of NRF2 and one of its downstream target 
sulfiredoxin (SRXN1) have been examined with relevance to breast cancer treatment. 
Peroxiredoxins are cytoprotective enzymes that function as scavengers of hydrogen 
peroxides175,176. Peroxiredoxins can become inactivated by hyperoxidation of their 
cysteine residues 176,177. SRXN1 is an antioxidant enzyme that reactivates 
peroxiredoxins from their hyperoxidative state177. SRXN1 is a downstream target of 
Nrf2 and activator protein 1 (AP-1) and have been reported to be overexpressed in 
various skin cancers178,179. NRF2 and SRXN1 SNPs were investigated in 452 breast 
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cancer patients and 370 controls180. The NRF2 SNP rs2886162 minor allele A was 
associated with low Nrf2 protein expression in tumour tissues (p=0.01) and in 
patients who had received adjuvant chemotherapy (n=79), the NRF2 rare 
homozygous AA genotype predicted poor survival compared to the more common 
GG and GA genotypes (p=0.019). This NRF2 minor allele was not associated with 
survival among patients who did not receive any adjuvant therapy. Similarly, the 
SRXN1 rs6116929 rare homozygous minor allele GG and rs2008022 rare alleles CA 
and AA were predictive of better outcome (p=0.01 and p=0.02 respectively). SRXN1 
rs6053666 common CC genotype was associated with better survival in patients who 
received radiotherapy (p=0.017).  
Studies in other cancers have shown that functional SNPs involving other antioxidant 
genes may be predictive of response to certain chemotherapeutic agents181-183. These 
SNPs could potentially become biological markers that will inform decision making 
on treatment options.  
1.4.3 Gemcitabine metabolizing enzymes 
 
Gemcitabine is a commonly used chemotherapeutic agent in pancreatic cancer 
treatment16 and enzymes metabolizing gemcitabine may modify response to 
treatment with gemcitabine in pancreatic cancer patients. Deoxycytidine kinase is 
responsible for phosphorylating and activating gemcitabine21. The tissue protein 
levels of deoxycytidine kinase was examined in 45 pancreatic cancer patients who 
had received adjuvant gemcitabine-based therapy following resection of their 
tumours184; deoxycytidine kinase expression score (intensity of staining and number 
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of cells  staining positive for deoxycytidine kinase) was dichotomized and patients 
with a low score demonstrated a strong and statistically significant correlation with 
disease-free and overall survival (p=0.001; HR=3.61, 95%CI 1.74 – 7.51 and p=0.0008; 
HR=3.44, 95% CI 1.66 – 7.44 respectively)184. 
1.4.4 DNA synthesis and repair enzymes  
 
Similarly, the expression levels of DNA repair and synthesis enzymes (excision repair 
cross complementary 1 [ERCC1] and ribonucleotide reductase subunit M1 [RRM1] 
respectively) were examined in a study involving 94 pancreatic cancer tissues from 
patients who had surgery for pancreatic cancer followed by adjuvant gemcitabine 
therapy for 87% of the cases; both enzymes (RRM1 and ERCC1) were not predictive 
of response to gemcitabine185. 
1.4.5 MicroRNAs 
 
MicroRNAs (miRNAs or miRs) are also gaining attention as potential markers to be 
investigated for predicting response to treatment in pancreatic cancer. Giovannetti 
et al.186 reported that miR-21 levels were approximately 1000-fold lower in normal 
pancreatic ductal epithelial cells (obtained from normal pancreas tissue organ donor 
program) compared to levels in tumour cells enriched by microdissection. In addition, 
in pancreatic cancer patients that received gemcitabine in both adjuvant (n=28) and 
metastatic setting (n=31) or in combined analysis (n=59), low miR-21 expression 
group was predictive of better survival than the high expression group186.   
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In a cohort of 82 South Korean patients who had undergone resection for pancreatic 
cancer, low miR-21 expression in tumour samples was predictive of better overall and 
disease-free survival in patients who subsequently had adjuvant chemotherapy 
[gemcitabine or 5-fluorouracil], combined chemoradiotherapy or both (n=52) 
whereas in patients who did not receive adjuvant therapy post-surgical resection 
(n=27), no association between miR-21 tumour tissue levels and outcome was 
found187. Similarly, in a validation cohort of 45 Italian pancreatic cancer cases who 
had adjuvant therapy (gemcitabine-based treatment), low miR-21 was associated 
with longer overall survival187.  
While no established biomarker(s) currently exists to predict pancreatic cancer 
patients’ response to treatment16, these studies put together, provide a role for the 
development and routine use of predictive biomarkers for current and future 
therapies.  
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1.5 Hypotheses 
 
1. UHRF1 contributes to oncogenesis in pancreatic cancer by regulating Keap1-    
Nrf2 pathway. 
2. That single nucleotide polymorphisms (SNPs) and proteins involving the Nrf2 and 
Nrf2 downstream target genes can predict survival in pancreatic cancer patients. 
1.6 Aims and objectives 
 
1. To investigate the functional effects of UHRF1 on Keap1-Nrf2 pathway in pancreatic 
cancer cells.  
a. Examine the effects of UHRF1 on Keap1-Nrf2 mRNA and protein expression, cell 
cycle regulation, oxidative stress response and chemosensitivity. 
2. To develop a method for analysis of KEAP1 promoter methylation in PDAC tissues. 
a. Quantify DNA isolated from laser microdissected PDAC tissues and determine the 
suitability of the isolated DNA for pyrosequencing analysis. 
3. To determine the functional effects of UHRF1 on Keap1-Nrf2 pathway from isolated 
mouse and human primary pancreatic stellate cells. 
a. Investigate the function of UHRF1 on oxidative stress response and cell 
proliferation and to examine the tissue stromal expression of UHRF1.                              
4. To investigate the predictive effect of UHRF1 protein and SNPs of NRF2, NQO1, and 
SRXN1 and their corresponding protein expression on overall survival in pancreatic 
cancer patients from retrospective randomised control clinical trials data. 
       a. Determine germline SNPs in patients with advanced PDAC. 
b. Quantify protein expression in PDAC tissue specimens from an independent 
cohort of patients who had surgical resection for locally resectable PDAC.     
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2 MATERIALS AND METHODS 
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2.1 Materials and Reagents 
 
All reagents were supplied by Sigma-Aldrich, UK or Thermo Fisher Scientific, UK 
unless otherwise stated. Details of the primary and secondary antibodies used for 
immunoblotting are detailed in Table 2.5. Pancreatic cell lines, MiaPaCa-2 and Panc1, 
were purchased from American Type Tissue Culture and Suit 2 cells from188. Mouse 
pancreatic cells from KPC mice were kindly isolated by Dr Michael Schmid, University 
of Liverpool.  
 
2.1.1 Sigma Aldrich 
The following were purchased from Sigma-Aldrich, UK with codes indicated in 
parentheses. RPMI medium (R0883, Sigma Aldrich), Penicillin/Streptomycin (P0781), 
L-glutamine (G7513), Dulbecco’s Modified Eagles Medium (DMEM, D6429), Iscove’s 
Modified Dulbecco’s Medium (IMDM, I3390), Dimethyl sulfoxide (DMSO, 276855), 
Mr Frosty (C1562-1EA), Diethyl maleate (DEM, D97703), Developer solution (P7042-
5GA), Fixer solution (P7167-5GA), Gemcitabine (Y0000675), RNAse A (R5125), Trypsin 
(T3924), HCl (320331), DPX mountant (06522), L-Ascorbic acid (A4403), 10% neutral 
buffered formalin (HT501128), Glycerol (G5516), Bromophenol blue (B5525), 
Dithiothreitol (DTT, D9779), Reference dye (R4526), SYBR green jumpstart ready mix 
(S4438) and Brustal (SML 1868). 
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2.1.2 Thermo Fisher Scientific 
The following were purchased from Thermo Fisher Scientific, UK with codes indicated 
in parentheses. Pierce bicinchoninic acid (BCA) assay (23225), Microplate reader 
(Multiskan FC), BCA protein standards (23208), SDS (BP1311-1), Protein ladder 
(26616), Glycine (BP381-5) and SDS (BP1311-1), NanoDrop spectrophotometer 
(NanoDrop 2000C), Quant-iT Broad-Range DNA assay kit (Q33130), Histological glass 
slides (1014356190), Xylene (X/0250/17), Oil Red O (15244664), T75 cell culture flask 
(10364131).  
 
2.2  Cell line maintenance 
 
2.2.1 Human pancreatic cancer cell lines 
 
The following pancreatic cancer cell lines, MiaPaCa-2, Panc-1 and Suit-2 were used in 
this study. Cell line characteristics are defined in Table 2.1. Cells were maintained in 
vented T75 cell culture flask containing RPMI medium, supplemented with 10% fetal 
bovine serum (FBS, 10500056, Life Technologies, UK) and 2 mM L-glutamine, and 
with 100 U/mL penicillin and 100 µg/mL streptomycin antibiotics. Cells were grown 
in a humidified 5 % CO2 incubator at 37oC and subcultured when approximately 80% 
confluent. Cells were genotyped prior to and during this thesis by amplifying isolated 
genomic DNA using the PowerPlex-16 HS system (Promega, USA) according to 
manufacturer’s protocol. Amplified fragments were analysed using Genetic Analyser 
(3130, Applied Biosystem, USA) and GeneMapper software (version 4.0, Applied 
Biosystem) as described previously99. 
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Table 2.1: Origin of established pancreatic cancer cell lines 189,190. 
Cell line Author and 
year 
Age 
(years) 
Sex Origin of 
tumour cells 
Common 
mutations 
Reference 
 
MiaPaCa-2 
 
Yunis et al.., 
1977 
 
65 
 
Male 
 
Primary 
tumour  
 
KRAS, TP53, 
p16INK4a, 
 
191 
 
Panc-1 
 
Lieber et al.., 
1975 
 
56 
 
Male 
 
Primary 
tumour  
 
KRAS, TP53, 
p16INK4a,  
 
192 
 
Suit-2 
 
Iwamura et 
al.., 1987 
 
73 
 
 
Male 
 
Liver 
metastasis 
 
KRAS, TP53, 
p16INK4a, 
188 
 
2.2.2 Primary mouse pancreatic cancer cells  
 
Primary mouse pancreatic cancer cells were isolated from tumours arising in K-RasLSL-
G12D/+, p53R172H/+ and Pdx1-Cre (KPC) mice see Table 2.2. Cells were maintained in 
humidified 5 % CO2 incubator at 37oC in Dulbecco’s Modified Eagles Medium (DMEM) 
supplemented with 10% FBS), 100 U/mL penicillin and 100 µg/mL streptomycin. 
Incubation and subculturing was as described earlier for human pancreatic cancer 
cell lines. Low passage KPC cells (<10) were used in this thesis. 
2.2.3 Pancreatic cancer associated primary fibroblast - R2875 
 
Primary pancreatic cancer associated primary (CAF) R2875 cells (Table 2.2) were 
isolated from the tumours of surgically resected pancreatic cancer patients by Dr 
Lawrence Barrera (University of Liverpool) as described previously122. Cells were 
maintained in humidified 5 % CO2 incubator at 37oC in Iscove’s Modified Dulbecco’s 
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Medium supplemented with 10% FBS, 4mM L-glutamine, 100 U/mL penicillin and 100 
µg/mL streptomycin. Incubation and subculturing was as described earlier for human 
pancreatic cancer cell lines. CAF and normal activated fibroblasts (NAF) primary cells 
with a low passage number (<10) were used in this thesis. 
 
Table 2.2: Origin of primary cells. 
Primary cells Isolated by Origin of cells References 
 
KPC  
(mouse cancer cell) 
 
 
Dr Michael 
Schmid 
 
GEMM of pancreatic 
cancer  
 
193 
 
CAF-R2875 
(pancreatic stellate 
cell) 
 
 
 
Dr Lawrence 
Barrera 
 
Human pancreatic 
cancer (stromal) 
tissue section 
 
CAF-R2910 
(pancreatic stellate 
cell) 
 
 
Dr Lawrence 
Barrera 
 
Human pancreatic 
cancer (stromal) 
tissue section 
 
NAF-R2797 
(pancreatic stellate 
cell) 
 
 
Dr Lawrence 
Barrera 
 
Adjacent normal 
human pancreatic 
cancer (stromal) 
tissue section 
 
NAF-R2796 
(pancreatic stellate 
cell) 
 
 
Dr Lawrence 
Barrera 
 
Adjacent normal 
human pancreatic 
cancer (stromal) 
tissue section 
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2.3 Cell counting 
 
Cell numbers were determined by using counting slides (145-0011, Bio-Rad, UK) and 
an automated cell counter (TC10, Bio-Rad) according to manufacturers’ instruction. 
Cells were uniformly resuspended in media and 10 µL of suspended cells were 
transferred to a counting slide chamber and then inserted into the automated cell 
counter. An average of 2 cell counts was used to determine cell numbers in 
subsequent experiments. 
2.4 Freezing of cell stocks 
 
Generally, 1mL of freezing media (70% RPMI, 20% FBS and 10% dimethyl sulfoxide 
containing approximately 2 x 106 pancreatic cancer cells uniformly resuspended were 
transferred to a 1.8mL screw caped cryovial (E3090-6222, Starlab, UK). The cryovials 
were subsequently transferred to a Mr Frosty and stored at -80oC for 24 hours and 
then transferred to liquid nitrogen storage tank.  
2.5 Culturing cells from frozen stocks 
 
Generally, frozen cells in cryovials were rapidly thawed in a 37oC water bath and 
transferred to a fresh warm 5mL RPMI medium for centrifugation in 15mL Falcon 
tubes (188271, Greiner Bio-One, Austria). Centrifugation was performed at 100 x g 
for 5 minutes and the supernatant obtained was discarded and the pellets were then 
resuspended in an appropriate volume of warm media and subsequently transferred 
to a vented T75 flask for culturing as described in section 2.2.1.  
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The same process of freezing (Section 2.2.3) and culturing as described above, applies 
to both KPC and CAF-2875 cells. However, for KPC and CAF-2875, DMEM was used in 
place of RPMI and for CAF-2875, the freezing medium was (75% DMEM, 20% FBS and 
5% DMSO). 
2.6 siRNA transfection 
 
2.6.1 siRNA stock preparation 
 
All siRNA were supplied lyophilized and then reconstituted in a class II biological 
safety cabinet with distilled water (B-003000-WB-100, Dharmacon, USA) and 5x 
siRNA buffer (B-002000-UB-100, Dharmacon, USA). 1x siRNA buffer was used to 
reconstitute lyophilized siRNAs to a final concentration of 20µM according to 
manufacturer’s instructions. Reconstituted siRNAs were aliquoted and stored at -
20oC until needed. 
2.6.2 Optimization of siRNA transfection for UHRF1 Knockdown 
 
All siRNAs used in this thesis were supplied by Dharmacon, USA. Optimum siRNA 
concentration and volume of lipofectamine 2000 (11668-500, Life Technologies)/well 
of a 6-well plate was determined using Suit-2 pancreatic cell line. A final siRNA 
concentration of 10 nM and 2 µL lipofectamine/well of a 6-well plate in a final volume 
of 3 mL was determined to be the optimum and used hereafter for subsequent 
transfections. 
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2.6.3 siRNA transfection 
Cells were plated in 6 well plates at seeding densities listed in Table 2.3 and placed 
for 24 hours in an incubator at 37oC with 5% CO2. After 24 hours media was removed 
and replaced with antibiotic free media to a final volume of 2.6 mLs. Two hundred 
microliters (200 µL) of Opti-MEM I 1x, (11058-021, Life Technologies), was incubated 
with 2µL of Lipofectamine 2000 for 5 minutes before combining with 200µL of Opti-
MEM I containing the required concentration of target siRNA Table 2.4 and 
incubating for a further 30 minutes. Four hundred microliters (400 µL) of combined 
solution was added to each well in a drop-wise fashion and placed in the incubator 
for 72 hours. Cells were then harvested and prepared as required for subsequent 
experiments. At least 2 control or targeting siRNAs are required to control for off 
target effects. In this thesis however, the siRNAs used have been previously validated 
for off target effects and specificity80, and except otherwise stated, single targeting 
siRNAs where used for each experiment. 
For experiments involving 96-well plates seeding densities and transfection reagents 
were scaled down accordingly to a final volume of 100µl and concentration used 
previously in 6 well experiments (see Table 2.3 and Table 2.4). 
Table 2.3: Seeding densities used for siRNA experiments. 
Cell line Seeding density (per 
6 well plate) 
Seeding density (per 96 well plate) 
72hr treatment 120hr treatment 
Suit-2 3 x 104 1.0 x 103 0.5 x 103 
MiaPaCa-2 5 x 104 1.5 x 103 1.0 x 103 
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Table 2.4: siRNAs used throughout this thesis including catalogue number and concentration used. 
 
Target Groups siRNA Catalogue No. Final 
Concentration 
Human UHRF1 targeting siRNA-3 D-006977-03 10nM 
Human UHRF1 targeting siRNA 
SMARTpool  
M-006977-01 10nM 
Human anti-Nrf2 siRNAs Human Nrf2 targeting siRNA-4 D-003755-04 10nM 
Human anti-Keap1 
siRNA 
Human Keap1 targeting siRNA-4 D-012453-04 10nM 
Human anti-NQO1 
siRNA 
Human NQO1 targeting siRNA 
SMARTpool 
M-005133-02 10nM 
Human anti-Srxn1 siRNA Human Srxn1 targeting siRNA 
SMARTpool 
M-015263-00 10nM 
Mouse targeting siRNA Mouse UHRF1 targeting siRNA 
SMARTpool 
D-055507-03 10nM 
ON-TARGETplus Non-targeting 
siRNA-1 
D-001810-01 10nM 
ON-TARGETplus Non-targeting 
siRNA-3 
D-001810-03 10nM 
ON-TARGETplus Non-targeting pool D-001810-10 10nM 
RISC-free siRNA D-001220-01 10nM 
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2.7 Harvesting cells 
 
Media was discarded from wells and cells were rinsed with phosphate buffered saline 
(PBS: 0.01M Phosphate buffer, 0.027M KCl, 0.137M NaCl, 20012019, Life 
Technologies). Cells were then detached with 1x trypsin-EDTA, suspended in PBS and 
transferred to 15mL Falcon tubes. Cells were centrifuged at 100 x g for 5 minutes and 
the supernatant discarded from the cell pellet. Forty microliters (40 µL) of ice-cold 
radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl, 0.1 % (v/v) Triton X-
100, 0.5 % (w/v) sodium deoxycholate, 0.1% (v/v) SDS, 50 mM Tris-HCl, pH 8.0) 
containing freshly added protease inhibitor cocktail tablet (11836170001, Roche, 
USA) was added to the cell pellet and stored at -20oC.  
 
2.8 Western blot analysis 
 
2.8.1 Preparation of protein lysate 
 
Cell pellets were lysed in RIPA buffer using a sonicator (Branson digital sonifier 250, 
Branson Ultrasonics, Shanghai, China) for 4 seconds. Protein lysate was then 
centrifuged at 10,000 x g for 10 minutes at 4oC. Protein lysates were quantified using 
a bichinchonic acid assay and stored at -20oC for short term (< 1 month) or long term 
at -80oC. 
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2.8.2 Protein quantification 
 
Pierce bicinchoninic acid (BCA) assay (23225, Thermo Scientific, Rockford, USA) was 
used to quantify the total protein concentration in each lysate according to 
manufacturer’s instruction. Briefly, a 1:10 dilution of sample lysate was prepared to 
a final volume of 25 µL and 200 µL of BCA assay working solution was added in 96-
well plates. Plates were incubated at 37oC for 30 minutes. Protein concentration was 
determined using a Multiskan FC microplate reader by measuring the absorbance at 
562 nm; comparison with standard curve from known protein standards was made 
to calculate the concentration in each sample. 
2.8.3 Protein sample preparation for SDS-PAGE 
 
A 20 µg protein lysate was diluted 4:1 with 5x loading buffer (10 % (v/v) SDS, glycerol 
50 % (v/v), 300 mM Tris-HCl pH 6.8, 0.05 % (w/v) bromophenol blue and 0.5 M 
dithiothreitol (DTT). Samples were vortexed, centrifuged briefly and denatured at 
92oC for 10 minutes. 
2.8.4 Gel electrophoresis and protein transfer 
 
Equal volumes of denatured protein containing 20 µg of protein/sample and 3 µL of 
protein standard were separated by SDS polyacrylamide gel electrophoresis (SDS-
PAGE). Samples were loaded into an Any KD Mini-PROTEAN TGX precast gel (456-
9034, Bio-Rad) and separated at an initial constant voltage of 100 volts for 10 minutes 
then at 200 volts for 25 minutes in an SDS-PAGE running buffer (0.025 M Tris base 
(648311, Calbiochem, USA), 0.192 M glycine and 0.1 % (w/v) SDS). The resolved 
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proteins on the precast gels were transferred onto polyvinylidene difluoride (PVDF) 
membrane (170-4156, Bio-Rad) using a semi-dry electroblotting system (Trans-Blot 
Turbo Transfer System, Bio-Rad); transfer was undertaken using the turbo blot 
programme and mixed molecular weight setting at 25 volts for 7 min.  
 
2.8.5 Blocking and protein detection 
 
For all western blotting experiments undertaken during this thesis, 5 % non-fat dry 
milk (170-6404, Bio-Rad) in PBS + 0.1 % Tween 20 (PBST) was used for both blocking 
and primary and secondary antibody dilutions. Successful transfer of proteins onto 
PVDF membrane was followed by blocking at room temperature on an oscillator. 
After 1 hour of blocking, the 5 % milk was discarded and membranes were probed 
with appropriate primary antibody (Table 2.5) overnight at 4oC on an oscillator. Next, 
the membranes were washed with PBST 3 x 5 min washes and probed with 
appropriate horseradish peroxidase (HRP) conjugated secondary antibody (Table 2.5) 
for 1 hour at room temperature and then washed with PBST 3 x 5 min washes. Protein 
bands were visualized with enhanced chemiluminescence reagent (ECL, 
NEL105001EA PerkinElmer, USA) and signals were either detected on light sensitive 
radiographic film (47410 19289, Fuji Medical X-Ray Film, Japan) in a dark room using 
a developer and fixer or in a ChemiDoc imaging system (1708371, Bio-Rad) according 
to manufacturer’s guidelines. 
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Table 2.5: Primary and secondary antibodies used for immunoblotting, immunocytochemistry and 
immunohistochemistry. The dilutions for IHC and ICC are shown in bold. 
 
Antibody Molecular 
weight 
Dilution for 
immunoblotting 
Catalogue number and 
Supplier 
UHRF1 90 kDa 1:1000 
 
(1:100 for IHC) 
 
(1:250 for ICC) 
 
sc-136264, Santa Cruz 
UHRF1 90 kDa 1:1000  sc-98817, Santa Cruz ( KPC - 
mouse only) 
Keap1 69 kDa 1:1000 sc-15246, Santa Cruz 
Nrf2 68/100 kDa 1:1000 ab62352, Abcam 
NQO1 31 kDa 1:1000 
 
(1:20,000 for IHC) 
(1:500 for ICC) 
 
MA1-16672, Thermo Scientific 
Srxn1 13 kDa 1:1000 sc-373829, Santa Cruz 
α-SMA 42 kDa 1:500 
 
(1:50 for IHC) 
 
ab-7817, Abcam 
GAPDH 38 kDa 1:1000 sc-25778, Santa Cruz 
β-actin 42 kDa 1:20,000 A5441, Sigma-Aldrich 
Anti-mouse HRP  1:2000 P0447, Dako 
Anti-rabbit HRP  1:2000 P0448, Dako 
Anti-goat HRP  1:2000 P0449, Dako 
Mouse Ig G2a 
isotype control 
  
1:100 for IHC 
sc-3878, Santa Cruz 
Mouse Ig G1 
isotype control 
  
1:20,000 for IHC 
X0931, Dako 
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2.9 Cell viability and proliferation assay 
 
Cells were seeded (Table 2.3) and transfected in 96-well (655180, Greiner Bio-One) 
plates as described earlier (Section 2.6.3). Cells were transfected with control, UHRF1 
and Nrf2 siRNA (10nM each). Proliferation was determined either at 72 h or 96 h by 
MTS EZ4U kit (BI-5000, Biomedica, Vienna, Austria) as described in Tonack et al., 
2011.194. Briefly, at indicated time points, media in cells were replaced with 100 µL of 
fresh medium containing substrate (SUB) and activator (ACT) solution (1:10) and 
absorbance was measured hourly for 4 hrs using Multiskan EX plate reader (Thermo 
Scientific) at 450nm and then at 650nm to adjust for background.  
2.10 Cytotoxicity test 
 
Cells were seeded (Table 2.3) in 96-well plates and treated for a total of 120 hours. 
In the first 48 hours, cells were transfected with either 10nM control or UHRF1 siRNA 
as described earlier (Section 2.6.3). Media was then replaced with fresh antibiotic 
free media containing varying concentrations of gemcitabine ranging from 0.1 µM to 
100 µM for a further 72 hours. Proliferation was determined as described earlier 
(Section 2.9) and sigmoidal dose response curves constructed using GraphPad Prism 
version 5.00 for Windows, GraphPad Software, San Diego California USA. 
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2.11 Cell cycle analysis 
 
MiaPaCa-2 and Suit-2 cells were seeded at 5 x 104 and 3 x 104 cells/well respectively 
in 6-well plates. Cells were transfected with 10 nM siRNA (control, Nrf2, UHRF1 and 
Keap1) as described earlier (Section 2.6.3). After 72 h, cells were harvested, washed 
in PBS and centrifuged at 130 x g for 5 min. The resulting cell pellet was suspended in 
50 µL of PBS and then fixed in 1 mL ice-cold 70 % ethanol added drop-wise with cells 
continuously agitated during ethanol addition. Cells were incubated at 4oC for 24 h 
and then pelleted at 130 x g for 5 min. Cells were then washed twice in PBS and 
centrifuged as before. Pelleted cells were resuspended in 25 µL of RNAse A and 
incubated at 37oC. After 15 min, 300 µL of 2 µg/mL of propidium iodide (PI, P3566, 
Invitrogen, USA) solution was added to RNAse A-cell pellet mix and incubated at room 
temperature for 15 min in the dark. Cells were then subjected to flow cytometry 
analysis using BD FACS Canto II (BD Biosciences, USA). PI solution (PI in PBS+ 0.1 % 
Triton X-100) was prepared fresh for each experiment.  
 
2.12 Analysis of oxidative stress 
 
2.12.1 Reactive oxygen species assay 
 
Measurement of reactive oxygen species generation was determined by incubating 
cells with 2’,7’-dichlorodihydroflourescein diacetate (H2DCFDA - D399, Life 
Technologies, UK). Briefly, after seeding and transfecting cells (10 nM control, Nrf2, 
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UHRF1, Keap1 siRNAs) as described earlier (Section 2.6.3) for 72 hours in 6-well 
plates, media was discarded and cells were rinsed with PBS. Cells were then detached 
by adding trypsin which was subsequently quenched by adding fresh culture media 
(trypsin: culture media, 1:4). Detached cells were centrifuged at 130 x g for 5 minutes 
and the supernatant was discarded. The resulting cell pellets were resuspended in 5 
µM H2DCFDA working solution (5 µM H2DCFDA final concentration in pre-warmed 
PBS) and incubated for 30 minutes at 37oC with intermittent agitation. Next, cells 
were centrifuged at 130 x g for 5 minutes and the H2DCFDA working solution 
supernatant was discarded. The cell pellet obtained was washed with fresh pre-
warmed PBS, centrifuged at 130 x g for 5 minutes and the supernatant discarded. The 
cell pellet was finally suspended in 500 µL of fresh pre-warmed PBS and subjected to 
flow cytometry (BD LSRFortessa) for ROS detection using laser excitation at 488 nm 
(495 nm) and detection at 535 nm (525 nm). Data was analysed with FlowJo v 10.0.8. 
2.12.2 Glutathione assay 
 
MiaPaCa-2 cells were seeded at a density of 5 x 104 cells/well in 6-well plates. 
Transfection (Control, Nrf2 and UHRF1 siRNA) was undertaken as described earlier in 
section 2.6.3 for 72 h. Diethyl maleate (DEM) at 1 mM final concentration in RPMI 
was added to one set of control siRNA treated wells for 1 h. Cells were lysed in 350 
µL of 10mM HCl and 70 µL lysate was transferred to a 0.5 mL microcentrifuge (S1605-
0000, Starlab, UK) for Bradford assay and the rest to a separate 0.5 mL 
microcentrifuge for glutathione (GSH) assay. Lysates were stored immediately at -
80oC and both assays were performed the following day. Dr Adedamola Olayanju, 
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(University of Liverpool, UK) assisted by performing both Bradford and GSH assays. 
Total sample GSH content was quantified using 5,5’-dithiobis-2-nitrobenzoic acid-
GSH reductase recycling method as previously described195. Sample GSH 
concentrations were calculated with reference to a standard GSH curve and further 
normalised to total protein content using Bradford assay.  
 
2.13 Dual-Glo Luciferase assay 
 
The conditions for transfecting firefly and renilla luciferase plasmids were optimized 
by varying the concentrations of firefly and renilla plasmids and the ratio of firefly to 
renilla plasmids. A plasmid DNA to lipofectamine 2000 of 1 µg DNA : 2 µL of 
lipofectamine ratio was used. For all reporter transfections, pGL4.74 renilla luciferase 
reporter was used as an internal control. pGL4.11 firefly luciferase reporter plasmid 
containing eight antioxidant response elements (8xAREs), was a kind gift from Dr Jo 
Walsh and Professor Chris Goldring (University of Liverpool, UK). 
1 x 103 MiaPaca-2 and Suit-2 cells/well were each seeded into white 96-well plates 
(655083, Greiner Bio-One) and transfected with 10 nM control, UHRF1 and Nrf2 
siRNA as described earlier (Section 2.6.3) for 48 h at 37oC in humidified 5% CO2. Media 
was replaced and cells were transfected with pGL4.11 firefly luciferase reporter 
plasmid (Promega) containing 8xAREs as described previously 196 in a final 
concentration of 150 ng/100 µL/well and pGL4.74 renilla luciferase reporter plasmid 
(E6921, Promega) both in a final volume of 100 µL/well for 24 h. A ratio of 100:1 for 
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firefly : renilla plasmid was used in this thesis for both MiaPaCa-2 and Suit-2 cells. 
Luciferase activity was measured 24 h later using Dual-Glo luciferase assay system 
(E2920, Promega) according to manufacturer’s instructions. Briefly, following firefly 
and renilla plasmids transfection, media was replaced with 50 µL of serum free RPMI 
and an equal volume of Dual-Glo luciferase reagent was added and mixed on a shaker 
(400 rpm) for 15-20 min. Firefly luminescence was then quantified using a 
luminometer (Modulus microplate reader, Turner BioSystems, USA). Dual-Glo Stop 
and Glo reagent 50 µL/well was next added and mixed on a shaker (400 rpm) for 15-
20 min and renilla luminescence was measured using the same luminometer.  
2.14 Culturing cancer associated fibroblast with conditioned media from cancer 
cells 
 
Cancer associated fibroblasts R2875 were seeded at 20,000 cells/well in a 24-well 
plate (662160, Greiner Bio-One) for at least 72h in IMDM as described earlier (Section 
2.2.3) before culturing in conditioned media from MiaPaCa-2 cells. MiaPaCa-2 cells 
were grown in a vented T75 flask and at 80 % confluence, the media was discarded 
and cells were rinsed twice in warm PBS before further culturing in serum free RPMI 
media. After 36 h, conditioned media was harvested and centrifuged at 300 x g for 
10 min and the supernatant obtained was filtered through 0.22 µm sterile filter 
(SLGP033RS, Merck Millipore, Ireland). The filtrate was then used to culture and 
transfect CAF-2875 with pGL4.11 firefly luciferase reporter plasmid in a final 
concentration of 60 ng/100 µL and a final volume of 1200 µL/well of a 24 well plate 
with pGL4.74 renilla luciferase reporter plasmid as described in section 2.13 for 
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MiaPaCa-2 and Suit-2 plasmid transfection. A ratio of 10:1 for firefly to renilla was 
used in this thesis for CAF-2875. After 36 h, Dual-Glo Luciferase assay was performed. 
Briefly, media was discarded from the 24-well plate and 75 µL of serum free RPMI 
and an equal volume of Dual-Glo luciferase reagent was added and mixed on a shaker 
(400 rpm) for 15-20 min. The contents of each well were then transferred into a 0.5 
mL microcentrifuge and centrifuged at 10, 000 x g for 5 min. Next, 100 µL of the 
supernatant was carefully pipetted into each well of a white 96-well plates and 
subsequent steps were as described above for MiaPaCa-2 and Suit-2 Dual-Glo 
luciferase assay. 
 
2.15 RNA isolation 
 
Total RNA was isolated from cultured cells using RNeasy kit (74104, Qiagen, UK) 
according to manufacturer’s instructions and as described previously80. Briefly, cells 
were harvested using cell scrapper (541 070, Greiner Bio-One) and transferred into 
1.5 µL microcentrifuge tubes (S1615-5500, Starlab, UK). Cells were pelleted at 300 x 
g for 5 min and then disrupted with 350 µL of buffer RLT by repeated pipetting. 
Disrupted cells were then centrifuged at 10,000 x g for 3 min and 350 µL of 70 % 
ethanol was added to the homogenized lysate and mixed by repeated pipetting. The 
entire 700 µL sample lysate were transferred to an RNeasy spin column placed in a 2 
mL collection tube and centrifuged for 15 sec at 10,000 x g. The spin column was 
placed in a clean empty 2 mL collection tube and 350 µL of buffer RW1 was added 
and centrifuged for 15 sec at 10,000 x g. DNase I incubation mix (cat. no. 79254), was 
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added directly to the spin column membrane, incubated at room temperature for 15 
min and washed twice with 500 µL of buffer RPE at 10,000 x g for 15 sec and 2 min 
respectively. With the spin column empty and a new 2 mL collection tube, another 
centrifugation at 10,000 x g for 1 min was performed. The spin column was then 
transferred to a new 1.5 mL microcentrifuge tube and 40 µL of RNase free water was 
added directly to the spin column, incubated for 1 min at room temperature and 
eluted at 10,000 x g for 1 min. The quantity and quality of eluted DNA was determined 
by NanoDrop spectrophotometer (ND-1000, NanoDrop Technology, Wilmington, 
USA) and stored at -80oC.  
2.16 cDNA synthesis 
 
cDNA was synthesized from RNA using ImProm-II reverse transcription system 
(A3800, Promega) according to manufacturer’s instructions and as described 
previously80. Approximately 2 µg of RNA + 1 µL of random primers scaled up to a final 
volume of 20 µL with dH2O was reverse transcribed by incubating for 5 min at 70oC 
followed by rapid cooling on ice. Reverse transcriptase master mix, 20 µL (8 µL of 
ImProm-II 5 x reaction buffer, 6.4 µL 25 mM MgCl2, 1 µL 0.5 mM dNTP mix and 2 µL 
ImProm-II reverse transcriptase and 2.6 µL of PCR water) was added to each sample, 
briefly mixed and incubated under the following thermal cycling conditions: 25oC for 
5 min, 42oC for 1 h and 70oC for 15 min. Samples without random primers, dNTPs and 
reverse transcriptase were used as controls. The quantity and quality of synthesized 
cDNA was determined by NanoDrop spectrophotometer and then stored at -80oC. 
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2.17 Quantitative real-time PCR  
 
Quantitative real-time PCR (qRT-PCR) was performed for UHRF1, NRF2, KEAP1 and 
housekeeping gene GAPDH using SYBR green jumpstart ready mix according to 
manufacturer’s instructions. Primers (Table 2.6) were designed using Primer Express 
Software (Applied Biosystem, UK) and synthesized by Eurofins Genomics, Ebersberg, 
Germany. Briefly, qRT-PCR was performed in a white 96-well PCR plate (I1402-9909-
BC, STARLAB, UK) in a final volume of 20 µL/reaction. Twenty nanogram of 
cDNA/reaction was mixed with 2x SYBR green jumpstart ready mix, forward and 
reverse primers (each primer 400 nM/reaction final concentration) and reference dye 
0.4 µL/reaction, see Table 2.7. Samples without cDNA were used as no-template 
negative control. PCR was performed using Light Cycler machine (ABI PRISM, 7000 
sequence detection system, Applied Biosystem) under the following thermal cycling 
parameters: Reactions were denatured initially at 95oC for 10 min, then cycled at 95oC 
for 15 sec and annealing/extension at 60oC for 1 min for 40 cycles. mRNA 
quantification was analysed using ABI PRISM 7000 SDS software SYBR green template 
mode and fold change was calculated by Δ (ΔCT) method. Experiments were 
performed in triplicate (biological and technical) and normalized to GAPDH.  
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Table 2.6: Primer sequences used for qRT-PCR  
  Gene Primer sequence 
Forward 5’- ATG CTC AAC TAC AAC CCC GA - 3’ 
Reverse 5’- CTC TTC CGT CTC ATG GGG TT - 3’ 
Forward 5’- AAA CCA GTG GAT CTG CCA AC - 3’ 
Reverse 5’- GAC CGG GAA TAT CAG GAA CA - 3’ 
Forward 5’- CAG ATT GGC TGT GTG GAG TT - 3’ 
Reverse 5’- GCT GTT CGC AGT CGT ACT TG - 3’ 
Forward 5’- GGC CTC CAA GGA GTA AGA CC - 3’ 
Reverse 5’- AGG GGT CTA CAT GGC AAC TG - 3’ 
 
Table 2.7: Reagents for SYBR Green JumpStart ready mix 
Reagent Volume (µL) 
2x SYBR Green JumpStart ready mix 10 
Forward primer 0.8 
(400 nM final concentration) 
Reverse primer 0.8 
(400 nM final concentration) 
Water 4 
Reference dye 0.4 
cDNA template 4 (20 ng/reaction) 
Total 20 
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2.18 Method development for investigating DNA methylation in pancreatic 
cancer tissues 
 
Dylan Williams kindly assisted with the following experiments. DNA methylation 
analysis including CT conversion, PCR amplification and pyrosequencing is as 
described previously197. 
2.18.1 Laser capture microdissection  
 
Five formalin-fixed and paraffin embedded (FFPE) pancreatic cancer tumour blocks 
were selected by a specialist pancreas histopathologist, Professor Fiona Campbell. 
Five sections, 10 µm thick from each block were cut onto microdissection frame slides 
(11505151, PET-Membrane, Leica), incubated at 40oC overnight and hematoxylin and 
eosin (H & E) staining was then performed. The protocol for H & E is as described 
below in section 2.20 with the immersion time in haematoxylin restricted to 30 sec 
only and no requirement for cover slips. Pancreatic cancer cells and adjacent stromal 
cells were separately laser captured using Leica LMD7000 (Leica Microsystems).  
2.18.2 Isolation of genomic DNA from pancreatic cancer tissues 
 
DNA was isolated using the QIAamp DNA FFPE Tissue kit (56404, Qiagen). The 
manufacturer’s protocol was varied as part of the optimization (varying reagent 
volume, incubation time, temperature and excluding or including initial treatment 
with xylene). The following 3 protocols were used:  
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Protocol I: adhering to manufacturer’s protocol. Briefly, 180 µL of buffer ATL plus 20 
µL of proteinase K, were added to sample pellet in 1.5 mL microcentrifuge tubes and 
agitated briefly. Samples were incubated for 1 h each at 56oC and 90oC. RNAse A, 2 
µL was added to each sample and incubated for 2 min at room temperature followed 
by the addition of 200 µL of buffer AL and then 200 µL of 100 % ethanol with agitation 
between additions. Entire lysates were transferred into QIAamp MinElute columns in 
2 mL collection tubes. Columns were centrifuged at 6000 x g for 1 min and filtrate 
was discarded. The columns were washed twice sequentially with 500 µL of buffer 
AW1 and AW2 by centrifugation at 6000 x g for 1 min each. The columns were then 
centrifuged dry at 17,000 x g for 3 min and transferred to a new 1.5 mL 
microcentrifuge tube followed by the addition of 30 µL of elution buffer ATE to the 
center of the membrane and incubation at room temperature. After 1 min of 
incubation samples were eluted at 17,000 x g for 1 min.  
To improve DNA yield, protocol II was developed. Briefly, the initial incubation at 56oC 
lasted 24 h in contrast to 1 h for protocol I and the second incubation was set at 70oC 
in contrast to 90oC for protocol I. Proteinase K, 20 µL (not used at this step in protocol 
I) was added to 200 µL of buffer AL. Ethanol (100 %), 230 µL rather than 200 µL was 
used at this step. Centrifugation was performed at 2000 x g for 4 min rather than at 
6000 x g for 1 min and 700 µL of buffer AW1 and AW2 were used instead with an 
additional wash with 700 µL of buffer AW2 by centrifugation at 6000 x g for 1 min 
each. Columns were transferred to a new 1.5 mL microcentrifuge tube and incubated 
with 30 µL of elution buffer ATE for 30 min in comparison to protocol I and 
centrifugation performed at 17,000 x g for 3 min rather than 1 min. 
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Protocol III, was an alteration of protocol II. Protocol III required the agitation of laser 
dissected tissues in xylene briefly, followed by centrifugation to obtain a pellet and 
subsequent washing with 100 % ethanol. After washing with ethanol, samples were 
pelleted and subsequent steps were the same as for protocol II. 
After elution in buffer ATE, DNA quality and quantity was determined with NanoDrop 
2000 and Quant-iT Broad-Range DNA assay kit (Q33130, Thermo Scientific) and 
samples were stored at -20oC. Dr Michael Davies, University of Liverpool kindly 
performed the broad range assay. 
2.18.3 CT conversion  
 
Bisulfite conversion (CT conversion) was performed on extracted genomic DNA using 
EZ DNA Methylation-Gold kit (5005, Zymo Research) according to manufacturer’s 
instructions. Briefly, 130 µL of CT conversion reagent was added to 20 µL of DNA 
sample in a PCR tube, agitated briefly and incubated using the following thermal 
cycling steps: 98oC for 10 min, 64oC for 2.5 h and at 4oC for 30 min x 1 cycle. A mixture 
of M-Binding buffer and 1 µL of 500 ng/µL of tRNA was prepared in a 1.5 mL and 
bisulfite treated DNA was added and agitated. The entire mixture was next 
transferred to Zymo-spin IC column in collection tubes. Columns were centrifuged at 
10,000 x g for 30 sec and the filtrate discarded followed by a column wash with 500 
µL M-Wash buffer with centrifugation at 10, 000 x g for 30 sec. To each column 200 
µl of M-Desulphonation buffer was added and incubated at room temperature. After 
20 min samples were centrifuged at 10,000 x g for 30 sec followed by 2 washing steps 
with 500 µL and 200 µL of M-Wash buffer with centrifugation at 10,000 x g for 30 sec 
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and 4 min respectively. Columns were transferred to a new 1.5 mL microcentrifuge 
tube and 10 µL of M-Elution buffer was added directly to column matrix, incubated 
for 2 min at room temperature and centrifuged at 10,000 x g for 1 min. 
Eluted/bisulfite treated DNA was stored at -20oC and used for downstream analysis 
the next day.  
2.18.4 KEAP1 pyrosequencing primer design 
 
KEAP1 primers Table 2.8 were designed by Pyromark  Assay Design Software, 
Qiagen and synthesized by Eurofins Genomics, Ebersberg, Germany.  
 
Table 2.8: PCR amplification and pyrosequencing primer sequences 
 
Region Primer Primer sequence 5’-> 3’ Size 
(bp) 
CpGs 
Forward BIO-AAAGGAGAATAGTAGATGGTGG 
Reverse CCCCTTCTCACTATCCCT 
Pyrosequencing TTCTCACTATCCCTTCC 
Forward GGGTAGGTTATTATGATTAAGTAGA 
Reverse BIO-CTCCTAAAACCAAAACCC 
Pyrosequencing ATTATGATTAAGTAGAGT 
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2.18.5 PCR amplifications 
 
PCR was performed using PyroMark PCR kit (978703, Qiagen) according to 
manufacturer’s instructions. PCR optimization was performed with bisulfite treated 
lymphocyte DNA. Briefly, a 1:2 (final concentration of 3.75 µM:7.5 µM) mixture of 
biotin-tagged to non-tagged primer mix each for KEAP1a and KEAP1b primers were 
prepared. A total volume of 20 µL/PCR reaction was prepared, Table 2.9 + 1 µL (10ng) 
of bisulfite treated lymphocyte DNA or no-template negative control.  
 
Table 2.9: Reagents for PCR PyroMark kit optimization 
COMPONENT Volume (µL) 
PCR grade water 5.6 
Pyromark Master mix, 2x 10 
25 Mm MgCl2 0.4 
CoralLoad Concentrate, 10x 2 
Biotin-tagged to non-tagged primer mix (1:2) 1 
Total 19 
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Thermal cycling parameters were set at an initial denaturation of 95oC for 15 min, 
then at 94oC for 30 sec, annealing at 51oC to 56oC for 30 sec, extension at 72oC for 30 
sec and final extension for 10 min at 72oC for 45 cycles. Annealing at 6 temperature 
points (51oC to 56oC) as stated above, was performed for each biotin-tagged/non-
tagged primer mix. After optimization of PCR amplification with bisulfite treated 
lymphocyte DNA, subsequent PCR was performed using bisulfite treated tumour and 
stromal DNA. A total volume of 30 µL/PCR reaction was prepared (see Table 2.10) + 
4 µL of bisulfite treated tumour or stromal DNA or no-template negative control. 
 
Table 2.10: Reagents for PCR PyroMark kit final optimised reaction 
COMPONENT Volume (µL) 
PCR grade water 6.2 
Pyromark Master mix, 2x 15 
25 Mm MgCl2 0.6 
CoralLoad Concentrate, 10x 3 
Biotin-tagged to non-tagged primer mix (1:2) 1.2 
Total 26 
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Thermal cycling parameters were as described for bisulfite treated lymphocyte DNA 
with the annealing temperature set at 51oC. The quality and quantity of PCR products 
were determined by resolving 4 µL of amplicons in a mixture of 2 % (w/v) agarose gel 
with 0.5X Tris/Borate/EDTA (TBE: tris 0.11M, borate 90 mM, EDTA 2.5 mM; pH 8.3) 
and Safe View DNA binding dye 1:20,000 (NBS-SV1, NBS Biologicals, Cambridgeshire, 
UK). Resolved DNA was visualized with a UVP VisionWorks LS instrument. 
2.18.6 Pyrosequencing 
 
Pyrosequencing was performed using streptavidin sepharose high performance kit 
(17-5113-01, GE Healthcare Life Sciences) according to manufacturer’s instructions. 
Briefly, 75 µL of binding premix (50 µL of binding buffer + 2 µL of beads + 48 µL of 
dH2O) was added to 25 µL of PCR amplicon and transferred into a round bottom 96-
well plate. Plates were temporarily sealed and agitated for 10 min and transferred to 
a PyroMark vacuum station (PyroMark Q96 Workstation, Qiagen). With the suction-
filter probes of the PyroMark station on, the probes were placed in sterile water for 
30 sec and then into the round bottom 96-well plate containing the PCR amplicon-
streptavidin mixture for binding double stranded DNA, followed by washing in 70 % 
ethanol for 10 sec, denaturation in 0.2 M NaOH for 20 sec and neutralization in 1 % 
Tris acetate, pH 9 for 10 sec. The single stranded biotin-tagged templates were 
released into a new PyroMark Q96-well plates containing 45 µL annealing mix 
(annealing buffer 43.5 µL of + 1.5 µL of sequencing primer)/well followed by 
continuous agitation and incubation at 80oC for 2 min. The plates were then cooled 
for 2 min and placed in a pyrosequencer (PyroMark Q96ID, Qiagen). 
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Pyrosequencing assays were undertaken using PyroMark Gold Q96 SQA reagents 
(972812, Qiagen) according to manufacturer’s instructions. Briefly, PyroMark Gold 
Q96 SQA reagents were loaded into PyroMark Q96 cartridge and placed in the 
pyrosequencer and pyrosequencing performed. Each run contained at least 1 internal 
bisulfite control and a no-template control. CpG site methylation was automatically 
determined by PSQTM 96 MA software and given as a percentage. 
 
2.19 Animals 
 
In this study, mice were bred according to the regulations contained in the Animals 
and Scientific Procedure Act (1986) of the United Kingdom and University of Liverpool 
local guidelines. Homozygous Nrf2 null (−/−) and Nrf2 wild-type (+/+) mice (C57BL/6J 
strain) utilised in this study have been described elsewhere198,199. Nrf2+/+ and 
Nrf2−/− mice of approximately 10 weeks of age were used for isolating quiescent 
pancreatic stellate cells and mice of approximately 10 months of age for H & E stain. 
Both Nrf2+/+ and Nrf2−/− mice were housed at temperatures between 19°C –23°C 
under a 12 hour light/dark cycle and had free access to food and water. Mice were 
sacrificed by exposure to a rising CO2 concentration and then sustained until death 
was confirmed. Pancreata harvested from non-fasted male mice were used 
throughout the present study. The mice used in this study were kindly donated by 
Professor Chris Goldring (MRC Centre for Drug Safety Science, University of 
Liverpool). 
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2.20 Haematoxylin and Eosin stain 
 
Harvested pancreata were immediately fixed in 10% neutral buffered formalin for 24 
hours at room temperature before paraffin embedding. The entire pancreas 
harvested from each mouse was sectioned at 5 µm thickness and mounted onto 
histological glass slides. They were dried at 40oC and subjected to H & E staining as 
follows; mice pancreatic tissue sections were deparaffinised in xylene (X/0250/17, 
Fisher Scientific, UK) for 5 minutes and subsequently agitated in fresh xylene for 1 
minute. Next, sections were rehydrated through decreasing concentration of ethanol 
(100%, 90% and 70% for a min each) and then rinsed under running tap water. Tissues 
were next immersed in haematoxylin for 5 minutes and subsequently rinsed under 
running tap water until clear. The sections were agitated for 30 seconds each in acid 
water (0.25% HCl/dH2O), Scott’s tap water (1g potassium hydrogen carbonate, 10g 
magnesium sulphate in 500mL dH2O) and 100% ethanol with a rinse under running 
tap water after each agitation. Tissues were placed in eosin Y (3801600E, Leica 
Microsystems, UK) for 2 minutes, then ethanol for 2 minutes and finally in xylene for 
90 seconds. Cover slips were mounted on tissues using DPX mountant for microscopic 
examination and scoring when dry. All sections were reviewed by specialist 
pancreatic histopathologist, Professor Fiona Campbell. 
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2.21 Isolating quiescent pancreatic stellate cells 
 
The isolation of quiescent pancreatic stellate cells (PSCs) were as described previously 
using density gradient centrifugation122. Briefly, harvested pancreas were 
immediately placed into a 50 mL Falcon tube containing ice-cold 0.9% NaCl solution 
and further isolation steps were undertaken in a class II biological safety cabinet. The 
pancreas was digested with a mixture of collagenase P, protease and Dnase in Gey’s 
balanced salt solution (GBSS) by injection into the pancreatic tissue until all 
pancreatic lobules were clearly separated. The digested tissues were washed and 
subsequently suspended in a solution of 11.4 % (w/v) Nycodenz in GBSS which was 
then layered underneath a solution of 0.3 % (w/v) bovine serum albumin in GBSS in 
a round-bottom centrifuge tube. This was centrifuged at 1400 x g for 20 min at 4o C. 
Mouse PSCs separated into a hazy band just above the interface of Nycodenz and 
bovine serum albumin aqueous solution. Quiescent PSCs cells were harvested, 
washed and maintained in a humidified 5 % CO2 incubator at 37oC in Iscove’s Modified 
Dulbecco’s Medium supplemented with 10% FBS, 4mM L-glutamine, 100 U/mL 
penicillin and 100 µg/mL Streptomycin. Culture medium was changed at 24 hours 
post isolation and every other day subsequently.  
Purity of freshly isolated PSCs was assessed at 24 h hours post-isolation by 
fluorescence microscopy for cytoplasmic lipid droplets using Oil Red O staining as 
described previously 200. Briefly, freshly isolated quiescent PSCs were cultured on 
sterile cover slips in 24 well plates for 24 hours. Media was discarded from the wells, 
rinsed twice with PBS pH 7.2 (20012019, Life Technologies, UK) and cells were fixed 
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by adding 10% neutral buffered formalin for 60 minutes. All procedures involving 
formalin were conducted in a fume hood and subsequent steps after cell fixation 
were performed at room temperature. Formalin was discarded appropriately and the 
wells were rinsed twice with distilled water and 60% isopropanol was next added for 
5 minutes and discarded. A fresh working solution of Oil Red O was next added and 
incubated for 10 minutes after which wells were rinsed with tap water until clear. 
Cells were next incubated with DAPI (1: 2000) for 1 minute and cells on cover slips 
were mounted onto histological glass slides with Prolong Gold Antifade reagent 
(P36930, Invitrogen) and subjected to fluorescent microscopic examination. 
 
2.22 Rescue of pancreatic stellate cells  
 
L-Ascorbic acid (vitamin C) stock solution was prepared by dissolving L-ascorbic acid 
in water; immediately aliquots were made and quickly wrapped in foil paper, as 
ascorbic acid is light sensitive, and stored promptly at - 80oC. Single use aliquots of 
freshly thawed ascorbic acid were added to Nrf2 null PSCs IMDM culture media in 
increasing doses of 10 µM, 25 µM, 100 µM and 200 µM final concentration in IMDM. 
 
2.23 Antibody validation 
 
Antibody validation was first undertaken using western blotting prior to performing 
immunocytochemistry or immunohistochemistry for a selected antibody. siRNA 
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mediated depletion and western blotting is as described previously in section 2.6.3, 
2.7 and 2.8. Dr Claire Jenkinson kindly performed NQO1 antibody validation. 
 
2.24 Processing and paraffin embedding of MiaPaCa-2 cell pellet 
 
As described in section 2.6.3, siRNA mediated depletion of proteins of interests was 
performed but with a scale up using T75 flasks for each treatment. MiaPaCa-2 cells 
were harvested at 72 h using Trypsin followed by the addition of 10 mL PBS, pH 7.2 
and the subsequent transfer of the entire T75 flasks content into a 15 mL Falcon tube. 
Cell pellet was obtained by centrifuging Falcon tubes at 75 x g for 5 mins and 
discarding the supernatant. Cell pellets were resuspended and fixed in 10 mL of 10% 
neutral buffered formalin and left incubating overnight at 4oC on a roller. Procedures 
involving formalin were conducted in a fume hood. Following the overnight 
incubation, the Falcon tubes where left to stand for 3 - 5 hours at 4oC and the 
resulting supernatant was appropriately discarded. A 2% molten agar was maintained 
in a 60oC water bath. 
Two hundred and fifty microliters (250 µL) of the molten agar was used to resuspend 
the cell pellet which was subsequently transferred into a hollow and narrow 
cylindrical base and left to cast on ice. Portions of the casted agar containing the cell 
pellet were visibly identified and cut out of the remaining cast. The cell pellet cast 
was placed in 10% neutral buffered formalin and sent for paraffin embedding. 
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2.25 Immunocytochemistry for UHRF1 detection in MiaPaCa-2 and pancreatic 
fibroblast cell pellets 
 
Pancreatic fibroblasts cell pellets were prepared by Dr Lawrence Barrera and the 
sections were cut by Drs Claire Jenkinson, Karen Aughton and Anthony Evans. Freshly 
cut 5µm sections of paraffin embedded cell pellets were dried overnight at 40oC. The 
conditions for the immunocytochemistry (ICC) were optimized for antigen retrieval 
buffer and anti-UHRF1 antibody (sc-136264, Santa Cruz Biotechnology) 
concentration. Target retrieval solution pH 9.0 (K8004 [high pH], Dako, Denmark) and 
anti-UHRF1 antibody (sc-136264) 1:250 concentration were determined to be the 
optimum and used hereafter for subsequent ICC. Step-wise, antigen retrieval was 
performed using a PT Link (PT10126, Dako). Tris buffered saline (TBS, 2.4g Tris base, 
8.8g NaCl in 1L of dH2O, pH7.6) was used to make a 0.1% Tween 20 solution in TBS 
(TBS+T). After antigen retrieval, sections were rested in TBS+T for approximately 10 
minutes and subsequently washed using TBS+T. After each washing step, excess 
TBS+T on the slides was removed by tilting and drying the edges with tissue. Further 
steps after antigen retrieval were performed at room temperature. Sections were 
next blocked for 10 minutes with peroxidase blocking reagent (4007, Dako) and then 
washed with TBS+T 3 x 5 min washes. Primary anti-UHRF1 antibody was diluted 
(1:250) in antibody diluent (S2022, Dako) and incubated for 1 hour and then washed 
with TBS+T 3 x 5 min washes. Labelled polymer anti-mouse secondary antibody 
(4007, Dako, UK) was applied to the sections for 1 hour and then washed. Sections 
were next incubated with DiAminoBenzidine (DAB) reagent for 10 minutes and 
washed with TBS+T followed by a resting step in TBS+T for 5 minutes. Sections were 
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then counterstained for 45 seconds in Gill III haematoxylin (3801540BBE, Leica 
Microsystems, UK) and subsequently washed under tap water for 1 minute. Sections 
were rinsed in 0.25% hydrochloric acid water for 5 seconds and then placed in Scott’s 
tap water (as mentioned previously) for a further 30 seconds. Sections were next 
dehydrated through 90% and 100% ethanol for 1 minute and 2 minutes respectively. 
Finally, sections were placed in xylene for two 1 minute incubations and mounted 
with cover slips using DPX mountant for microscopic examination and scoring. 
 
2.26 Statistical Analysis 
 
 Data analysis was performed using GraphPad Prism version 6.00 for Windows, 
GraphPad Software, La Jolla California USA. 
 
2.27 Samples and Methods for single nucleotide polymorphism and tumour 
tissue protein expression 
 
2.27.1 Single nucleotide polymorphism - study population 
 
Blood samples obtained with informed consent and ethical approval (11/NW/0083) 
were taken from patients with advanced pancreatic cancer (n = 149), enrolled in the 
TeloVac (telomerase vaccine) and ViP (vandetanib in pancreatic cancer) clinical trials. 
Patients in both trials received gemcitabine therapy (either alone or in combination 
with other drugs). The TeloVac trial was a phase III open-label randomized trial 
assessing the efficacy and safety of gemcitabine plus capecitabine with or without 
telomerase peptide vaccine in patients with advanced pancreatic cancer (locally 
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advanced and metastatic pancreatic cancer)29. The ViP trial was a randomized phase 
II trial investigating the addition of the tyrosine kinase inhibitor Vandetanib to 
gemcitabine chemotherapy30. 
2.27.2 Gene and single nuclueotide polymorphism selection 
 
An extensive literature search was undertaken to select candidate genes and SNPs. 
PubMed/ (http://www.ncbi.nlm.nih.gov/pubmed) was used as the search platform 
for published literature related to the subject of interest. Keywords used in the search 
were ‘redox gene polymorphism and cancer’, ‘antioxidant gene polymorphism and 
cancer’, ‘Nrf2 polymorphism and cancer’. Three genes were selected based on their 
putative function in antioxidant and xenobiotic metabolism: NRF2 and two of its 
downstream target genes NQO1 and SRXN1 involved in cellular redox homeostasis. 
A SNP search was further performed on the selected candidate genes using the NCBI 
SNP database (http://www.ncbi.nlm.nih.gov/snp/). Additional sources linked to the 
NCBI database201 were also consulted. The following criteria were applied to select 
candidate SNPs from each of the selected genes: firstly SNPs for each gene were 
identified that had the highest number of PubMed publications related to cancer 
survival or risk, and secondly these must have been validated in humans. After 
applying these criteria, three SNPs were chosen for allelic discrimination and further 
analysis in our patient cohorts, one for NRF2, SRXN1 and NQO1. 
2.27.3 DNA isolation for single nucleotide polymorphism study 
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Genomic DNA was isolated from anticoagulated whole blood obtained from two 
clinical trial (TeloVac and ViP trial) samples using MagNa Pure Compact Nucleic Acid 
Isolation Kit I (Roche Diagnostics 03730964001) according to manufacturer’s 
instructions. DNA quality and quantity was evaluated using a NanoDrop 
spectrophotometer (NanoDrop 200C). Isolated genomic DNA was diluted to a final 
volume and concentration of 50µL and 25ng/µL respectively. 
TaqMan SNP Genotyping Assays for each SNP (C___2091255_30: rs1800566,  
 C_316023_10:rs2886162, C_29328574_30:rs6053666, Thermo Fisher Scientific) 
were supplied at 40x and 20x concentration and diluted 1:3 or 1:1 respectively to 10x 
concentration before use in a PCR mix. LightCycler 480 Probe PCR Master mix 
(4707494001 Roche Diagnostics) and TaqMan SNP Genotyping Assay mix were 
prepared as shown (Table 2.11) to make up the final mix for the PCR. 
Table 2.11: Reagents for genotyping assay PCR mix 
                Reagent Volume (µL) 
DNase free water 3 
Light Cycler 480 PCR Master Mix 10 
TaqMan SNP genotyping assay mix 2 
Total 15 
 
 
To each well of a white 96-well PCR plate (STARLAB, UK), 15µL of PCR master mix was 
added followed by 5µL of 25ng/µL patient genomic DNA or no-template negative 
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control in triplicate. PCR was performed with LightCycler 480 PCR machine (Roche 
Diagnostics GmbH, Germany) under the following thermal cycling parameters: 
reactions were denatured initially at 95oC for 5 min, then cycled at 95oC for 10 sec, 
57oC for 30 sec, 50oC for 30 sec and 72oC for 3 sec for 45 cycles, followed by a final 
cooling step at 40oC for 10 sec. The end-point genotyping software in the LightCycler 
480 PCR machine, made the call for allelic discrimination for individual genes tested. 
This work was undertaken alongside Dr Claire Jenkinson, with each of us contributing 
to 50% of the effort. 
 
2.27.4 Tissue microarray construction    
 
Permission was obtained from the ESPAC-Tplus Trial Steering Committee (ET011-16) 
to examine for potential stratification of chemotherapeutic response in pancreatic 
cancer patients based on tissue levels of cytoprotective biomarkers.  
Formalin-fixed paraffin-embedded pancreatic cancer tissue sections were 
qualitatively reviewed by an experienced specialist pancreas histopathologist 
(Professor Fiona Campbell). 
Tissue microarrays (TMAs) were kindly constructed by Mr Leigh Shannon. Cores were 
taken from tumour regions within tissue blocks that had been identified and marked 
by Professor Campbell using haematoxylin and eosin stained sections. TMAs were 
prepared with two or more cores (0.6mm in diameter) for each patient from the 
treatment and observation only groups. Control cores from colon, liver, kidney, 
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normal pancreas and chronic pancreatitis were used on all arrays constructed to 
serve as orientation cores. Sections of 5µm thickness were cut and mounted onto 
histological glass slides by Mr Leigh Shannon. After drying overnight at 40oC, IHC was 
undertaken within 24 h.  
 
2.27.5 Immunohistochemical staining of TMA sections for NQO1 and UHRF1 
 
The steps for optimization and subsequent IHC are as described in chapter 2.25 for 
ICC using the following antibody concentrations: anti-UHRF1 antibody (sc-136264, 
Santa Cruz Biotechnology), 1:100 and anti-NQO1 antibody (MA1-16672, Thermo 
Scientific) 1:20,000. Dr Claire Jenkinson kindly performed NQO1 antibody validation; 
work on Nrf2 and Srxn1 antibody validation and optimization was shared equally with 
Dr Jenkinson while optimization of the UHRF1 antibody and IHC for NQO1 and UHRF1 
on the ESPAC TMAs were performed by myself. 
 
2.27.6 Scoring 
 
 
2.27.6.1 Manual scoring 
 
TMAs stained for NQO1 and UHRF1 were scored independently and blindly alongside 
Professor F. Campbell. Where there was a disagreement, both investigators re-scored 
until a consensus was reached.  
2.27.6.2 Definiens software scoring 
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In addition to the manual scoring of cores, computer aided scoring was undertaken 
using Definiens software (Definiens Tissue Studio version 3.51, Germany). TMA core 
images were acquired using Aperio ScanScopeTM (Leica Microsystems, UK). The 
Definiens settings for IHC analyses for both NQO1 and UHRF1 is documented in 
Appendix 15 and Appendix 16. UHRF1 Positive index (PI) = number of UHRF1-stainied 
positive (brown) cancer cells (highlighted as yellow by Definiens) ÷ sum of purple 
staining (haematoxilin) cancer cells (highlighted as blue) plus brown staining(yellow 
marked) cancer cells. Definiens software computes a histological score (HS) NQO1 
value after analysis of the region of interest (ROI, cancer cell cytoplasm); HS = 
(proportion of weak staining x 1) + (proportion of moderate staining x 2) + (proportion 
of strong staining x 3). 
 
2.27.7 Statistical analysis 
 
Chi-square (χ2) analysis was undertaken to test the concordance of the genotypes 
with Hardy-Weinberg equilibrium (HWE), using SPSS for Windows software version 
14.0. Overall survival (OS) was estimated with the Kaplan-Meier (KM) method. Cox 
Proportional Hazard models were used to assess the univariate association between 
NRF2/NQO1/SRXN1 and overall survival for combined data and by trial and treatment 
arm. Cox models by arm and NRF2/NQO1/SRXN1 with a treatment interaction terms 
were analysed. Multivariate models were fitted for prognostic variables but excluding 
NRF2/NQO1/SRXN1. Prognostic variables for ViP patients included age, sex, 
treatment arm, Eastern Oncology Cooperative Group (ECOG) performance status, 
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differentiation status, histology, stage, tumour type and log CA19-9; for Telovac 
patients sex, treatment arm, stratum, log CA19-9; and for combined ViP and TeloVac 
analysis, prognostic variables were sex and log CA19-9. 
Significant variables were included in these multivariate models. NRF2/NQO1/SRXN1 
as prognostic variables were fitted into a univariate model for the combined ViP and 
TeloVac data. NRF2/NQO1/SRXN1 were added to the multivariate models (for ViP, 
TeloVac and combined data) and significant prognostic variables selected. Data 
analysis was performed using Stata (version 14) by Dr Richard Jackson and Mr James 
Dodd of the Liverpool Clinical Trials Unit, University of Liverpool.  
Statistical analysis for UHRF1 and NQO1 protein expression including survival analysis 
for ESPAC-1 and ESPAC-3 data were undertaken using MedCalc Statistical Software 
version 17.6 (MedCalc Software bvba, Ostend, Belgium, 2017). 
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3 INVESTIGATING THE FUNCTION OF 
UHRF1 ON THE KEAP1-NRF2 PATHWAY 
IN PANCREATIC CANCER CELLS 
 
 
 
 
 
 
 
 
109 
 
3.1 Introduction 
 
We have previously reported that UHRF1 is overexpressed in pancreatic cancer79, 
whereas Keap1, the main negative regulator of transcription factor Nrf2 was not 
expressed in approximately 70% of PDAC cases99. Following-up on these findings, 
Abu-Alainin et al. showed that methylation of Keap1 promoter in pancreatic cancer 
cell lines was possibly a contributing factor to the reduced expression of Keap1. 
Moreover, an inverse correlation between Keap1 and UHRF1 expression in PDAC 
tissues was observed and Abu-Alainin et al. found that Keap1 protein levels were 
increased when UHRF1 was depleted from pancreatic cancer cell lines. 
Accompanying the increase in Keap1, Nrf2 protein and several target genes (HO, 
CYP2A6) were also downregulated80. 
The conclusion from the study by Abu-Alainin and colleagues was that UHFR1 
expression maintains Keap1 promoter methylation and this contributes to keeping 
Keap1 levels low, which in turn allows Nrf2 levels to remain elevated and 
corresponding Nrf2 downstream proteins to be expressed in pancreatic cancer. The 
conclusion although interesting and novel, needed to be strengthened. In order to 
support their initial findings and to further demonstrate the regulatory function of 
UHRF1, additional functional studies were necessary.  
To achieve these, functional examination of the consequences of Keap1 knockdown 
and simultaneous depletion of both Keap1 and UHRF1 were undertaken. 
Additionally, Nrf2 downstream target genes monitored to show loss of Nrf2 activity 
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namely aldo-keto reductase 1C1 (AKR1C1) and NAD(P)H:quinone oxidoreductase 1 
(NQO1), were also examined.  
On the basis that the Nrf2 activity is usually manifest by alterations in intracellular 
reactive oxygen species (ROS) and free GSH98,99,202, these parameters were 
additionally evaluated. Furthermore, the expression of an ARE-driven luciferase 
reporter gene in the context of UHRF1 mediated regulation of Nrf2 was also 
examined. ARE is commonly found in the promoter region of genes encoding various 
antioxidant and cytoprotective detoxifying proteins and enzymes. Nuclear 
transcription factor Nrf2 binds to the ARE in the promoter region and mediates ARE-
regulated induction of these genes such as NQO1, AKR1C1 and CYP2A6203-205. 
The aims of this chapter were: (I) to examine the effects of UHRF1 on Keap1-Nrf2 
mRNA and protein expression, cell cycle regulation, oxidative stress response (II) to 
determine whether UHRF1 activity alters response to gemcitabine chemotherapy 
and (III) to develop a method for analysis of Keap1 promoter methylation in 
pancreatic cancer tissues. 
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3.2 Results 
 
 
3.2.1 Optimization for transfection 
 
A number of transfection conditions were tested in order to determine the optimum 
concentration of control siRNA in combination with the volume of lipofectamine that 
least affected the target protein level and cell viability, whilst achieving the maximum 
depletion of the target protein with the indicated target siRNA. The level of UHRF1 
protein and the corresponding cell viability was highest in cells that were not 
transfected with either siRNA or incubated with lipofectamine (Figure 3.1 A, lane 1, 
Figure 3.1 B) and this was used as a reference to compare changes to protein level 
and viability in the transfected cells. All treatments (lipofectamine alone or 
lipofectamine plus siRNA) decreased UHRF1 protein level (Figure 3.1 A, lanes 2 to 13) 
or cell viability (Figure 3.1 B).  
Lipofectamine treatment alone or in combination with 10 nM control siRNA 
diminished cell viability but the impact was greatest and significantly different (p < 
0.001) between 2 µL and 4 µL (Figure 3.1 B) based treatments with 4 µL treatments 
more severely impairing cell proliferation than 2 µL treatments. A similar trend in cell 
viability was seen between 2 µL and 4 µL based treatments with 20 nM control siRNA 
and 2 µL and 4 µL treatments with 30 nM control siRNA (Figure 3.1 B).  
 
 
112 
 
UHRF1 was depleted to undetectable levels at all UHRF1 siRNA concentrations used 
(10, 20 and 30 nM, Figure 3.1 A, lanes 6, 7, 12 and 13). Given that 4 µL based 
lipofectamine treatments with control siRNA decreased cell viability significantly 
more than with 2 µL (Figure 3.1 B), all 4 µL based treatments were considered not 
suitable. Furthermore, the lack of significant difference in cell viability between 2 µL 
lipofectamine plus 30 nM control siRNA and 2 µL lipofectamine plus 30 nM UHRF1 
siRNA (Figure 3.1 B) suggested higher siRNA in particular, control siRNA was 
detrimental to cells and the 30 nM based siRNA treatment was also considered 
unsuitable. The treatment response profile with 2 µL lipofectamine plus either 10 nM 
or 20 nM siRNA (Figure 3.1 B) were similar and therefore 10 nM based siRNA 
concentration was carried forward for use in subsequent experiments.  
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Figure 3.1. Transfection optimization. Suit-2 cells were transfected with varying concentrations and 
volumes of control and UHRF1 siRNAs and Lipofectamine respectively. (A) Western blot images and 
(B) MTS assay for corresponding transfection conditions. Lipofectamine 2 µL and 4 µL is indicative of 
the volume of lipofectamine per well of a 6-well plate that was required to make up a predetermined 
siRNA concentration in a final volume of 3000 µL of transfection mixture (lipofectamine alone or in 
combination with siRNA plus culture media); the same siRNA concentration was used in both 6-well 
and 96-well plates as indicated. * P < 0.05, *** p <0.001 
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3.2.2 UHRF1 depletion is associated with Keap1-Nrf2 pathway deactivation  
 
Dr Wafa Abu-Alainin (then a PhD student within our research laboratory) found that 
depletion of UHRF1 protein in human pancreatic cancer cell lines, led to an 
upregulation of Keap1 and a downregulation of Nrf2 proteins80. To expand on her 
findings, I depleted either Nrf2, Keap1 or UHRF1 in human pancreatic cancer cell lines 
and a primary mouse pancreatic cancer cell line (KPC) and observed the effect on 
Keap1, Nrf2, and Nrf2 downstream target genes. Depletion of UHRF1 and Nrf2 in Suit-
2 cells resulted in downregulation of Nrf2 and Nrf2 downstream targets NQO1 
(NAD(P)H:quinone oxidoreductase 1 and AKR1C1 (aldo-keto reductases 1C1) (Figure 
3.2A). Similarly, knockdown of UHRF1 and Nrf2 in MiaPaCa-2 cells led to a 
downregulation of Nrf2 protein (Figure 3.2B). Furthermore, Keap1 depletion was 
undertaken to determine if this would reverse the effect of UHRF1 depletion on Nrf2. 
Although, Keap1 knockdown alone led to only a modest increase in Nrf2 protein 
(Figure 3.2B), it substantially increased the growth of pancreatic cancer cells 80. 
Simultaneous depletion of both UHRF1 and Keap1 abrogated the inhibitory effect of 
UHRF1 depletion alone on Nrf2 in MiaPaCa-2 cells (Figure 3.2B). In primary KPC cells, 
UHRF1 depletion was also accompanied by upregulation of Keap1 and a concomitant 
downregulation of Nrf2 (Figure 3.2C). The effect of a time-dependent UHRF1 
depletion on mRNA was next investigated. In Suit-2 cells, knockdown of UHRF1 
(Figure 3.2D), led to enhanced KEAP1 transcript levels at 24h but decreased at 48h 
and 72h to control mRNA level post-UHRF1 depletion (Figure 3.2E), whereas, NRF2 
transcripts initially increased at 24h and 48h to finally decline to its lowest level below 
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control mRNA level at 72h post-UHRF1 depletion; of note, Nrf2 depletion itself 
caused NRF2 transcript downregulation at 24h declining further at 48h before 
beginning to recover albeit below control mRNA at 72h (Figure 3.2F). These data 
suggest that Keap1-Nrf2 pathway is active in pancreatic cancer and that UHRF1 
contributes to the regulation of this pathway. 
 
Figure 3.2. UHRF1 regulates Nrf2-Keap1 pathway by inactivating Keap1. Western blot images of 
indicated proteins following 72h UHRF1, Nrf2, Keap1, UHRF1 + Keap1-targeting siRNAs treatment in 
(A) Suit-2, (B) MiaPaCa-2 cells and (C) primary PDAC cells from KPC mouse, SMARTpool siRNA 10 nM 
Table 2.4; n=2 for MiaPaCa-2 and Suit-2, n=3 for KPC. GAPDH and β-actin are used as loading controls. 
(D, E, F) RT-PCR for UHRF1, KEAP1 and NRF2 transcripts relative to GAPDH in control and UHRF1 or 
Nrf2 depleted Suit-2 cells n=3. 
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3.2.3 Suppression of Keap1 by UHRF1 is required for the maintenance of low 
oxidative states 
 
In order to determine if modulation of the Keap1-Nrf2 pathway impacted on the 
intracellular redox status of pancreatic cancer cells, reactive oxygen species (ROS) 
and glutathione (GSH) levels were measured following the indicated treatments in 
(Figure 3.3). Treatment of MiaPaCa-2 cells with GSH depleter diethyl maleate (DEM) 
and Nrf2 targeting siRNA (both as positive controls) caused a significant depletion of 
total GSH. UHRF1 depletion also led to a modest albeit significant depletion of GSH 
(Figure 3.3 E). Both UHRF1 and Nrf2 depletion significantly increased ROS levels in 
MiaPaCa-2 cells and the rise in ROS levels was reversed with simultaneous Keap1 and 
UHRF1 depletion. Keap1 depletion alone did not have significant effect on ROS levels 
(Figure 3.3 A and B). Since Nrf2 antioxidant effect is mediated through the antioxidant 
response element (ARE) present in the promoter region of its downstream target 
genes, I sought to determine if this was the mechanism of UHRF1-mediated effects 
on Nrf2 targets. Using Nrf2 targeting siRNA as positive control, depletion of UHRF1 
resulted in a significant decrease in ARE-luciferase reporter activity (Figure 3.4 A). In 
Suit-2 cells, similar results were also observed (Figure 3.4 B). Put together, UHRF1 
through the suppression of Keap1 is able to activate Nrf2 which drives the 
maintenance of a low intracellular oxidative status in pancreatic cancer cells to 
promote their proliferation. 
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Figure 3.3. UHRF1 contributes to the regulation of oxidative stress through activation of Nrf2. (A, C) 
Flow cytometry profiles of reactive oxygen species following 72 h of the indicated treatments in 
MiaPaCa-2 and Suit-2 cells respectively. (B, D) Corresponding mean ± SEM plots for MiaPaCa-2 (n=3). 
In Suit-2 cells, n=2 hence statistical analysis not undertaken as data obtained from 2 experiments is 
not sufficient enough to draw a significant conclusion from.(E) Glutathione (GSH) levels after 72 h of 
the indicated treatments in MiaPaCa-2 cells. Data represents mean ± SEM from three independent 
experiments performed in triplicates. *p < 0.05; **p < 0.01; ***p < 0.001, ns, not significant. 
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Figure 3.4. Depletion of UHRF1 inhibits Nrf2 pathway and pancreatic cancer cell growth. (A, B) The 
activation of Nrf2 dependent 8x ARE-reporter was measured following 72 h of the indicated 
treatments in MiaPaCa-2 and Suit-2 cells respectively. pGL4.74 [hRluc/TK] plasmid served as 
transfection control to normalize luciferase values; n=3 MiaPaCa-2 and Suit-2. . Data represents mean 
± SEM from three independent experiments performed in replicates. *p < 0.05; **p < 0.01. (C) MTS 
assay following 72 h of the indicated treatments in MiaPaCa-2 cells; n=2 and hence statistical analysis 
not undertaken as data obtained from 2 experiments is not sufficient enough to draw a significant 
conclusion from. 
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3.2.4 UHRF1 depletion causes G2-M cell cycle arrest 
 
To determine the effect of UHRF1 on cell cycle in pancreatic cancer, cells were 
depleted of UHRF1 and FACS analysis undertaken. In MiaPaCa-2 cells, a greater 
proportion of cells were arrested in G2-M phase of the cell cycle after UHRF1 
depletion (Figure 3.5 A and B) while a more prominent G2-M block was observed 
following Nrf2 knockdown. This similar cell cycle profile between UHRF1 and Nrf2 
depletion may be linked to the fact that both UHRF1 and Nrf2 knockdown led to Nrf2 
downregulation (Figure 3.2B). Moreover, depletion of Keap1 caused a greater G1 cell 
proportion indicative of a speedy progression though the cell cycle. Interestingly, 
simultaneous knockdown of both Keap1 and UHRF1 restored cell cycle to that of 
control siRNA cell cycle profile. Cell cycle profiles did not change to any significant 
degree with UHRF1 or Nrf2 knockdown in Suit-2 cells (Figure 3.6A and B).   
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Figure 3.5. Suppression of Keap1 by UHRF1 is required for cell cycle progression in MiaPaCa-2 cells. 
(A) Flow cytometry profiles of PI-stained MiaPaCa-2 cells after 72 h of the indicated treatments. (B) 
Corresponding mean ± SEM plots for 3 independent experiments. 
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Figure 3.6. Suppression of Keap1 by UHRF1 is required for cell cycle progression in Suit-2 cells. (A) 
Flow cytometry profiles of PI-stained Suit-2 cells after 72 h of the indicated treatments. (B) 
Corresponding mean ± SEM plots for 2 independent experiments. 
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3.2.5 UHRF1 depletion does not confer increased sensitivity to gemcitabine 
 
Since (I) gemcitabine treatment has been the common chemotherapeutic agent of 
choice for pancreatic cancer, (II) approximately 86% of PDAC tissues overexpress 
UHRF180 and (III) UHRF1 knockdown showed a significant decrease in cell 
proliferation (Figure 3.4 C), examination of the potential benefit of a combined 
UHRF1 knockdown and gemcitabine treatment was undertaken. Knockdown of 
UHRF1 is demonstrated in Figure 3.7 B and D for MiaPaCa-2 and Suit-2 respectively. 
However, UHRF1 knockdown followed by gemcitabine treatment had no additive or 
synergistic benefit in both MiaPaCa-2 (IC50, p = 0.53, Figure 3.7 A) and Suit-2 cells 
(IC50, p = 0.51 Figure 3.7 C).  
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Figure 3.7. Depletion of UHRF1 in pancreatic cancer cells does not increase sensitivity to 
gemcitabine. (A, C) Dose response curve for MiaPaCa-2 and Suit-2 respectively; cells were treated for 
an initial 48 h with either Ctrl, UHRF1 siRNA or no siRNA followed by 72 h gemcitabine treatment. (B, 
D) MTS assay for MiaPaCa-2 and Suit-2 respectively; after an initial 48 h treatment with the indicated 
siRNAs, cells were cultured for a further 72 h in antibiotic free FBS supplemented RPMI. Data 
represents mean ± SEM from 3 independent experiments performed in at least 4 replicates. *p < 0.05; 
**p < 0.01; ns, not significant. 
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3.2.6 Method development for KEAP1 gene promoter analysis 
 
Given that (I) Keap1 expression has been shown to be absent in approximately 70% 
of PDAC tissues99, (II) KEAP1 promoter has been reported by others to be methylated 
in other cancers100,101 as well as by our group in pancreatic cancer cell lines80 and (III) 
KEAP1 promoter methylation may explain the absence of Keap1 protein in PDAC, 
examination of the methylation status of KEAP1 gene promoter in PDAC was 
necessary. Laser capture microdissection (LCM) is a useful technique for isolating 
homogenous cell populations from a heterogenous specimen. The aim here was to 
develop a method to isolate pancreatic cancer cells by LCM from FFPE tissues (Figure 
3.8), extract genomic DNA and determine if the extracted genomic DNA was sufficient 
and suitable for downstream DNA analysis.  
 
 
Figure 3.8. Representative images from laser captured microdissection. (A) Cancerous duct 
highlighted in yellow before laser capture. (B) After laser capture. 
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3.2.6.1 DNA isolation, quantification and annealing temperature determination 
 
Following cancer cell isolation by laser capture microdissection, different DNA 
extraction protocols were employed to determine the best yielding DNA extraction 
method. As described in the method section (2.18.2), three different optimization 
protocols were evaluated. We found that protocol III with an initial xylene pre-
treatment step gave the highest yield of genomic DNA and the DNA obtained was 
carried forward for pyrosequencing analysis (Table 3.1 A). However, given the low 
260/230 ratio absorbance reading, which could have been the result of contaminants 
and probably contributed to DNA estimation, a more accurate DNA measurement 
with dsDNA Broad Range Assay kit was used (Table 3.1 B). DNA estimation with Broad 
Range Assay yielded lower DNA concentration than with the spectrophotometer, 
reflecting the specificity of the broad range assay for double stranded DNA. A PCR 
annealing temperature of 51oC was determined to be optimal for both KEAP1a and 
KEAP1b primers (Figure 3.9). 
 
Figure 3.9. Amplification products for KEAP1a and KEAP1b primers. A, Annealing temperature 
optimization for KEAP1a and KEAP1b primers using bisulphite treated lymphocyte derived DNA; 
optimal annealing temperature = 51OC for both primers based on the abundance of amplicons 
(thickest white band). 
 
 
126 
 
Table 3.1. DNA yield from different extraction protocols. 
A. Genomic DNA measurement with NanoDrop Spectrophotometer from 30 µL  
eluted DNA sample before bisulphite treatment 
 
 
Extraction 
protocol 
 
Sample 
DNA 
concentration 
(ng/µL) 
Absorbance 
(nm) 
260/280 
Absorbance 
(nm) 
260/230 
Tumour-1 25.7 1.93 3.84 
Stroma-1 9.4 2.34 1.29 
Tumour-2 40.5 2.56 1.02 
Tumour-3 86.0 2.70 1.07 
Tumour-4 46.4 2.41 1.01 
Stroma-4 15.2 2.21 1.04 
Tumour-5 101.5 2.66 1.13 
Stroma-5 26.9 2.58 0.97 
 
 
B. Genomic DNA measurement with dsDNA Broad Range Assay from 30 µL  
eluted DNA sample before bisulphite treatment 
 
Sample DNA concentration (ng/µL) 
Tumour-4 7.7 
Stroma-4 3.2 
Tumour-5 11.8 
Stroma-5 3.5 
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3.2.6.2 Probing KEAP1 methylation from laser captured microdissected samples 
 
Pyrosequencing was used to quantitatively determine the methylation levels of 
KEAP1 promoter in PDAC tissues. The pyrosequencing data showed no differential 
CpG promoter hypermethylation in the 2 promoter regions analysed between the 
tumour and stromal DNA (Table 3.2 and Appendix 1-4). Two patients DNA were 
analysed (patient 4 and 5); for each patient, DNA from tumour cells were analysed 
separately from DNA isolated from adjacent stromal cells. Tumour DNA from patient 
4 did not have any KEAP1 promoter methylation for the region probed by KEAP1a 
primer and with KEAP1b primer only 11% promoter methylation was detected at one 
of the CpG sites while the rest of the CpG sites were negative for KEAP1 methylation. 
Stromal DNA from patient 4 with tumour and stromal DNA from patient 5 had less 
than 7% promoter methylation at the CpG sites examined. Overall, except at 1 CpG 
site, the rest of the CpG sites had very low to no methylation.  
 
Table 3.2. Percentage methylation for KEAP1 promoter. The table shows the degree of 
methylation at CpG sites within KEAP1 promoter region spanned by KEAP1a and KEAP1b 
primers.  
Sample KEAP1a (% methylation) KEAP1b (% methylation) 
Tumour-4 0 0 0 0 0 0 0 0 11 0 0 
Stroma-4 2 0 6 4 5 4 0 0 4 0 0 
Tumour-5 2 0 6 3 5 0 0 3 5 3 4 
Stroma-5 2 2 6 3 4 0 0 0 5 0 0 
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3.3 Discussion 
 
Cell transfection such as with nucleic acids and/or transfection reagents could have 
untoward effects that blurs the understanding of cellular processes206. Optimizing the 
transfection protocol used in this thesis helped determine the optimum reagent 
volume and concentration to use and more importantly, to observe how transfection 
reagents can interfere with cell processes such as proliferation and as observed, 
higher volume of lipofectamine and higher concentration of siRNAs (both control and 
targeting siRNA) were associated with increased lethality to cells. As one of the 
proteins under investigation in this thesis is a stress related protein (Nrf2), achieving 
a transfection protocol that interfered minimally with the cell function was required 
in order to determine a clear difference between control and targeted treatment. 
Having established an optimum transfection protocol that was reasonably possible, 
undertaking subsequent transfection based cell experiments was reassuring of the 
experimental cell response outcome to either control or targeted treatment.  
Given that both UHRF1 and Nrf2 proteins have been reported to be overexpressed in 
pancreatic cancer and that Keap1 protein, the negative repressor of Nrf2 was found 
not to be expressed in approximately 70% of pancreatic cancers99, it was justified to 
further investigate the functional role of UHRF1 in the regulation of Nrf2 via Keap1-
Nrf2 pathway. UHRF1 is an epigenetic regulator that has DNA methylation and 
histone modification functions69. Here, evidence is provided at the transcript and 
protein level that UHRF1 regulates the Keap1-Nrf2 pathway and we propose a model 
(Figure 3.10). In MiaPaCa-2 and primary mouse KPC cell line, siRNA depletion of 
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UHRF1 was accompanied by upregulation of Keap1 and downregulation of Nrf2 and 
in Suit-2 cells, depletion of UHRF1 was also followed by a decrease in Nrf2 and Nrf2 
downstream targets, NQO1 and AKR1C1. Of note, concomitant depletion of UHRF1 
and Keap1 in MiaPaCa-2 cells restored Nrf2 protein to control levels. The mRNA 
transcript profile was however variable following UHRF1 depletion in Suit-2 cells. 
UHRF1 transcripts decreased steadily over the time course of the 24h, 48h and 72h 
as expected but KEAP1 transcripts upregulation was not sustained following UHRF1 
knockdown. The reason for this KEAP1 mRNA response could not be established but 
suggests Keap1 protein upregulation is an early event during UHRF1 depletion. 
Although Copple et al.87 reported the half-life of Keap1 in murine hepatoma cell lines 
(Hepa-1c1c7) was 11.3h, further investigation such as measuring Keap1 protein half-
life in PDAC cells may help clarify the discrepancy between upregulated Keap1 
proteins and low Keap1 mRNA at 72h following UHRF1 depletion. But there also 
remains the possibility that the functional significance of UHRF1 depletion may be 
due to epigenetic silencing of other (than KEAP1) targets. To provide evidence in 
support of whether or not KEAP1 promoter is methylated, the methylation status of 
the KEAP1 gene promoter in PDAC tissues needed to be investigated. Towards this 
end, a method for analysing KEAP1 gene promoter was developed to make way for 
future studies that will study KEAP1 promoter in PDAC samples. The lack of KEAP1 
promoter hypermethylation in the two tumour DNA samples investigated could 
suggest the possibility that in these patient samples Keap1 protein was expressed as 
a previous study reported that 30% of PDAC specimens examined expressed Keap199; 
however, I did not establish the Keap1 protein expression status of these patients 
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tumours. In addition, although no KEAP1 methylation was found in the stroma DNA, 
future experiments with normal pancreatic ducts as controls will be most ideal. This 
was only a method development and meaningful conclusion cannot be obtained from 
2 sample analysis. More importantly, this study demonstrates that sufficient DNA 
from five sections of FFPE tissue, each 10 µm thick can be isolated for downstream 
DNA analysis. Further research with a larger patient number will be required before 
conclusions can be reliably made. 
 I did not test for Keap1 protein levels in Suit-2 cells in my experiments as a colleague 
had previously demonstrated upregulation of Keap1 proteins at 72h following UHRF1 
knockdown. siRNA mediated Nrf2 depletion resulted in NRF2 transcript 
downregulation as expected. Depletion of UHRF1 led to a demonstrable NRF2 
transcript mRNA suppression at 72h after an initial NRF2 transcript upregulation at 
24h and 48h. The reason for this initial NRF2 transcript upregulation following UHRF1 
depletion could possibly be explained by an initial protective stress response 
mechanism by Suit-2 cells to UHRF1 knockdown. Nevertheless, a consistent finding 
and agreement between the Nrf2 mRNA and protein of Suit-2 cells after 72h of 
UHRF1 depletion is suppression Nrf2 mRNA and protein. These findings taken 
together demonstrate that UHRF1 may contribute to the regulation of Nrf2 at the 
mRNA and protein levels but importantly brings to focus the fact that UHRF1 may 
also be regulating NRF2 transcription in addition to silencing KEAP1 transcription. 
With this, a possible mechanism emerges, where UHRF1 regulates Nrf2 levels 
independent of Keap1. To test this model, further analysis such as examination of the 
effects of UHRF1 knockdown on Nrf2-null cells, chromatin immunoprecipitation 
131 
 
(ChIP) experiments and examination of the effects of UHRF1 depletion or 
overexpression on Nrf2 in Keap1-null cells will be required.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10. An illustration of the working model of UHRF1 in pancreatic cancer. Working model for UHRF1 
mediated regulation of Nrf2 via Keap1 silencing; UHRF1 indirectly stabilises Nrf2 protein levels by repressing 
KEAP1 transcription which is a negative regulator of Nrf2.  
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Nrf2 protects pancreatic cancer cells from oxidative stress98. Depletion of UHRF1 and 
Nrf2 independently, in both MiaPaCa-2 and Suit-2 cells increased the level of 
oxidative stress as determined by ROS in both cells whereas Keap1 knockdown and 
concomitant Keap1 and UHRF1 knockdown restored ROS to basal control levels. 
Additionally, ARE-driven luciferase reporter and GSH measurements both showed a 
significant decrease in ARE activity and GSH levels with independent siRNA mediated 
UHRF1 and Nrf2 knockdown. These findings further demonstrate that UHRF1 through 
deactivation of Keap1-Nrf2 pathway protects cells from cellular stress. 
UHRF1 may play an important role in regulating PDAC growth. Independent depletion 
of UHRF1 and Nrf2 caused both MiaPaCa-2 and Suit-2 cells to arrest in G2-M phase of 
the cell cycle although this effect appeared to be cell specific as the G2-M arrest was 
more prominent in MiaPaCa-2 than Suit-2 cells. It has been previously reported that 
Nrf2-null alveolar endothelial cells also arrested in G2-M207 and in other cancers 
UHRF1 depletion has led to G2-M arrest64. These findings further corroborate the cell 
cycle findings in this thesis and altogether, the findings of this chapter reinforce the 
role of UHRF1 in the regulation of Keap1-Nrf2 pathway in pancreatic cancer. 
Although, more mechanistic evidence of UHRF1 regulation of Keap1-Nrf2 pathway 
will be valuable in understanding this interaction. 
The lack of increased pancreatic cancer cell sensitivity to gemcitabine following 
UHRF1 depletion in this study could have been related to the activation of other 
survival response or regulatory pathways. Similarly, as presented in chapter 5.2.16 of 
this thesis, UHRF1 protein expression was not associated with survival in patients 
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who received gemcitabine chemotherapy. Gemcitabine induced-ROS and growth 
inhibition in pancreatic cancer has been reported previously208. A study by Yin et al.209 
demonstrated that Bmi1 (B-cell-specific Moloney murine leukemia virus insertion site 
1) promoted pancreatic cancer cell resistance to gemcitabine chemotherapy, an 
effect that was conferred by the antioxidant role of Bmi1 in regulating antioxidant 
genes and stimulation of NF-Kb signalling; importantly, they showed that certain 
doses of gemcitabine induced Bmi1 expression in pancreatic cancer cell lines and 
further demonstrated that Bmi1 depletion enhanced ROS production and enhanced 
pancreatic cancer cell sensitivity to gemcitabine cytotoxic effects 209. Bmi1 has been 
shown to be overexpressed in PanIN, pancreatic cancer tissues and pancreatic cancer 
cell lines where it is implicated in the growth and invasiveness of pancreatic cancer 
and in the regulation of pancreatic cancer stem cells210. It is tempting to speculate 
that combined depletion of UHRF1 and other protein targets in pancreatic cancer 
together with chemotherapy may effectively increase response to treatment.  
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4 INVESTIGATING THE FUNCTION OF 
UHRF1 ON THE NRF2 PATHWAY IN 
PANCREATIC STELLATE CELLS 
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4.1 Introduction 
 
In chapter 3, having investigated the role of UHRF1 in contributing to the Keap1/Nrf2 
pathway in pancreatic cancer cells, I sought to investigate the function of UHRF1 in 
pancreatic stellate cells (PSCs), one of the prominent cellular elements in pancreatic 
cancer211. Pancreatic cancer stroma is very heterogeneous and comprises of 
pancreatic stellate cells, immune cells, endothelial cells and extracellular matrix 
(desmoplasia), which have been attributed to contributing to pancreatic cancer’s 
immune escape, resistance to chemotherapy, proliferation and metastasis212-216. The 
desmoplasia seen in pancreatic cancer is thought primarily to be due to PSC 
activation212 and they play a prominent role in the tumour microenvironment217,218 .  
Owing to the growing interest in understanding the role of PSCs in pancreatic cancer 
progression and in developing potential targets for pancreatic cancer treatment, it 
was of interest to investigate the role of UHRF1 in PSCs. PSCs share similarities with 
fibroblasts108,121 and given that fibroblast activation can be mediated in part by 
epigenetic mechanisms like DNA methylation in kidney fibroblasts143, it was 
reasonable to conceive that UHRF1 which plays a key role in maintenance of DNA 
methylation65 might also be crucial to epigenetic processes in pancreatic stellate 
cells. Given the role myself and others in the group elucidated for UHRF1 in regulating 
Nrf2 in pancreatic cancer cells80, I sought to test the hypothesis that UHRF1 also 
controlled the growth rates and redox status in PSCs through Nrf2. To address this, 
quiescent mouse PSCs were isolated by myself and Dr Lawrence B. Barrera (University 
of Liverpool) from the pancreas of both Nrf2-null (Nrf2-/-) and Nrf2-wild type (Nrf2+/+) 
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mice. I also used human PSCs that were isolated by Dr Lawrence B. Barrera from 
pancreatic cancer patient tumours. The mice used in this study were kindly donated 
by Professor Chris Goldring (MRC Centre for Drug Safety Science, University of 
Liverpool). 
The aim of the study described in this chapter was therefore to (I) investigate the 
function of UHRF1 on Keap1/Nrf2 antioxidant pathway in PSCs (II) investigate the role 
and mechanism of UHRF1 in PSC activation (III) investigate the effect of conditioned 
media from pancreatic cancer cells on PSCs oxidative status and (IV) to examine the 
pancreas of Nrf2-null mice for pathological abnormalities.  
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4.2 Results 
 
4.2.1 Isolated stellate cells from the pancreas of both Nrf2 wild-type and Nrf2 null 
mice exhibit a quiescent phenotype 
 
In order to investigate the role of UHRF1 in pancreatic stellate cells, it was first 
important to characterize their phenotype. Pancreatic stellate cells were isolated 
from the pancreas of 10 week old Nrf2 wild-type and Nrf2 null mice. 
Immunofluorescence imaging of pancreatic stellate cells isolated from both mice 
revealed the presence of cytoplasmic vitamin A-containing lipid droplets (Figure 4.1) 
which is a marker of quiescent (inactivated) stellate cells122. Over the course of 
stellate cell expansion in culture, the amount of lipid droplets decreased 
progressively as the cells assumed an activated phenotype (Figure 4.2). 
 
4.2.2 Pancreatic stellate cell rescue 
 
Pancreatic stellate cells from both Nrf2+/+ and Nrf2-/- mice expanded well in culture 
in the first few days post-isolation (Figure 4.2 – top row). At 10 days post-isolation 
however, Nrf2-/- cell expansion decreased and cell death began to be observed 
(Figure 4.2 – bottom right). Attempts were made to prevent these cells from dying.  
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Figure 4.1. Immunofluorescence images of Nrf2+/+ stellate cells (left column) and Nrf2-/- stellate cells 
(right column) 24 h post-isolation from the pancreas of Nrf2+/+ and Nrf2-/- mouse respectively. Blue 
- DAPI, Red – lipid droplets. Magnification x 63 (oil immersion). 
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Figure 4.2. Pancreatic stellate cells in culture. Phase contrast microscopy of isolated Nrf2+/+ (left 
column) and Nrf2-/- (right column) stellate cells in culture at 5 days post-isolation (top row) and 10 
days post-isolation (bottom row). There is a lower cell density in Nrf2-/- PSCs culture compared to 
that of Nrf2+/+ PSCs. White arrow-head indicates a stellate cell with residual lipid droplets (white dots) 
surrounding the nucleus; black arrow-head indicates a necrosing/apoptosing Nrf2-/- PSC. 
 
Nrf2 null PSCs were treated with L-ascorbic acid (vitamin C) in increasing 
concentrations of 10 µM, 25 µM, 100 µM and 200 µM in IMDM (as vitamin C has been 
reported to provide a survival advantage in cells exposed to oxidative stress219. This 
was unsuccessful and the Nrf2-/- stellate cells could not be rescued (Figure 4.3).  
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Figure 4.3. Nrf2 -/- stellate cells rescue in culture. Phase contrast microscopy of isolated Nrf2-/- PSCs 
(A) at day 9 and (B) at day 13 after initiating L-ascorbic acid (vitamin C) treatment. White arrows 
indicate positions of tracked stellate cell during rescue effort. 
 
4.2.3 Differential expression of UHRF1 and α-SMA in PDAC cell lines and primary 
pancreatic stellate cell lines  
 
As the attempt to investigate the role of UHRF1 in the regulation of Nrf2 in PSCs 
derived from Nrf2-/- mice was unsuccessful, I now sought to investigate the function 
of UHRF1 in the regulation of Nrf2 in primary human pancreatic stellate cells (cancer 
associated fibroblasts, CAFs – pancreatic stellate cells isolated from within human 
pancreatic cancer tissue; normal activated fibroblasts, NAFs - pancreatic stellate cells 
isolated from adjacent normal pancreatic tissue derived from human pancreatic 
cancer tissue) isolated from human pancreatic tissues. To achieve this, the expression 
of UHRF1 in primary CAFs was first examined. Despite previous reports of UHRF1 
expression in fibroblasts61,62, UHRF1 protein was undetectable in primary pancreatic 
CAFs (Figure 4.4). As this was unexpected, additional primary isolated PSCs were 
examined. The result interestingly still confirmed the initial finding, which is a lack of 
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UHRF1 expression in all five PSCs examined while PDAC cell lines expressed UHRF1 
(Figure 4.5).  
 
Figure 4.4. Basal expression of UHRF1 and Nrf2. (A, B) Representative western blot images of 
indicated proteins from whole cell lysates of PDAC cell lines (MiaPaCa-2 and Suit-2) and primary 
pancreatic CAFs (CAF-R3088, CAF-R2875). UHRF1 1:1000, Nrf2 1:1000; β-actin and GAPDH were used 
as loading controls. n=2. 
 
To confirm that the primary PSCs cell lines used where myofibroblast-like (aPSCs), the 
expression of α-SMA a marker of aPSC122 was investigated. Characteristically, only 
PSCs expressed α-SMA while its expression was undetectable in PDAC cell lines 
despite over exposing the membranes (Figure 4.6).  
 
Given that one of the aims of this chapter was to investigate the role of UHRF1 in the 
regulation of Nrf2 in PSCs, the expression of Nrf2 was examined despite the lack of 
UHRF1 expression in PSCs. Notably, PSCs expressed Nrf2 in comparable and possibly 
higher levels to PDAC cells (Figure 4.4).   
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Figure 4.5. Basal expression of UHRF1. Representative western blot image of the indicated protein 
from whole cell lysates of PDAC cell lines and primary PSCs and fibroblasts. CP – chronic pancreatitis, 
HFF - (Human foreskin fibroblast) cell line. UHRF1 expression was overexposed. UHRF1 1:1000; GAPDH 
was used as loading control. n=2. 
 
Figure 4.6. Basal expression of α-SMA and UHRF1. Representative western blot image of the indicated 
protein for PDAC cell lines and primary PSCs and fibroblast cells. The membrane in Figure 4.5 above 
was stripped and used to probe α-SMA. HFF - (Human foreskin fibroblast) cell line. α-SMA expression 
were overexposed. α-SMA 1:500; GAPDH was used as loading control. n=2. 
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As part of the antibody validation and optimization for IHC, both western blotting and 
ICC were undertaken. UHRF1 antibody specificity was confirmed by western blotting 
which showed a single predominant 90kDa UHRF1 band following control and 
UHRF1-targeted siRNA depletion of UHRF1 in MiaPaCa-2 cells (Figure 4.7 A). UHRF1 
cell localization was determined by ICC in MiaPaCa-2 cells which detected brown 
nuclear staining in control treated cells (Figure 4.7 B – I) and predominantly blue 
nuclear cells in UHRF1 depleted cells (Figure 4.7 B – II). Using MiaPaCa-2 cells as 
positive controls, ICC was simultaneously undertaken for pancreatic CAFs and NAFs. 
As observed previously by western blotting CAFs lacked UHRF1 immunoreactivity but 
interestingly, only a few NAF cells in each of the 2 primary NAF cell lines examined 
expressed nuclear UHRF1. (Figure 4.8).  
 
 
Figure 4.7. Specificity of UHRF1 antibody used for immunocytochemistry and 
immunohistochemistry. (A) Western blot image of UHRF1 expression following siRNA mediated 
depletion in MiaPaCa-2 cells. UHRF1 1:1000; β-actin was used as loading control. (B) 
Immunocytochemistry for UHRF1 expression after (I) control siRNA and (II) UHRF1 targeting siRNA 
depletion in MiaPaCa-2 cell line. Brown nuclei immunoreactivity indicates positive UHRF1 staining. 
UHRF1 1:250 dilution; Scale bar = 100 µm. 
144 
 
 
Figure 4.8. Basal UHRF1 expression in primary PSCs. Immunocytochemistry showing basal UHRF1 
expression in CAFs (top row) and NAFs (bottom row). Black arrows indicates cells positive for nuclear 
UHRF1 within the field of view shown for NAF-R2797 and NAF-2796. CAF-R2875, CAF-R2910, NAF-
R2797 and NAF-R2796 have passage numbers 9, 6, 8 and 6 respectively. UHRF1 1:250 dilution; isolated 
primary human pancreatic fibroblasts courtesy of Dr Lawrence B. Barrera. Scale bar = 100 µm.  
 
4.2.4 Differential expression of UHRF1 and α-SMA in PDAC tissues 
 
Expanding on the above observations, TMA sections containing tissues from 
patients with PDAC were stained for UHRF1 and α-SMA. α-SMA stained tissues were 
undertaken by Ms Frances Atherton and Dr Anthony Evans in a previous study and 
we all used TMA sections obtained from the same TMA block; the difference being 
only in the depth at which the TMA sections were cut out from the block. Uniquely, 
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in all cores examined α-SMA was exclusively localized to the stromal compartment 
of the tumour microenvironment as have been previously reported220,221 whereas 
UHRF1 was detected as nuclear brown staining in cancer cells (Figure 4.9) with 
some occasional spindle shaped UHRF1 positive cells in the stroma (Figure 4.10). 
These observations correlated perfectly well with the readouts from western 
blotting and ICC.  
 
Figure 4.9. Examples of IHC TMA cores containing PDAC tissues stained for α-SMA (left column) and 
corresponding UHRF1 stained cores (right column). The corresponding cores for α-SMA and UHRF1 
were taken at different depths (106 and 134 respectively) from the same TMA block hence the slight 
variation in core appearance. Stromal brown immunoreactivity indicates positive α-SMA staining in 
CAFs (myofibroblast-like, spindle shaped) (left column) and nuclei brown staining indicates positive 
UHRF1 immunoreactivity in cancer cells (right column). UHRF1 1:100, α-SMA 1:50; α-SMA stained 
cores courtesy Ms Frances Atherton and Dr Anthony Evans. Scale bar = 100 µm. 
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Figure 4.10. Examples of stromal UHRF1 staining. Occasional spindle shaped UHRF1 positive staining 
cells (white arrows) were seen in PDAC stroma. Scale bar original image = 100 µm and magnified 
inset = 50 µm 
 
 
 
4.2.5 UHRF1 stromal expression in normal gastrointestinal tissues 
 
Most of the tissues examined so far were pathologically derived. Given PSCs share 
similarities with fibroblasts and myofibroblasts108,121, it was necessary to investigate 
these cells in other tissues. Fibroblasts and myofibroblasts have been shown to be 
present in normal intestinal stroma222. To determine if the absence of UHRF1 in 
other tissue fibroblast and myofibroblast was a recurring theme, the stroma of 
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normal tissues of the pancreas, liver, duodenum and colon were examined for 
UHRF1 expression. Rarely was UHRF1 expression observed in the stroma of normal 
liver (Figure 4.11), pancreas (Figure 4.12), duodenal and colonic tissues (Figure 
4.13). Interestingly, UHRF1 nuclei expression was observed in a distinct histological 
pattern in normal duodenal and colonic crypts (Figure 4.13,  
 
 
Figure 4.14). 
 
 
Figure 4.11. Representative images of a normal liver. H & E and UHRF1 stained sections of a normal liver showing 
hepatocytes and bile duct at 3 o’clock position negative for UHRF1 expression. UHRF1 1:100; scale bar = 200 µm 
(top row) and bottom row = 50 µm. 
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Figure 4.12. Representative images of a normal pancreas. H & E and UHRF1 stained sections of normal pancreatic 
sections negative for UHRF1 expression. Note the intralobular duct black arrow. The interlobular duct white arrow 
head surrounded by a thick fibrous layer. UHRF1 1:100; Scale bar = 200 µm (full core image) and magnified 
segment = 50 µm. 
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Figure 4.13. Representative images of normal duodenum and colon. H & E and UHRF1 stained sections of normal 
duodenum and colon sections. The mucosa is the innermost layer of duodenum and colon comprising of the 
glandular epithelium (GE), lamina propria (LP) and muscularis mucosae (MM). The submucosa (SM) is the next 
layer to the mucosa. The glandular epithelium, GE, forms crypts which are cylindrical structures. UHRF1 1:100; 
scale bar = 100 µm. 
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Figure 4.14. Representative image of a normal colon. UHRF1 stained sections of a normal colon. In the magnified 
image, UHRF1 staining is observed in some but not all of the basal crypt cells. The GE comprises of several cell 
types: stem cells, undifferentiated crypt cells, goblet cells, Paneth cells, absorptive cells and M cells. The LP 
provides connective stroma tissue support for the glandular GE. Note UHRF1 expression at the base of the crypts. 
Stem cells and other undifferentiated cells are located at the base of intestinal crypts. UHRF1 1:100; Scale bar = 
100 µm and magnified segment = 25 µm. 
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4.2.6 Conditioned media from cancer cells induces Nrf2 in pancreatic stellate cells 
 
To understand part of the functional interaction between pancreatic CAFs and 
pancreatic cancer, the effect of conditioned media from MiaPaCa-2 cell lines on 
primary CAF-R2875 was investigated using 8x ARE driven luciferase assay. An 
induction in Nrf2 activity was observed in CAF-R2875 following culture of CAF-R2875 
with conditioned media from MiaPaCa-2 cells (Figure 4.15). 
 
 
 
 
 
Figure 4.15. Induction of Nrf2 in CAF-R2875 primary cells with conditioned media from PDAC cell 
line dual-glo luciferase assay. The activity of Nrf2 dependent 8x ARE-reporter was measured after 36 
h of culturing CAF-R2875 cells in conditioned from MiaPaCa-2 cells. pGL4.74 [hRluc/TK] plasmid served 
as transfection control to normalize luciferase values.  N=2, hence statistical analysis not undertaken 
as data obtained from 2 experiments is not sufficient enough to draw a significant conclusion from. 
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4.2.7 Nrf2 null mice show differential weight gain and develop early signs of 
pancreatitis 
 
To investigate the effect of genetic deletion of Nrf2 on mice growth and pancreatic 
tissue morphology, four 10 month old mice (two Nrf2+/+ and two Nrf2-/-) were 
examined. Ten month old mice were chosen for this study to permit the detection of 
subtle changes over a longer period of observation in comparison to the 10 week old 
mice that were used for PSC isolation (Chapter 4.2.1) were the mean weight ± SD of 
both Nrf2+/+ and Nrf2 -/- mice was 21.1 ± 1.56g.  
There was a differential weight gain between the two 10 month old Nrf2+/+ mice 
compared with the two 10 month old Nrf2-/- mice; the mean weight of the two 10 
month old Nrf2+/+ mice was 53.2 g compared with the two 10 month old Nrf2-/- mice 
mean weight 34.45 g . As there were only 2 of each type of mice, no further statistical 
analysis was undertaken. Additional mice could not be sourced as the few we had 
were a gift and the mice are expensive. Importantly, acinar cell vacuolisation typical 
of that seen in early pancreatitis induced mice studies223,224 were observed and 
reported here for the first time in the pancreas of Nrf2-/- mice. No preneoplastic 
lesions, oedema, necrosis or areas of fibrosis where identified in the pancreas of 
either Nrf2+/+ or Nrf2-/- mice (Figure 4.16). 
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Figure 4.16. H and E sections of pancreatic tissue from Nrf2+/+ and Nrf2-/- mice (left column) and 
corresponding magnified images (right column). White arrows indicate vacuolated lesions in acinar 
cells from Nrf2 null pancreatic tissues. Scale bar = 100 µm 
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4.3 Discussion 
 
Pancreatic stellate cells (PSCs) play an important role in pancreatic cancer 
desmoplasia and in influencing the behaviour pancreatic cancer211. Identifying and 
understanding mechanisms and pathways by which PSCs interact with cancer cells 
and other stromal elements is crucial to developing strategies to intervene in this 
malignancy. 
Successful isolation of primary qPSCs from the pancreas of Nrf2-/- and Nrf2+/+ mice 
was demonstrated by the presence of vitamin A lipid droplets. Their subsequent 
activation in culture was also demonstrated by the gradual loss of vitamin A. Although 
the expression of α-SMA was not examined in the cultured PSCs, the disappearance 
of the vitamin A lipid droplets is in keeping with PSC activation in culture122,225. In 
culture however, both Nrf2-/- and Nrf2+/+ PSCs grew well initially but after an initial 
rapid expansion, the Nrf2-/- PSCs grew poorly. This observation is not surprising as 
Nrf2 is known to be vital to cell survival by maintaining the oxidative state of cells 
within physiological limits during basal and inducible oxidative metabolic states84. In 
an attempt to rescue the Nrf2-/- PSCs, vitamin C a water soluble antioxidant was 
added to cell culture medium. The rational for the use of vitamin C is based on 
findings from studies that show vitamin C enhanced the survival of oxidatively 
stressed cells219. However, despite vitamin C treatment, the Nrf2-/- PSCs did not 
survive in culture. Nrf2 deletion can gravely affect the entire repertoire of 
antioxidative and xenobiotic response and recovery219 with a resultant effect that 
mitigates the ability of the administered vitamin C in buffering the oxidative stress. 
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Vitamin C and glutathione (GSH) have been shown to cooperate in maintaining a 
potent antioxidant defence system219 and Nrf2 is known to induce the transcription 
of a host of genes that provide antioxidant, cellular defence and xenobiotic functions 
including enzymes glutamate cysteine ligase (GCL) that are crucial to GSH synthesis89. 
Of note, there was no differential weight gain between the 10 week old Nrf2-/- and 
Nrf2+/+ mice used for PSC isolation which is in keeping with previous reports226. This 
observation suggests that Nrf2-/- mice up to 10 weeks of age have similar growth 
patterns to their wild-type mice and this led to the gross assumption that when 
isolated, Nrf2-/- PSCs could survive in vitro forming the basis for a testable hypothesis. 
However, in culture Nrf2-/- PSCs failed to survive suggesting that their isolation and in 
vitro culture caused an inducible stress. The loss of the primary Nrf2-/- mouse PSCs 
meant the hypothesis relating to whether UHRF1 depletion affected proliferation and 
oxidative state in Nrf2-/- PSCs could not be tested.  
We have previously shown that loss of UHRF1 was followed by downregulation of 
Nrf2 and increased oxidative stress in pancreatic cancer cell lines and in the same 
study, we observed cytoplasmic UHRF1 expression in both cancer cells and stromal 
cells in addition to nuclear UHRF1 expression in cancer cells80. Given that a different 
anti-UHRF1 antibody was used for IHC in that report80 compared with the anti-UHRF1 
used in this thesis and our focus was not on the stroma, it was important to 
investigate whether UHRF1 was actually expressed in stromal cells. The anti-UHRF1 
used in this thesis only detected UHRF1 expression in the nucleus of cells. To 
demonstrate the role of UHRF1 on Nrf2 regulation and the potential epigenetic 
activation of primary human PSCs, the basal expression of UHRF1 was first examined. 
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Surprisingly, UHRF1 was undetectable by western blotting in primary PSCs (CAFs) as 
previous studies have demonstrated the expression of UHRF1 in fibroblasts61,62. 
However, on immunocytochemistry (ICC) a subset of primary PSCs (NAFs with a 
positivity of <3%) expressed nuclear UHRF1. Although the few positively staining 
UHRF1 NAF cells microscopically appeared identical to the rest of the UHRF1 negative 
NAF cells, it can be argued that they are a nonhomogeneous population of stromal 
cells as neither the nycodenz density gradient method nor the outgrowth method for 
PSCs isolation yields completely pure PSC population121; both methods were used to 
isolate PSCs used in this thesis. Despite the potential risk of not obtaining a pure PSC 
population, it is also possible that the very scanty UHRF1 staining NAF cells are truly 
PSCs in which case they could represent a subset of PSCs population. Moreover, 
subsets of fibroblasts population with different protein markers and functions have 
been proposed107,111. Previously, we reported variations in levels of UHRF1 at 
different stages of cell cycle in PDAC cells; it could be speculated that these UHRF1 
positive PSCs are in different stages of cell cycle. Obviously, more work needs to be 
undertaken before conclusions can be drawn. PSCs (CAFs and NAFs) however 
expressed α-SMA, a marker of activated PSCs which is absent in quiescent PSCs122,225. 
Conversely, MiaPaCa-2, Suit-2, Panc1 and other pancreatic cancer cell lines80 express 
UHRF1 but were negative for α-SMA. Importantly, Nrf2 expression was observed in 
both pancreatic cancer cell lines and primary pancreatic CAFs. IHC examination of 
pancreatic cancer tissues further supports the above findings where to a wider extent 
cancer cells express nuclear UHRF1 with very limited expression of UHRF1 in spindle 
shaped stromal cells whereas the tumour stroma was characterized by spindle 
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shaped cells expressing α-SMA. To ensure consistency in probing UHRF1, the same 
UHRF1 antibody was used throughout in this thesis for all the western blots, ICC and 
IHC undertaken. What is not yet known is whether qPSCs express UHRF1. Although 
qPSCs were not specifically stained for UHRF1 in freshly isolated PSCs, UHRF1 
expression was not observed in normal pancreas or liver sections. It can be 
speculated that qPSCs do not express UHRF1. To the best of our knowledge, this is 
the first report of UHRF1 expression in a subset of PSCs. 
Previous studies have documented the expression of UHRF1 in primary human 
fibroblasts cells61,62 and mouse embryonic fibroblast (MEFs)227. Mousli et al. showed 
UHRF1 expression in foetal primary lung fibroblasts, WI-38 and IMR-90 (derived from 
human lung foetuses at 12 and 16 weeks of gestation respectively), when grown and 
harvested under proliferating conditions (60–70% confluence), although UHRF1 
expression was lower in comparison to that in cancer cell lines62. Hopfner et al. also 
demonstrated UHRF1 expression in primary adult lung fibroblast cells (derived from 
adjacent normal lung tissue of a resected bronchial carcinoma patient) when grown 
and harvested under proliferating conditions; in addition, they examined UHRF1 
expression from non-growing 100% confluent fibroblasts that had been serum 
starved for 48 hours and reported a very weak expression of UHRF161. However, I 
harvested PSCs in culture at approximately 80% confluence as the primary interest 
was first to determine the basal levels of UHRF1. Nevertheless, pancreatic cancer 
tissue sections examined for UHRF1 in situ, only rarely expressed UHRF1 in tissue 
stroma. Furthermore, the foetal origin of lung fibroblast and the expression of UHRF1 
in adult lung fibroblast and basal crypts of the intestine raises the possibility that 
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UHRF1 may confer some degree of stemness in a cell type or age (foetal or adult) 
dependent manner. Based on these observations, it can be suggested that UHRF1 
expression in PDAC could be a marker of stemness or proliferative activity.  
The phenotypic effect of Nrf2 deletion was not evident at the early age of 10 weeks 
as both Nrf2-/- and Nrf2+/+ mice had similar weights which is in agreement with a 
previous study showing no early growth or phenotypic consequences in Nrf2-/- 
mice226. However, at 10 months of age, there was a differential weight gain with 
Nrf2+/+ mice weighing significantly more than the Nrf2-/- mice. More importantly, at 
10 months of age the pancreas of the Nrf2-/- mice showed early signs of 
pancreatitis223,224 as evidenced by the appearance of vacuolated lesions in acinar cells 
which were absent in Nrf2+/+ mice pancreas. Similar vacuolated lesions have been 
reported in different regions of the brain of Nrf2-/- mice older than 10 months of 
age92.The finding of vacuolated lesions in the pancreas of Nrf2-/- mice is novel to the 
best of our knowledge and further provide evidence in support of the vital function 
of Nrf2 in maintaining homeostasis at basal conditions. Taking advantage of this 
observation and looking at the positive side, Nrf2-/- mice or more specifically a 
targeted pancreas specific Nrf2 knockout could be used to investigate the protective 
and therapeutic role of Nrf2 in pancreatitis induced mouse models. With such a 
model, the development of early and florid pancreatitis picture is likely to allow for 
shortened time of experimentation in pancreatitis induced setting. Microscopic 
changes in the pancreas of Nrf2-/- and Nrf2+/+ mice at an earlier age of 10 weeks was 
not undertaken.  
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Several studies have demonstrated a cross-talk between pancreatic cancer cells and 
PSCs215,228. In investigating the mechanism by which pancreatic cancer cells promote 
PSC activity, conditioned media from MiaPaCa-2 was used to culture and induce Nrf2 
activity in PSCs (CAF-R2875). Although the Nrf2 induction in CAF-R2875 did not reach 
statistical significance, it is proof of principle that Nrf2 can be induced in CAFs. 
Nevertheless, additional experiments will be required to confirm this finding since it 
can be argued that conditioned media is spent which in itself could induce Nrf2 
activity independent of secreted factors from cancer cells. The significance of Nrf2 
induction can be seen from studies that have demonstrated glutathione (GSH) efflux 
from hepatic cells into the plasma to exert distant antioxidant extracellular effects229. 
Nrf2 contributes to the regulation of GSH synthesis by inducing the transcription of 
enzymes required for GSH synthesis89. It can be speculated that Nrf2 induction in 
PSCs (CAFs) by cancer cells provides additional drive for GSH synthesis which is 
subsequently effluxed229 into the tumour stroma where it can provide GSH substrates 
to the cancer cells as well as antioxidant and xenobiotic functions within the 
extracellular space of the tumour stroma. More recently, Martinez-Outschoorn et 
al.230 showed that H-Ras transformed immortalized keratinocytes (epithelial cancer 
cells) manifest an increased oxidative stress evidenced by increased ROS production, 
an effect which was rescued by n-acetyl cysteine (NAC); they further demonstrated 
that co-culture of epithelial Ras transformed cancer cells with fibroblasts reduced 
ROS production in these cancer cells suggesting that fibroblasts may protect adjacent 
cancer cells from oxidative stress by stimulating an antioxidant response in such 
cancer cells230. We speculate from our results that in response to secreted factors 
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from cancer cells, CAFs (aPSCs) induce their own antioxidant response and secrete 
antioxidant factors into the stroma to protect cancer cells. PSCs can also induce Nrf2 
in cancer cells as demonstrated by Wu et al.215. This observation suggests the 
possibility of a feedback loop and a vicious circle where both cancer cells and PSCs 
promote a potent antioxidant intracellular and extracellular defence environment. 
An interesting and new observation was made in normal tissues of intestine (colon 
and duodenum) which were used as orientation cores in TMA generated for use in 
this thesis. Briefly, the colonic epithelium makes invaginations called glandular 
crypts; at the base of the crypts are adult somatic stem cells that are responsible for 
regenerating the colonic epithelium231-233. Pericryptal myofibroblasts located around 
the colonic crypts form the stem cell niche and provide signalling factors that 
maintain the stem cells in an undifferentiated state222,231,233. The concentration of the 
signalling factors decrease from the basal crypts further away towards the luminal 
surface of the colonic epithelium; this creates a signalling gradient that determines 
cell behaviour at different histological levels of the colonic epithelium233. The UHRF1 
IHC data of normal duodenum and colonic epithelium from this thesis uniquely 
showed UHRF1 expression localised to histologically defined intestinal basal crypts 
areas where intestinal stem cells are known to reside233. These findings, although not 
the primary focus of my thesis are really interesting. UHRF1 expression has been 
observed in cancer cells and in proliferative areas of human appendix59,61. Using IHC, 
Hopfner et al.61 examined UHRF1 expression in the proliferative areas (glandular 
crypts) of human appendix and reported nuclei UHRF1 expression localized to the 
glandular crypts just as observed in this thesis. In addition, normal active tissues 
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(proliferative tissues) of foetal liver, foetal thymus, adult thymus and bone marrow 
were found to be tissues richest in UHRF1 mRNA whereas well differentiated tissues 
of the central nervous system and peripheral leucocytes were free of UHRF1 mRNA61. 
Studies in mouse embryonic stem cells have indicated a role for UHRF1 during 
embryogenesis and development227 and may explain UHRF1 expression within this 
defining proliferative stem cell layer (intestinal crypts) of intestinal epithelium in this 
case possibly functioning as marker of stemness. In this context, the expression of 
UHRF1 can be considered to be function specific, organ or tissue specific and when 
found with in an organ or tissue like the intestine its expression may have to be 
histologically defined within a normal intestinal mucosa. 
Only a few other studies have reported on the expression of UHRF1 in intestinal 
tissues. Kofunato Y. et al.78 and Wang F. et al.234 examined normal colon and colon 
cancer tissues and reported the absence of UHRF1 expression in non-neoplastic 
adjacent normal colonic epithelial cells and UHRF1 overexpression in colorectal 
cancer tissues78,234. None of these studies reported on the pattern of UHRF1 
expression in normal colon observed in this thesis. The differences in expression 
could reasonably be due to different anti-UHRF1 antibodies used in those studies 
compared to that used in this thesis and by Hopfner et al61. 
This is a novel finding of UHRF1 expression in the intestinal mucosa that can be 
carried forward. Understanding the signals that regulate the tight expression of 
UHRF1 within basal intestinal crypts and factors that aberrantly induce UHRF1 
expression in pancreatic ductal epithelium could provide better understanding of the 
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function of UHRF1 and in normal and diseased states. Taken together, these data 
suggest UHRF1 may have no role in the majority of adult human PSCs. The 
significance of UHRF1 expression in the subset of PSC population is undetermined 
and the classic histological distribution pattern of UHRF1 in intestinal epithelium may 
be worth investigating further. 
In conclusion, the findings in this chapter further reflect differences between non-
malignant stromal PSCs and cancer cells as having different molecular signatures and 
further suggests that PSCs have a role to play in modulating oxidative stress in PDAC. 
Deciphering the precise role of PSCs and its subtypes will greatly improve our 
approach to targeting the stroma as part of a combined therapeutic approach to 
addressing this disease.  
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5 EXAMINATION FOR POTENTIAL 
PREDICTIVE BIOMARKERS FOR 
PANCREATIC CANCER  
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5.1 Introduction 
 
The dismal outcome associated with pancreatic cancer235 needs to be improved. The 
widening understanding of the molecular and cellular basis of pancreatic cancer may 
potentially lead to more targeted and novel therapies16,236 but enhancing the 
predictability of patient response to both current and novel therapies could 
potentially change survival for pancreatic cancer patients146.  
Using patients’ tissue samples from the European Study Group for Pancreatic Cancer-
3 (ESPAC-3) trial, which did not show any significant overall survival benefit with 
adjuvant 5-fluorouracil (5-FU) plus folinic acid (551 patients) compared to 
gemcitabine (537 patients) treatment7, Greenhalf et al. showed that high levels of 
human equilibrative nucleoside transporter 1 (hENT1) was predictive for better 
survival in patients treated with gemcitabine but not with 5-FU146. Recent work within 
our research group, and presented in this thesis has indicated an important role for 
both UHRF1 and Nrf2 in contributing to the stabilization of oxidative stress in 
pancreatic cancer80,99. In other cancers, single nucleotide polymorphisms (SNPs) in 
antioxidant and drug detoxifying genes and tissue levels of putative proteins are 
emerging as predictive biomarkers170,171,237,238. However, in pancreatic cancer, there 
are currently no biomarkers in routine use that can predict which patients will 
respond to treatment16. 
The aims of the study described in this chapter were: (I) to investigate whether 
germline SNPs and tumour protein expression of oxidative stress and drug 
metabolising enzymes could be prognostic for survival or predict response to 
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chemotherapy treatment in pancreatic cancer patients and (II) to determine if an 
automated scoring system using Definiens software could complement manual 
scoring for the expression levels of proteins in IHC stained tissues. To address these 
aims, putative germline SNPs of NRF2, NQO1 and SRXN1 were analysed from whole 
blood from two clinical trials of advanced pancreatic cancer patients29,30. In addition, 
the analysis of the respective protein levels in pancreatic cancer tissues from 
adjuvant clinical trial samples was attempted146. Finally, UHRF1 protein expression in 
pancreatic cancer tissues was also examined and measured. 
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5.2 Results  
 
5.2.1 SNP genotyping 
 
Three SNPs one each for NRF2 (rs2886162), NQO1 (rs1800566) and SRXN1 
(rs6053666) were genotyped (Figure 5.1). Three different genotypes for each gene 
were observed (major homozygous, minor homozygous and heterozygous, Table 
5.1); however, for NQO1, there was only one patient with minor homozygous (TT) 
genotype, so they were grouped with heterozygous (CT) patient for further analysis. 
The SNP genotypes were tested for concordance with HWE; the observed genotype 
frequencies did not significantly deviate from the HWE (Table 5.1). 
 
 
 
 
 
 
 
Figure 5.1 Representative allelic discrimination plots for NRF2, NQO1 and SRXN1 SNPs. Minor homozygous 
allele VIC dye-labelled (wavelength 523 – 568) is on the X axis and major homozygous allele FAM dye-labelled 
(wavelength 483 – 533) is on the Y axis. The heterozygous genotype has a fluorescence intensity that is 
intermediate between that of homozygous major and minor alleles. Each SNP/patient was genotyped in triplicate 
and there was 100% concordance. Each patient is represented as three dots on each plot. 
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Table 5.1. Allelic and genotypic frequency table for 149 patients and genotype concordance with Hardy-
Weinberg equilibrium (HWE) based on a European population. 
Gene SNP ID Allele 
(minor/major) 
Allelic 
Frequencies 
(%) 
Homozygous 
minor 
(n) 
Homozygous 
major 
(n) 
Heterozygous 
(n) 
χ2 
P value 
for HWE 
 
NRF2 rs2886162 A/G 49/51 AA (34) GG (37) AG (78) 0.779 
NQO1 rs1800566 T/C 19.5/80.5 TT (1) CC (92) CT (56) 0.192 
SRXN1 rs6053666 C/T 34.9/65.1 CC (13) TT (58) CT (78) 0.173 
 
 
5.2.2 Patient dataset 
SNP data was ascertained for 106 ViP and 43 TeloVac patients. Of these, SNP data for 
97 (92%) VIP patients were analysed (as 9 of the samples were for patients screened 
and consented but ultimately not randomised). All 43 TeloVac patients were 
analysed, making a combined dataset of 140 patients.  
 
5.2.3 Analyses of ViP patients 
 
In ViP patients, univariate analysis for NRF2/NQ01/SRXN1 SNPs revealed no 
significant correlation between individual SNPs and overall survival (OS) (Appendix 5, 
Table A1). Multivariate models without NRF2/NQO1/SRXN1 SNPs were fitted for log 
CA19-9, ECOG status and differentiation status which were significantly associated 
with OS (p=0.008, 0.001 and 0.027 respectively, Appendix 7). NRF2/NQO1/SRXN1 
SNPs were added to the multivariate model with log CA19-9 and ECOG status and no 
SNP significantly correlated with OS (Appendix 5, Table A2). 
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5.2.4 Analyses of TeloVac patients 
 
In the univariate analysis for Telovac patients, only the NQO1 SNP rs1800566 was 
observed to be significantly associated with OS (p=0.038) with the major homozygous 
CC correlating with an unfavourable prognosis (Appendix 6, Table A3). Multivariate 
models without NRF2/NQO1/SRXN1 SNPs were fitted and log CA19-9 was 
significantly associated with OS (p=0.007,  
Appendix 8). NRF2/NQO1/SRXN1 SNPs were then added to the multivariate model 
with log CA19-9 and no SNP significantly correlated with OS although the NQO1 SNP 
showed a trend for an independent association with survival (p=0.053), (Appendix 6, 
Table A4). 
 
5.2.5 Overall survival analysis for ViP and TeloVac patients combined 
 
5.2.5.1 NQO1 genotype is an independent prognostic biomarker in advanced 
pancreatic cancer patients 
 
A Kaplan-Meier (KM) analysis for overall survival by trial (ViP and Telovac trials) and 
by SNP (both trials combined) is shown in Figure 5.2. There was no significant 
difference in OS between patients from either trial; the median (95% CI) survival for 
ViP patients was 9.38 (7.73, 11.48) months compared with 8.98 (4.80, 12.23) months 
for TeloVac patients (p=0.969, Table 5.2 and Figure 5.2 A). The median (95% CI) 
survival by SNP for combined ViP and TeloVac patients is shown in Table 5.2. NQO1 
rs1800566 showed a significant correlation with OS; patients with the NQO1 CC major 
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genotype had a significantly poorer outcome than patients with CT and TT NQO1 
genotypes combined (p=0.010 Figure 5.2 C).  No SNP–related differences in survival 
for NRF2 and SRXN1 SNPs were observed (p=0.405 and p=0.634 respectively, Figure 
5.2 B and D). Multivariate models without NRF2/NQO1/SRXN1 SNPs were fitted and 
log CA19-9 was significantly associated with OS (p=0.001, Appendix 9, Table A7). 
NRF2/NQO1/SRXN1 SNPs were then added to the model with log CA19-9, and only 
NQO1 SNP emerged as independently significantly associated with OS (p=0.028, 
Table 5.2).  
 
Table 5.2. Median overall survival of SNP genotypes for combined ViP and TeloVac data and the univariate 
and multivariate analysis.  
   Univariate Multivariate* 
Prognostic 
Variable 
No of 
patients 
(deaths) 
Median OS (95% 
CI) 
HR p HR p 
NRF2 
        AA 
        AG 
        GG 
 
30 (23) 
75 (62) 
35 (31) 
 
8.03 (4.77,17.00) 
8.95 (7.70,11.02) 
9.24 (5.00,13.03) 
 
1.34(0.84, 2.17) 
1.08 (0.63,1.86) 
0.405 
(0.353 AG 
and GG 
consolidated) 
  
0.511 
NQO1 
       TT/CT 
       CC 
 
55 (40) 
85 (76) 
 
11.34 (8.94,12.96) 
7.83 (5.19,10.86) 
 
 
1.66 (1.12,2.46) 
 
 
0.010 
 
 
1.56(1.04,2.32) 
 
0.028 
SRXN1 
       CC 
       CT 
       TT 
 
12 (10) 
75 (64) 
53 (42) 
 
11.77 (1.71,18.29) 
10.86 (7.73,12.43) 
 8.16 (5.33, 9.67) 
 
 
0.93 (0.43,1.86) 
0.83 (0.56,1.22) 
 
0.634 
  
0.295 
 
Trial 
    ViP 
    TeloVac 
 
97 (93) 
43 (23) 
 
9.38 (7.73, 11.48) 
8.98 (4.80, 12.23) 
 
  
0.969 
  
*Log CA19-9 included as explanatory variable, Trial as a stratified variable 
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Figure 5.2. Kaplan-Meier analysis of overall survival by trial and by SNP in advanced pancreatic cancer 
patients for the TeloVac and ViP trials. (A) Survival plot for TeloVac and ViP data. (B, C and D) Survival plot for 
combined VIP and TeloVac data by NRF2, NQO1 and SRXN1 respectively. P values were derived from univariate 
Cox regression analysis. 
 
 
5.2.5.2 Combined NQO1 and SRXN1 genotypes are independent prognostic biomarkers in 
advanced pancreatic cancer.  
 
Given that the median overall survival for heterozygous (CT) and minor homozygous 
(CC) SRXN1 genotypes were similar to each other and more importantly that they 
were different from the major homozygous (TT) SRXN1 genotype, patients with both 
the CT and the CC genotypes were consolidated and their survival compared against 
those with major homozygous (TT) SRXN1 genotypes (Figure 5.3). The median (95% 
CI) survival for patients with SRXN1 CC/CT of 10.86 (8.22, 12.8) months was not 
significantly different in comparison to 8.16 (6.02, 10.86) months for wild-type (TT) 
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homozygous SRXN1 (p=0.371). A further consolidation was undertaken between 
patients with SRXN1 and NQO1 SNPs to create new group variables (Table 5.3) given 
that the median overall survival for heterozygous and minor homozygous genotypes 
for both NQO1 and SRXN1 were similar to each other but different from their 
corresponding major homozygous genotypes.  
 
 
 
 
 
Figure 5.3. Kaplan-Meier survival curves of consolidated SRXN1 genotype. Survival plot for VIP and TeloVac 
data for combined CC and CT versus TT SRXN1 SNP. P value was derived from univariate Cox regression analysis. 
 
Table 5.3. New variables after SRXN1 and NQO1 genotype consolidation; group 1 - pure homozygous major 
genotypes; group 4 – pure heterozygous/homozygous minor genotypes and groups 2 and 3 together make 
the 3rd variant. 
              SRXN1  
 
 
 
Prognostic variable 
 
 TT 
 (homozygous major) 
CT/CC  
(heterozygous and 
homozygous minor)  
 
Total 
CC  
(homozygous major) 
 
    33 (Group 1) 
 
  52 (Group 2) 
 
85 
CT/TT  
(heterozygous and 
homozygous minor) 
 
    20 (Group 3) 
 
  35 (Group 4) 
 
55 
     Total 53 87 140 
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Interestingly, patients with purely heterozygous and homozygous minor genotypes 
for both SRXN1 and NQO1 (group 4) had significantly better survival with a median 
(95% CI) survival of 12.27 (8.95, 17.01) months than pure homozygous majors for 
both SRXN1 and NQO1 (group 1) with a median survival of 6.68 (4.77, 10.86) months 
or mixed homozygous major with heterozygous and homozygous minor genotypes 
for both SRXN1 and NQO1 (groups 2 and 3) with a median survival of 8.98 (7.5, 11.88) 
months (p=0.039, Figure 5.4, Table 5.4). In addition, multivariate analysis using Cox 
proportional hazard regression identified pure heterozygous and homozygous minor 
genotypes for both SRXN1 and NQO1 (group 4) as independent prognostic factors for 
overall survival in PDAC patients (hazard ratio = 0.5, 95% CI= 0.29 to 0.88, p=0.016). 
 
 
 
 
 
  
Figure 5.4. Kaplan-Meier survival curves of consolidated SRXN1 and NQO1 genotypes. Survival plot for VIP and 
TeloVac data for combined NQO1 and SRXN1 SNPs as shown in Table 5.3. P value was derived from univariate 
Cox regression analysis. 
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Table 5.4. Median overall survival of consolidated SRXN1 and NQO1 SNP genotypes for combined ViP and 
TeloVac data and the univariate and multivariate analysis. 
   Univariate Multivariate 
Prognostic 
Variable 
No of 
patients 
(deaths) 
Median OS (95% 
CI) 
HR p HR p 
 
(Group 1) 
 
 
33 (27) 
 
 
 
6.68 (4.77,10.86) 
 
 
 
1.0 (ref) 
 
   
 
 (Group 2  
and 3) 
 
 
72 (64) 
 
 
 
8.98 (7.5, 11.88) 
 
 
 
0.81 (0.52, 1.27) 
 
 
 
 
 
0.81 (0.51, 1.26) 
 
 
0.353 
 
(Group 4) 
 
35 (25) 
 
12.27 (8.95, 17.01) 
 
 
0.51 (0.29, 0.88 ) 
 
 
0.039 
 
0.5 (0.29, 0.88) 
 
0.016 
 
 
 
 
5.2.6 Evaluating the predictive effect of SNP on treatment 
 
Only patients from the ViP trial were evaluated for the predictive effect of SNP on 
treatment as patient numbers from the TeloVac trial were small and in addition had 
different treatments to those in ViP. The differential effect of treatment category for 
each type of SNP covariates were assessed by fitting multivariate models including 
treatment as a nested effect within each type of SNP to investigate the effect of 
gemcitabine alone compared with gemcitabine plus vandetanib for each category of 
SNP. Each multivariable model also included ECOG status as an independent 
prognostic variable. No SNP had a predictive effect on treatment in the multivariate 
models fitted but ECOG status correlated with survival in the multivariate models for 
NRF2 (p=0.004), SRXN1 (p=0.015) and was tending towards significance for NQO1 
(p=0.053, Appendix 10 and Appendix 11). 
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5.2.7 Antibody validation for immunohistochemistry in resected pancreatic cancer 
patients (ESPAC-1 and ESPAC-3) 
 
Antibodies for NQO1, Srxn1 and Nrf2 were validated using western blotting and were 
subsequently optimized for immunocytochemistry (ICC) and immunohistochemistry 
(IHC) with cell pellets and PDAC TMAs respectively. Western blotting for NQO1 
revealed a single band that was reduced in intensity following targeted siRNA 
mediated depletion (Figure 5.5). Nrf2 and Srxn1 immunoblots also revealed bands at 
the expected molecular weight that decreased in intensity following targeted siRNA-
mediated depletion of corresponding proteins, but in addition contained other 
nonspecific bands which were not affected by the knockdown (Figure 5.5).  
 
 
 
 
 
 
 
 
Figure 5.5. Antibody validation for NQO1, Srxn1 and Nrf2 in MiaPaCa-2 cells. Western blot images showing 
antibody specificity of indicated proteins following NQO1, Srxn1 or Nrf2 depletion by siRNA. 
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The specificity of all three antibodies for use with ICC was tested using siRNA-
mediated depletion of their corresponding proteins. The specificity of the antibodies 
for Nrf2 and Srxn1 could not be confirmed (Figure 5.6 A-D). Interestingly, Nrf2 
depleted cell pellets failed to remain adherent to the glass slides during routine 
antigen retrieval (heat induced) processing and therefore could not be stained for 
Nrf2; the reason for the detachment of Nrf2 depleted cells from glass slides during 
this step could not be ascertained in this study. Attempts were made to treat cells on 
cover slips and avoided the antigen retrieval steps but these also proved unsuccessful 
in confirming the specificity of the antibody (Figure 5.6). The NQO1 antibody was 
successfully optimized (Figure 5.6 E and F); the results differentiated NQO1 depleted 
cells from control treated cells and as a result, only the NQO1 antibody was carried 
forward for use on the ESPAC TMAs.  
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Figure 5.6 Assessment of antibody specificity for immunocytochemistry. MiaPaCa-2 cells treated with control or 
indicated targeting siRNAs were embedded in paraffin and stained for Srxn1 (C, D) and NQO1 (E, F) while Nrf2 
siRNA-treated cells and the corresponding control cells were prepared on cover slips (A, B). In both Nrf2 and Srxn1 
depleted cells, no observable differences in staining was seen between control treated and targeted protein 
depleted cells. NQO1 control treated cells expressed brown positive cytoplasmic staining (E) while no staining is 
seen in NQO1 depleted cells indicative of antibody specificity. Scale bar = 100 µm 
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5.2.8 UHRF1 and NQO1 immunohistochemistry staining in normal pancreatic 
tissues 
 
Normal pancreatic tissues were first examined for UHRF1 and NQO1 expression. In 
normal pancreatic tissues, UHRF1 expression was not observed in intralobular or 
interlobular ducts or ductules whereas in serial tissue section, NQO1 expression was 
variable ranging from no expression in intralobular ducts and/or ductules to weak 
cytoplasmic staining in interlobular ducts (Figure 5.7). No UHRF1 nor NQO1 staining 
was seen in acinar tissues. 
 
 
 
 
 
 
 
 
Figure 5.7. Representative micrographs of normal pancreatic tissue. (A) Matched core sections of a normal 
pancreas with intact acinar and ductal architecture; magnified inset shows normal intralobular duct (red arrow) 
surrounded by a layer of fibrous sheath (FS) and normal intralobular ductule (black arrow) with no or very scanty 
fibrous sheath. Tissues were stained for UHRF1 and NQO1 as indicated and both ducts, ductules and acinar tissue 
did not express UHRF1 or NQO1. (B) Matched core sections of a normal pancreas showing one of the main ducts 
(black arrow) at the centre of the core surrounded by thick fibrous sheath (FS) with red arrows indicating a visible 
part of the ductal epithelium; normal acinar tissue (white arrows) can be seen at 12 and 7 o’clock positions and 
NQO1 positively-stained (brown) ducts. Magnified inset shows cytoplasmic NQO1 staining in interlobular ducts 
but no corresponding UHRF1 immunoreactivity. Scale bar = 200µm and magnified inset 50µm.  
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5.2.9 UHRF1 and NQO1 immunohistochemistry staining in adjacent normal 
pancreatic tissues and ducts 
 
Adjacent normal pancreatic tissue with normal appearing pancreatic ducts were also 
examined and variable UHRF1 expression was observed between patients, ranging 
from negative expression in some patients to positive nuclei expression in others; 
NQO1 expression was observed in the cytoplasm of all normal appearing ducts of 
matched adjacent normal pancreatic tissues (Figure 5.8 and Appendix 12). Within 
pancreatic cancer cores, adjacent normal-appearing ducts generally had weaker 
cytoplasmic NQO1 expression than malignant ducts; an example of normal duct 
transformation (cancerization) further illustrates this differential NQO1 expression 
where normal ducts stain weakly for cytoplasmic NQO1 and the transformed (cancer) 
cells stain strongly (Figure 5.9 and Appendix 12). Neither UHRF1 nor NQO1 expression 
was observed in acinar tissues.  
Interestingly, some lymphoid cells within pancreatic lymphoid tissue obtained from 
adjacent PDAC tissues expressed UHRF1 (Figure 5.10), with some of these also 
observed in the stroma of some PDAC patients (Figure 5.9 and Appendix 14, image 
C). NQO1 also stained endothelial cells in pancreatic tissues (lymphoid and malignant 
tissues, Figure 5.10 and Appendix 14, image B), in keeping with previous studies that 
reported NQO1 staining in blood vessels147.  
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Figure 5.8. Representative micrographs of adjacent normal pancreatic tissues. (A) Matched core sections of 
adjacent normal pancreas from healthy tissue donor with intact acinar and ductal architecture; magnified inset 
shows normal appearing intralobular duct. No ductal (black arrow with a circle) UHRF1 immunoreactivity is 
observed but NQO1 has positive cytoplasmic immunoreactivity. (B) Matched core sections of adjacent normal 
pancreas from PDAC patient showing normal looking ducts and acinar tissue architecture; magnified inset shows 
normal appearing interlobular duct with a few brown nuclei staining for UHRF1 and positively-stained brown 
cytoplasmic NQO1 immunoreactivity. Tissues stained with haematoxylin and eosin, or for UHRF1 and NQO1 as 
indicated. Scale bar = 200µm and magnified inset 50µm.  
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Figure 5.9. Example of normal duct cancerization. Magnified inset of matched cores from a PDAC patient showing 
normal duct undergoing transformation; cancer cells can be seen arising from 1 o’clock and 3 – 6 o’clock position 
with a distorted nuclei arrangement whilst the remaining normal ductal epithelia maintained uniform nuclei 
alignment. Tissues stained for UHRF1 and NQO1 as indicated. No UHRF1 immunoreactivity is observed within the 
normal and malignant ductal cells but a few cells in the stroma stain positively for UHRF1. Stronger NQO1 
expression is seen in the malignant area of the ductal epithelium while a weak cytoplasmic NQO1 staining is 
observed in the remaining aspect of the normal epithelium. Scale bar = 200µm and magnified inset 50µm 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10. Representative micrographs of pancreatic lymphoid tissues from PDAC patients. (A) Matched core 
sections of a lymphoid tissue. Tissues stained for UHRF1 and NQO1 as indicated and brown positive UHRF1 
immunoreactivity of some lymphoid/immune cells can be seen; brown immunoreactivity for NQO1 (red arrow) 
stains blood vessels but not lymphoid/immune cells. (B) Matched core sections of a lymphoid tissue from a PDAC 
patient. Both lymphoid tissue and pancreatic ducts can be seen in this core. Magnified inset – smaller positively 
staining brown UHRF1 lymphoid/immune cells can be seen whilst larger positive UHRF1 staining pancreatic duct 
nuclei can be seen to the right extending from 2 to 5 O’clock position. NQO1 vividly stains pancreatic ducts. Scale 
bar = 200µm and magnified inset 50µm.  
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5.2.10 UHRF1 and NQO1 immunohistochemistry staining in normal colon and 
duodenum 
 
Normal tissue cores of duodenum and colon which were present on the PDAC TMAs 
as orientation cores were also examined for UHRF1 and NQO1 expression. UHRF1 
uniquely stained glandular epithelial cells limited to the basal crypts with no 
immunoreactivity in the glandular epithelia located proximal to the luminal part of 
the intestinal epithelium in both colon and duodenum (Figure 5.11). NQO1 
expression was inversely related to UHRF1 expression; in areas where UHRF1 was 
expressed, NQO1 was negligibly or weakly expressed. Similarly, in areas of the 
intestinal epithelium were UHRF1 was not expressed, NQO1 was strongly expressed 
resulting in a gradient of NQO1 expression across the entire intestinal epithelium 
(Figure 5.11). 
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Figure 5.11. Example micrographs of UHRF1 and NQO1 expression in matched normal duodenum and colon 
from donor tissues. (A) Duodenum (B) Colon (C) Colon. In both colon and duodenum, UHRF1 nuclei expression is 
seen within the basal part of the glandular epithelial (GE) cells with an abrupt loss of UHRF1 beyond this zone 
towards the luminal layer of the GE. A gradient of NQO1 expression is seen in both colon and duodenum with 
weak cytoplasmic expression in GE cells in the basal aspect of the GE and stronger expression towards the luminal 
surface. LP, lamina propria; MM, muscularis mucosae; SM, submucosa. Scale bar = 100µm 
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5.2.11 UHRF1 and NQO1 immunohistochemistry staining and manual scoring in 
PDAC 
 
UHRF1 expression was confined to the nuclei and tumour in cores were scored as 
either abundant (≥ 75 %), moderate (25 % to < 75 %), scanty (5 % to < 25 %) or 
negative (< 5 %) based on the proportion of the tumour cells expressing UHRF1 
(Figure 5.12 and Appendix 13), whilst NQO1 cores were scored as: (I) strong, 
moderate, weak or negative for cytoplasmic immunoreactivity, (II) positive or 
negative for nuclei expression and (III) positive or negative stromal expression (Figure 
5.13 and Appendix 13).  
 
 
 
 
 
 
 
 
 
 
Figure 5.12. Example micrographs of UHRF1 expression in PDAC samples and cells. (A) Negative expression (B) 
Scanty nuclei expression (C) Moderate nuclei expression (D) Abundant nuclei expression. Red arrow - normal 
appearing adjacent duct negative for UHRF1 expression. Note the distorted pancreatic architecture with loss of 
acinar tissue in PDAC. Scale bar 200µm   
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Figure 5.13. Example micrographs of NQO1 expression in PDAC samples and cells. (A) Negative tumour 
expression (B) Weak cytoplasmic tumour expression (C) Moderate cytoplasmic tumour expression (D) Strong 
cytoplasmic tumour expression (E) Moderate cytoplasmic tumour expression with positive nuclei staining and 
stromal expression of NQO1. Scale bar = 200µm. (F) Weak cytoplasmic and (G) Moderate cytoplasmic tumour 
expression of NQO1 with positive nuclei expression. Scale bar = 50µm. 
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5.2.12 UHRF1 and NQO1 immunohistochemistry staining and Definiens (software) 
scoring in PDAC 
 
Given that automation can be time saving, robust and can yield reproducible high-
throughput data, an attempt was made to use Definiens software to complement 
manual scoring for TMAs stained for UHRF1 and NQO1. Depending on the type of 
analysis executed, several output data are generated; for UHRF1 ‘nuclei and marker 
area’ analysis was used which generated, amongst other values, a positive index (PI) 
(Figure 5.14), whilst for NQO1 a ‘marker area’ analysis was used which generated a 
histologic score (H-score) (Figure 5.15). Comparative statistical analyses were 
undertaken to assess the correlation between manual UHRF1 versus Definiens PI 
score (Figure 5.16A and B), and manual cytoplasmic NQO1 versus Definiens H-score 
(Figure 5.16C and D). A statistically significant correlation between manual and 
Definiens scores was seen for both UHRF1 and NQO1 (Figure 5.16A, B, C and D). With 
the exception of a nonsignificant difference between NQO1 moderate and strong 
cytoplasmic scores and Definiens H-score (Figure 5.16C), there is an overlap in 
assignment of Definiens analysis scores for a corresponding manually scored UHRF1 
or NQO1 expression.  
In the case of UHRF1 expression analysis by Definiens, both brown UHRF1 nuclear 
and blue haematoxylin nuclear staining cancer cells were required to compute the PI 
score as described previously in section 2.27.6.2. An overestimation or 
underestimation is introduced when blue haematoxylin-stained or the brown UHRF1-
stained cells respectively are not captured in the computation of PI (Figure 5.14).  
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In the case of NQO1 expression analysis by Definiens, cytoplasmic NQO1 expression 
was of interest. However, some patients displayed nuclear NQO1 in addition to 
cytoplasmic staining. Their H-scores were falsely higher because nuclear expression, 
which generally had a stronger NQO1 immunoreactivity, was automatically included 
in the computation of H-score (Figure 5.15). In summary, use of Definiens led to 
overestimation or underestimation of PI values for UHRF1 for some patients, and 
overestimation of H-score values for cytoplasmic NQO1 in some cases (Figure 5.16). 
Only manual scores were carried forward for subsequent data analysis. 
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Figure 5.14. Representative images of Definiens software ‘NUCLEI and MARKER AREA’ analysis for UHRF1. (A 
and D) are two original IHC images before Definiens analysis. Definiens software computes a positive index (PI) % 
value after analysis of the region of interest (ROI, cancer cell nuclei); (B and E) Initial Definiens analysis with a PI 
of 15% and 12% for patients (B) and (E) respectively. After correcting for the ROI, the PI increased markedly for 
(B) from 15 to 53% (C) and increased slightly for (E) from 12 to 17% (F). However, there are numerous cancer 
nuclei (red arrows) not included in the PI analysis as they have remained purple during the analysis (not 
highlighted blue). 
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Figure 5.15. Representative images of Definiens software ‘MARKER AREA’ analysis for cytoplasmic NQO1. (A, 
no NQO1 expression; C, strong NQO1 expression; E, weak with some moderate expression and G, moderate 
cytoplasm with positive nuclei) are four original IHC images before Definiens analysis. (B, D, F and H) Images after 
Definiens analysis of the corresponding images to the left; Green corresponds to weak, orange corresponds to 
moderate and red corresponds to strong NQO1 expression. H-scores B = 0; D = 255.63; F= 134; H = 192. Note, 
positive nuclei staining in (G) appearing as red in (H) has skewed the H-score towards higher values.  
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Figure 5.16. Comparison of manual UHRF1 and NQO1 scores with Definiens positive index (PI) for UHRF1 and 
H-score for NQO1. (A and B = UHRF1), (C and D = NQO1). (A) Four group manual UHRF1 scores vs PI values. (B) 
Consolidated UHRF1 manual - low (negative plus scanty) and high (moderate plus abundant). (C) Four group 
manual NQO1 scores vs H-score values. (D) Consolidated NQO1 manual - low (negative plus weak) and high 
(moderate plus strong). Two tailed t-test, (B and D), ANOVA, (A and C). ns, not significant; ***, p<0.001 
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5.2.13 UHRF1 and NQO1 immunohistochemistry data analysis  
 
Nine tissue microarrays representing 349 patients, 318 adjuvant chemotherapy-
treated (gemcitabine or 5FU/folinic acid) patients plus 31 observation only (true 
resection only) patients, were each analyzed for UHRF1 and NQO1 expression. Of the 
chemotherapy treated, 181 (56.9%) patients with 362 cores together with 18 
observation only patients (58.1%) with 74 cores for UHRF1 and 187 (58.8%) 
chemotherapy-treated patients with 374 cores together with 20 (64.5%) observation 
only patients with 81 cores for NQO1 were suitable and included in the final analysis. 
To be included in the final analysis, patients must have 2 or more eligible cores. 
Reasons for ineligibility included patients with one single representative core, 
completely missing cores, folded cores or no histological evidence of cancer cells on 
the core. 
5.2.14 UHRF1 and NQO1 are overexpressed in pancreatic cancer 
 
Although only a few normal pancreatic specimen were available to be examined and 
compared with resected pancreatic cancer tissues, both UHRF1 and NQO1 were 
observed to be overexpressed in comparison to adjacent normal pancreatic ducts 
within the same tumour cores (Figure 5.7 and Figure 5.9), as expected80,160. Eighteen 
(9.1%) patient tumours scored negative for UHRF1 and 181 (90.9%) scored positive; 
of those who scored positive for UHRF1, 80 (40.2%) scored scanty, 57 (28.6%) scored 
moderate and 44 (22.1%) scored abundant. NQO1 staining was also variable between 
patients.  
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Ten (4.8%) patients scored negative for NQO1 whilst 197 (95.2%) patients’ tumours 
were positive cytoplasmic NQO1; in patients who were positive for cytoplasmic 
NQO1, 62 (30%) scored weak, 109 (52.7%) scored moderate and 26 patients (12.6%) 
scored strong. Nuclei and stromal expression were also observed for NQO1 with 124 
(59.9%) and 19 (9.2%) of the patients scoring positive for nuclei and stromal NQO1 
respectively. There was a bias in the classification of nuclei NQO1 scores in patients 
who had moderate to strong cytoplasmic NQO1 as it was difficult to identify their 
nuclear expression; as a result further NQO1 nuclei analysis was not undertaken. 
Patients who scored negative for cytoplasmic NQO1 were also negative for nuclear 
and stromal NQO1 immunoreactivity.  
 
5.2.15 Clinicopathological correlation of UHRF1 and NQO1 in pancreatic cancer  
 
The association between UHRF1 and NQO1 with clinical and tumour characteristics 
was investigated. UHRF1 levels were dichotomized into low (negative and scanty) and 
high (moderate and abundant). UHRF1 expression was significantly associated with 
tumour staging (p=0.048) and diabetic status (p=0.029, Table 5.5). Statistical 
significance was lost after retesting using negative, scanty, moderate and abundant 
UHRF1 levels versus tumour staging (p=0.374, Table 5.6) whilst for diabetic status, 
statistical significance further improved (p=0.005, Table 5.6). A trend emerged where 
an inverse relationship between UHRF1 level and diabetic status was observed; 
patients with diabetes are less likely to express high UHRF1 (Figure 5.17).  
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NQO1 cytoplasmic protein levels were also dichotomized into low (negative and 
weak) and high (moderate and strong) but no statistically significant association with 
clinicopathological parameters was observed (Table 5.7). 
The association between UHRF1 and cytoplasmic NQO1 was also investigated; high 
UHRF1 expression correlated significantly with high cytoplasmic NQO1 (p=0.003) and 
stromal positivity (p=0.009, Table 5.8). Patients with high cytoplasmic NQO1 were 
significantly associated with a positive NQO1 stromal expression (p=0.022, Table 5.9). 
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Table 5.5. Relationship between UHRF1 protein levels and clinicopathological parameters.  
 
Characteristic   Number Low UHRF1 High UHRF1 P 
Stage 
  1    11  9  2  0.048 † 
  2    43  19  24   
  3    106  48  58   
  4    8  6  2 
 
Lymph node status 
  Negative   38  23  15  0.128 † 
  Positive   150  70  80 
 
Tumour grade 
  Well    14  8  6  0.641 † 
  Moderate   113  57  56 
  Poor    56  25  31 
 
Maximum tumour  
diameter 
  <30 mm   79  42  37  0.538 † 
  ≥30 mm   103  50  53 
 
Diabetes 
  No    138  60  78  0.029 † 
  Yes    45  28  17   
 
Sex 
  Male    106  51  55  0.674 † 
  Female   82  42  40 
 
Age, y 
  <60    71  35  36  0.971 †  
  ≥60    117  58  59 
 
†, χ2 test two-tailed  
 
 
 
 
 
 
194 
 
Table 5.6. Relationship between tumour stage and diabetes versus UHRF1 protein levels (negative, scanty, 
moderate and abundant)  
 
UHRF1 
Characteristic Number Negative    Scanty    Moderate    Abundant              P 
Stage 
  1  11  2          7                  2                    0  0.374 † 
  2  43  3         16              11      13   
  3  106  7         41             32      26   
  4  8  1         5              1        1 
 
 
Diabetes 
  No  138   7                   53               40                38                0.005 † 
  Yes  45   9         19               12                 5   
 
†, χ2 test two-tailed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.17. Relationship between UHRF1 and diabetes. Bar chart showing the inverse relationship between 
UHRF1 protein levels and diabetic status. Patient numbers are indicated at the top of each bar.  no = no diabetes; 
yes = diabetes. 
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Table 5.7. Relationship between NQO1 protein levels and clinicopathological parameters. 
 
Characteristic   Number Low NQO1 High NQO1 P 
Stage 
  1    13  5  8  0.569 †  
  2    49  14  35 
  3    105  42  63 
  4    7  3  4 
 
Lymph node status 
  Negative   45  15  30  0.683 †  
  Positive   150  55  95 
 
Tumour grade 
  Well    12  4  8  0.406 † 
  Moderate   116  37  79 
  Poor    62  26  36 
 
Maximum tumour  
diameter 
  <30 mm   92  33  59  0.923 † 
  ≥30 mm   93  34  59 
 
Diabetes 
  No    146  49  97  0.185 † 
  Yes    45  20  25 
   
Sex 
  Male    82  33  49  0.282 † 
  Female   113  37  76 
 
Age, y 
  <60    77  27  50  0.845 † 
  ≥60    118  43  75 
 
†, χ2 test two-tailed; Low and High NQO1 = Low and High cytoplasmic NQO1 expression  
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 Table 5.8. Relationship between UHRF1 and NQO1 protein levels  
Protein expression  Number Low UHRF1 High UHRF1 P 
Cytoplasmic NQO1 
  Low    56  36  20  0.003 †  
  High    104  41  63 
 
 
Stromal NQO1 
  Negative   143  74  69  0.009 *  
  Positive   17  3  14 
 
†, χ2 test two-tailed; * Fischer’s exact test two-tailed 
 
 
 
 
 Table 5.9. Relationship between cytoplasmic and stromal NQO1 protein levels  
Protein expression  Number Low NQO1 High NQO1 P 
Stromal NQO1 
       Negative   188  70  118  0.022 *  
       Positive   19  2  17 
 
†, χ2 test two-tailed; * Fischer’s exact test two-tailed Low and High NQO1, Low and High 
cytoplasmic NQO1 expression 
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5.2.16 Overall survival analysis  
 
5.2.16.1 NQO1 protein levels but not UHRF1 protein levels are associated with 
survival in pancreatic cancer 
 
Overall survival was estimated using Kaplan-Meier survival curves and compared 
using log-rank tests. Available retrospective data from ESPAC-1 and ESPAC-3 trials 
were used to test for differences in survival between adjuvant chemotherapy treated 
patients and resection only (observation only) patients. The median overall survival 
for adjuvant chemotherapy treated patients was 20.2 (95% CI=16.7 to 22.7) months 
compared with 8.6 (95% CI=6.1 to 15.2) months for observation only patients 
(p=0.021, Figure 5.18) and in agreement with the results from ESPAC-1 and -3 (v1) 
trial with a statistically significant difference between adjuvant chemotherapy (5-FU) 
versus resection only19.   
There was no difference in survival for patients treated with gemcitabine, median 
survival 21.0 months (95% CI=16.3 to 24.8) months versus 5FU/folinic acid treated 
patients, median survival 18.5 (95% CI=15.3 to 22.3) months (p=0.997, Figure 5.18 B) 
and consistent with the previous report from ESPAC-3 (v2) trial where adjuvant 5-
FU/folinic acid was not superior to adjuvant gemcitabine7. No statistically significant 
difference in median overall survival was observed for UHRF1 expression.  
The median (95% CI) overall survival for negative, scanty, moderate and abundant 
UHRF1 expression was 16.8 (6.3 to 27.6), 22.1 (16.4 to 26.5), 15.2 (13.7 to 20.12) and 
18.5 (14.2 to 29.3) months respectively (p=0.581, Figure 5.18 C). In the dichotomized 
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plot, median (95% CI) overall survival for low and high UHRF1 protein expression was 
21.3 (16.4 to 26.5) and 16.7 (14.3 to 20.6) months respectively (p=0.478, Figure 5.18 
C).  
In the case of NQO1 protein expression analysis, an increasing trend in median overall 
survival was observed. The median (95% CI) overall survival for negative, weak, 
moderate and strong expressers was 10.2 (7.6 to 32.3), 13.4 (10.9 to 15.8), 18.8 (15.5 
to 24.5) and 25 (17.3 to 39.1) months respectively (p=0.007, Figure 5.18 D). When 
patients were dichotomized into high and low expression, the median (95% CI) overall 
survival for low and high NQO1 protein expressers was 13.4 (10.9 to 15.3) and 20.9 
(16.7 to 25.1) months respectively, (p=0.003, Figure 5.18 D). 
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Figure 5.18. Kaplan-Meier overall survival curves stratified by (A) treatment arm- chemotherapy (Gemcitabine 
and 5Flourouracil/folinic acid versus observation only (resection only); (B) treatment arm- Gemcitabine versus 5-
Flourouracil/folinic acid; (C) UHRF1 and (D) by NQO1 protein expression. P values were determined by log-rank 
testing. All statistical tests were 2-sided. 5FU = 5 Fluorouracil plus folinic acid; GEM = Gemcitabine. 
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5.2.16.2 NQO1 protein levels but not UHRF1 protein levels may be associated with 
response to treatment in pancreatic cancer 
 
To determine if UHRF1 or NQO1 protein levels are predictive of response to 
treatment in PDAC patients, pairwise comparisons were undertaken for both proteins 
(Figure 5.19 and Figure 5.20). UHRF1 protein levels were not prognostic in the 
observation only group [median (95% CI) survival of 15.2 (6.8 to 18.8) months in high 
UHRF1 group versus 6.5 (5.4 to 32.4) months in low UHRF1 group, p=0.882, Figure 
5.19 B], nor were they predictive of response to treatment (p=0.79, Figure 5.19A, C, 
D, E and F, Table 5.10). 
The median survival of patients treated with gemcitabine with low NQO1 levels was 
13.7 (95% CI 10.2 to 16.8) versus 24.2 (95% CI 16.3 to 29.5) months in patients with 
high NQO1 expression (p=0.013, Figure 5.20 D). In 5FU/folinic acid treated patients, 
the median survival difference was tending towards significance with 13.4 (95% CI 
10.9 to 19.6) months for low NQO1 levels compared with 21.8 (95 % CI 16.9 to 25.7) 
months for patients with high NQO1 levels (p=0.083, Figure 5.20 C). Although NQO1 
levels were significantly associated with response to treatment in the gemcitabine 
group, there is no sufficient evidence to suggest its levels are predictive of response 
to treatment. NQO1 levels were not prognostic of survival for the observation only 
group [median (95% CI) survival of 6.8 (6.0 to 18.8) months in high NQO1 group versus 
5.4 (4.8 to 14.3 months in low NQO1 group, p=0.301, Figure 5.20 D). Other pairwise 
comparisons were not found to be significant (Figure 5.20 E and F, Table 5.11). 
 
201 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.19. Kaplan-Meier overall survival curves stratified by (A) chemotherapy and UHRF1 protein expression 
(B) observation only (resection only) and UHRF1 protein expression; (C) 5-Flourouracil/folinic acid and UHRF1 
protein expression; (D) Gemcitabine and UHRF1 protein expression  (E) Gemcitabine or 5FU/folinic acid treated 
patients expressing low UHRF1 (F) Gemcitabine or 5FU/folinic acid treated patients expressing high UHRF1. P 
values were determined by log-rank test. All statistical tests were 2-sided. 5FU = 5 Fluorouracil plus folinic acid; 
GEM = Gemcitabine 
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Figure 5.20. Kaplan-Meier overall survival curves stratified by (A) chemotherapy and NQO1 protein expression 
(B) observation only (resection only) and UHRF1 protein expression; (C) 5-Flourouracil/folinic acid and NQO1 
protein expression; (D) Gemcitabine and NQO1 protein expression  (E) Gemcitabine or 5FU/folinic acid treated 
patients expressing low NQO1 (F) Gemcitabine or 5FU/folinic acid treated patients expressing high NQO1. P values 
were determined by log-rank test. All statistical tests were 2-sided. 5FU = 5 Fluorouracil plus folinic acid; GEM = 
Gemcitabine.  
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Table 5.10. Median survival for UHRF1 levels by treatment group. Differences between groups was determined 
by Kaplan-Meier curves and Log-rank test. 5FU = 5 Fluorouracil/folinic acid, GEM = Gemcitabine; CI = confidence 
interval Multivariate Cox proportional hazard regression analysis stratified by chemotherapy 
 
Variable No of patients 
(deaths) 
Median OS (95% 
CI) 
p 
 
5FU_High  
 
 
 
42 (37) 
 
 
 
15.0 (10.9, 20.2) 
 
 
5FU_Low  
 
 
 
49 (43) 
 
 
 
22.3 (16.4, 27.3) 
 
 
GEM_High 
 
 
 
44 (39) 
 
 
 
20.6 (14.6, 24.5) 
 
 
GEM_Low  
 
 
 
35 (31) 
 
 
 
21.3 (15.4, 31.4) 
 
 
Table 5.11. Median0 survival for NQO1 levels by treatment group. Differences between groups was determined 
by Kaplan-Meier curves and Log-rank test. 5FU = 5 Fluorouracil/folinic acid, GEM = Gemcitabine; CI = confidence 
interval Multivariate Cox proportional hazard regression analysis stratified by chemotherapy 
 
Variable No of patients 
(deaths) 
Median OS 
(95% CI) 
p 
 
5FU_High  
 
 
 
56 (48) 
 
 
 
21.8 (16.9, 25.7) 
 
 
5FU_Low  
 
 
 
35 (30) 
 
 
 
13.4 (10.9, 19.6) 
 
 
GEM_High 
 
 
 
55 (48) 
 
 
 
24.2 (16.3, 29.5) 
 
 
GEM_Low  
 
 
 
29 (26) 
 
 
 
13.7 (10.2, 16.8) 
 
 
 
 
 
0.794 
0.024 
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5.2.16.3 NQO1 protein expression is not an independent predictive biomarker of response to 
adjuvant gemcitabine treatment. 
 
Univariate Cox proportional hazard analysis (Table 5.12) revealed that gemcitabine 
treated PDAC patients with high cytoplasmic NQO1 exhibited higher overall survival 
with a hazard ratio (HR) of 0.55 (95% CI=0.34 to 0.89, p=0.018) compared with 
patients with low NQO1 cytoplasmic expression. In the case of 5FU/folinic acid 
treated PDAC patients, NQO1 levels were not significantly associated with better 
survival (HR=0.66, 95% CI=0.42 to 1.06, p=0.09) for high cytoplasmic NQO1 
expressers compared with low expressers. When gemcitabine and 5FU/folinic acid 
treated patients were combined, NQO1 was significantly associated with survival 
(HR=0.59, 95% CI=0.43 to 0.84, p=0.003). Additionally, tumour stage, lymph node 
status, tumour grade, maximum tumour diameter and resection margin were 
significantly associated with overall survival (Table 5.12).  
To explore the effects of several covariates on survival, a multivariable Cox 
proportional hazard regression model was fitted for variables that were significant 
(p<0.1 for gemcitabine treatment arm) in the univariate analysis. NQO1 protein levels 
did not emerge as an independent predictive factor (HR=0.69, 95% CI=0.39 to 1.2, 
p=0.19, for high NQO1 levels compared with low NQO1) in adjuvant gemcitabine 
treated patients (Table 5.13). NQO1 as a covariate in 5FU/folinic acid treated patients 
remained nonsignificant in the multivariate analysis (HR=0.86, 95% CI=0.51 to 1.43, 
p=0.56, Table 5.13).   
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Table 5.12. Univariate Cox proportional hazard analysis of survival factors stratified by chemotherapy* 
                       HR (95%) CI 
                         Chemotherapy 
Characteristic   5-FU/folinic acid   Gemcitabine  Total  
Stage    n = 110   n = 99   n = 209 
  1   1.00 (ref) p=0.119 1.00 (ref) p=0.223 1.00 (ref) p=0.018 
  2   1.42 (0.63 to 3.20) 1.55 (0.37 to 6.57) 1.45 (0.73 to 2.89) 
  3   2.07 (0.98 to 4.40) 2.35 (0.57 to 9.70) 2.15 (1.12 to 4.13) 
  4   1.22 (0.36 to 4.06) 1.96 (0.36 to 10.81) 1.48 (0.58 to 3.75) 
 
Lymph node status  n = 111   n = 100   n = 211  
  Negative  1.00 (ref) p=0.0003 1.00 (ref) p=0.085 1.00 (ref) p=0.0001 
  Positive  2.61 (1.48 to 4.60) 1.55 (0.92 to 2.61) 2.02 (1.39 to 2.95) 
 
 
Tumour grade   n = 108   n = 98   n = 206 
  Well   1.00 (ref) p=0.82  1.00 (ref) p=0.04  1.00 (ref) p=0.21 
  Moderate  0.76 (0.30 to 1.90) 1.07 (0.46 to 2.51) 0.92 (0.50 to 1.72) 
  Poor   0.83 (0.31 to 2.19) 1.97 (0.81 to 4.80) 1.25 (0.65 to 2.39) 
 
Maximum tumour    
Diameter   n = 108   n = 92   n = 200 
  <30 mm  1.00 (ref) p=0.250 1.00 (ref) p=0.014 1.00 (ref) p=0.016 
  ≥30 mm  1.27 (0.84 to 1.93) 1.78 (1.11 to 2.86) 1.46 (1.07 to 1.98) 
 
Resection margin   n = 111   n = 100   n = 211 
  Negative  1.00 (ref) p=0.068 1.00 (ref) p=0.153 1.00 (ref) p=0.019 
  Positive  1.46 (0.97 to 2.20) 1.37 (0.89 to 2.10) 1.06 (1.05 to 1.91) 
 
Diabetes   n = 107   n = 98   n = 205 
  No   1.00 (ref) p=0.95  1.00 (ref) p=0.48  1.00 (ref) p=0.64 
  Yes   1.02 (0.60 to 1.73) 1.21 (0.72 to 2.02) 1.09 (0.76 to 1.58) 
 
Sex    n = 111   n = 100   n = 211 
  Female   1.00 (ref) p=0.79  1.00 (ref) p=0.31  1.00 (ref) p=0.65 
  Male   1.06 (0.71 to 1.58) 0.80 (0.53 to 1.23) 0.93 (0.70 to 1.25) 
 
Age, y    n = 111   n = 100   n = 211  
  <60   1.00 (ref) p=0.75  1.00 (ref) p=0.19  1.00 (ref) p=0.31 
  ≥60   0.94 (0.62 to 1.41) 0.74 (0.48 to 1.15) 0.86 (0.64 to 1.15) 
 
Smoking    n = 102   n = 95   n = 197 
  Never   1.00 (ref) p=0.89  1.00 (ref) p=0.14  1.00 (ref) p=0.71 
  Past   0.98 (0.62 to 1.56) 1.30 (0.81 to 2.07) 1.11 (0.80 to 1.54) 
  Present  0.88 (0.49 to 1.57) 2.00 (1.03 to 3.90) 1.18 (0.76 to 1.82) 
 
NQO1    n = 91   n = 84   n = 175 
  Low   1.00 (ref) p=0.09   1.00 (ref) p=0.018 1.00 (ref) p=0.003 
  High   0.66 (0.42 to 1.06) 0.55 (0.34 to 0.89) 0.59 (0.43 to 0.84) 
 
UHRF1    n = 91   n = 79   n = 170 
  Low   1.00 (ref) p=0.35  1.00 (ref) p=0.92  1.00 (ref) p=0.48 
  High   1.24 (0.79 to 1.93) 0.98 (0.61 to 1.57) 1.12 (0.82 to 1.55) 
 
* All statistical test were two-tailed. 5-FU = 5-Fluorouracil; CI = confidence interval; HR = hazard 
ratio; ref = reference   
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Table 5.13. Multivariable Cox proportional hazard regression analysis stratified by chemotherapy* 
                       HR (95%) CI 
                         Chemotherapy 
Characteristic   5-FU/folinic acid (n=85) Gemcitabine (n=75) Total (n=160)  
 
Lymph node status    
  Negative  1.00 (ref)  1.00 (ref)  1.00 (ref)  
  Positive  3.75 (1.74 to 8.09) 2.18 (1.21 to 3.94) 2.73 (1.73 to 4.31) 
   p=0.0008   p=0.0095   p<0.0001 
Maximum tumour    
Diameter    
  <30 mm  1.00 (ref)  1.00 (ref)  1.00 (ref)  
  ≥30 mm  1.22 (0.76 to 1.95) 1.99 (1.16 to 3.42) 1.47 (1.04 to 2.08)
   p=0.41   p=0.01    p=0.03 
 
Tumour grade   
  Well   1.00 (ref)  1.00 (ref)  1.00 (ref)  
  Moderate  0.47 (0.11 to 2.04) 1.23 (0.50 to 3.01) 0.91 (0.44 to 1.91) 
   p=0.32   p=0.65   p=0.81 
  Poor   0.67 (0.15 to 3.01) 2.46 (0.94 to 6.43) 1.44 (0.66 to 3.11) 
   p=0.60   p=0.07   p=0.36 
 
NQO1     
  Low   1.00 (ref)  1.00 (ref)  1.00 (ref)  
  High   0.86 (0.51 to 1.43) 0.69 (0.39 to 1.2)  0.73 (0.50 to 1.05) 
   p=0.56   p=0.19    p=0.09 
 
 
           
* All statistical test were two-tailed. 5-FU = 5-Fluorouracil; CI = confidence interval; HR = hazard 
ratio; ref = reference    
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5.3 Discussion  
 
This study is the first analysis in advanced pancreatic cancer patients to show an 
interesting link between an NQO1 C609T (rs1800566) germline polymorphism and 
survival. Of the three SNPs investigated (one each for NRF2 (rs2886162), NQO1 
(rs1800566) and SRXN1 (rs6053666) only the NQO1 SNP was associated with survival. 
Patients with the NQO1 CC major homozygous genotype had a significantly 
unfavourable outcome compared to patients with TT and CT NQO1 genotypes 
combined. Individuals with homozygous NQO1 TT express little or no active enzyme, 
the heterozygous CT express intermediate activity with a half-life of 1.2 h and 
homozygous major CC have a half-life of over 18 h169. Although, NQO1 (rs1800566) 
SNP was the only individual SNP associated with survival, our analysis indicates that 
combining pure heterozygous and homozygous minor genotypes for both NQO1 and 
SRXN1 SNPs gave a better survival difference. This suggests that combining 
biomarkers may be a better strategy for prognosticating patient subgroups. In this 
study, we could not establish an association between any SNP and a particular type 
of treatment.  
To the best of our knowledge, there are no published reports on the prognostic or 
predictive effects of the germline NQO1 C609T polymorphism in advanced pancreatic 
cancer. The NQO1 SNP has been studied in other cancers where Fagerholm et al.171 
and Kolesar et al.170 reported a poor OS for homozygous minor TT NQO1 C609T in 
breast and lung cancer respectively. Fagerholm et al. was a Finnish study undertaken 
in breast cancer patients [n=2,167 with 71 (3.3%) homozygous TT minor] who had 
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surgery followed by adjuvant anthracycline-based chemotherapy with epirubicin171. 
Similarly, the study by Kolesar et al. [n=152 with 24 (16%) homozygous TT minor] 
involved non-small cell lung cancer (NSCLC) patients (where 85% of the patients were 
Caucasians) who had surgical resection for stages II and IIIa NSCLC followed with 
radiotherapy or combined radiotherapy plus chemotherapy cisplatin and 
etoposide170. In both studies, major and heterozygous (CC and CT) genotypes were 
grouped as one category (as the survival curves of NQO1 heterozygotes resembled 
that of homozygous wild-types171) and compared against TT; CC/CT genotypes had a 
better OS than homozygous minor TT. In our study however (n=140), the comparison 
was between NQO1 homozygous major CC and heterozygous and homozygous minor 
CT/TT as there was just one TT patient. Nevertheless, a significant difference in 
survival between CC and CT/TT was observed in our study (UK based study) and it is 
possible that the differences between these studies and ours may be related to 
disease-specific or treatment-specific effects since NQO1 C609T polymorphism was 
investigated in patients with different cancers170,171 who had surgical resection 
followed by adjuvant chemotherapy with different treatment agents compared to 
patients in our dataset who had advanced pancreatic cancer (and were therefore not 
suitable for surgical resection) and received systemic gemcitabine based 
regimens29,30. 
This study had some limitations. Analysis, particularly for the TeloVac patients, was 
confined to the small number of patients available for this study. It was not possible 
to meaningfully investigate whether the minor homozygote TT for NQO1 was 
prognostic for OS as only one patient with NQO1 TT was observed in this study. 
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Furthermore, the lack of a treatment naïve (observation only) group in this study 
limits our conclusion on whether this NQO1 polymorphism is only prognostic of 
survival or is also predictive of response to treatment. Analysis of this NQO1 SNP in 
the context of chemotherapy and in an observation only arm will permit the 
assessment of this SNP as a prognostic only survival variable or a predictive treatment 
specific response variable. However, observation only without any form of 
intervention would be unethical. A predictive biomarker is more useful clinically than 
a prognostic biomarker, as it relates to treatment. 
In our study, the nuclear expression of UHRF1 is as previously reported80 and the 
pattern of NQO1 expression (cytoplasmic and nuclear) is also consistent with 
previous studies160,239. However, the stromal expression of NQO1 in PDAC reported 
in our study is a new observation.  
In the context of normal intralobular and interlobular ducts and ductules, we went 
further to examine the expression of UHRF1 and NQO1. UHRF1 was not detected in 
intralobular ductules and ducts nor in interlobular ducts of normal pancreas 
consistent with our previous observation that UHRF1 is infrequently detected in 
normal pancreatic ductal cells80. In matched tissue sections, NQO1 was also not 
detectable in intralobular ductules and ducts of normal pancreas. However, in 
interlobular ducts of normal pancreas, NQO1 was expressed in the cytoplasm. 
Whether the histological location of a pancreatic duct (intralobular or interlobular) 
has any implication on the expression of NQO1 in normal pancreas is a question that 
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will require further investigation. Overall, future studies involving larger numbers of 
normal pancreas tissue samples will be beneficial in elucidating these findings.  
We have previously reported that UHRF1 depletion in pancreatic cancer cell lines was 
accompanied by down regulation of Nrf2 and of Nrf2 downstream proteins including 
NQO180. In this study, our finding of a significant association between NQO1 and 
UHRF1 expression in PDAC tissues is consistent with a regulatory relationship 
between UHRF1 and antioxidant protein NQO1. In the analysis of tissue levels of 
UHRF1 and NQO1, manual scoring was used as it was more accurate. Despite 
attempts, we could not use Definiens software analysis to complement manual 
scoring because of the propensity of Definiens to computational errors.  
This study is the first to report that high tumour NQO1 protein levels in PDAC patients 
is associated with better survival. There was no sufficient evidence to suggest that in 
adjuvant gemcitabine treated group, NQO1 protein levels were associated with 
response to treatment. In order to investigate the prognostic effect of NQO1 
expression on overall survival, a limited number of control group (resection only) 
were examined but no evidence was found that NQO1 protein levels were prognostic.  
Our finding that NQO1 expression was not associated with any patient 
clinicopathological characteristic is in contrast to the findings by Ji et al. who found 
high tumoural levels of NQO1 to be significantly associated with lymph node 
metastasis and TNM stage in PDAC160. Their findings further conflicts ours where they 
reported a poor overall survival in patients who expressed high levels of NQO1.  
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Moreover in our study, high NQO1 levels were associated with better survival in 
gemcitabine treated patients and high levels of NQO1 were also associated with 
better overall survival when all treatment arms, including gemcitabine, 5FU and 
observation only were considered. The discrepancy between our findings and Ji et 
al.160 may be due to differences in patient cohorts; our study evaluated PDAC in 
patients from 159 pancreatic cancer centers in Europe, Australasia, Japan and 
Canada7 while the study by Ji et al.160 was undertaken in a Chinese cohort. Secondly, 
it was not stated whether their patients received adjuvant treatment.  
Multivariable Cox proportional hazard analysis in gemcitabine treated patients, 
revealed that NQO1 expression was not an independent predictive factor in PDAC, 
suggesting that in the presence of other covariates, NQO1 protein levels are not 
significantly associated with survival. 
The basis for the increased survival associated with patients receiving gemcitabine 
requires further investigation. Anticancer agents such as β-Lapachone have been 
reported to require NQO1 specific activation to kill cancer cells through elevated ROS 
levels148. The conventional mechanism of action of gemcitabine is by interfering with 
DNA synthesis22. More recently, gemcitabine has been reported to induce pancreatic 
cancer cell death through ROS mediated effects240. It is likely that the full spectrum 
of the mechanisms of action of gemcitabine are not yet fully understood.  
In this evaluation of UHRF1 in ESPAC material, UHRF1 expression was upregulated in 
PDAC tissues, consistent with our previous observation80. An association with UHRF1 
expression and survival could not be established, in agreement with the study by Abu-
212 
 
Alainin et al.80 but contrary to the study undertaken by Cui et al.81, where a high 
UHRF1 expression was associated with poor survival outcome. The difference could 
be due to patient cohort; the study by Cui et al. was undertaken in a Chinese cohort, 
reflecting a possible difference in genetic background. Furthermore, in Cui et al. 
UHRF1 expression was cytoplasmic. In our study, patients were recruited from 159 
pancreatic cancer centers in Europe, Australasia, Japan and Canada7. In addition, 
UHRF1 localization in our study was nuclear. Moreover, UHRF1 has been described 
to be a nuclear protein62.  
A surprising finding in this study was the inverse relationship between UHRF1 
expression and diabetes. Diabetes is an area of intense interest in our research group 
and this finding will be followed up.  Although, we also reported here that UHRF1 
expression was significantly associated with tumour staging, this may be due chance 
association and further evaluation will be required. 
 Finally, we report an interesting observation of a limited number of PDAC samples 
on the immunoreactivity of subgroups of lymphoid cells to UHRF1. Obata Y. et al. 
recently reported on the epigenetic function of UHRF1 in promoting the proliferation 
and maturation of colonic regulatory T (Treg) cells241. Treg cells regulate immune 
responses and prevent autoimmune or severe immune responses242. Obata Y. et al. 
showed that UHRF1 was required for the maintenance of gut immunological 
homeostasis by demonstrating that colonization of germ-free mice with gut 
microbiota upregulated UHRF1 in intestinal Treg cells and prevented the 
development of severe colitis an effect that was observed in T cell-specific deficient 
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UHRF1 mice. They further showed that in T cell-specific deficient UHRF1 mice, p21 
(cyclin-dependent kinase inhibitor) promoter was hypomethylated which resulted in 
Treg cell-cycle arrest241. The study by Obata Y. et al. brings to focus the subsets of 
UHRF1 immunoreactive lymphoid cells identified in this thesis as to their possible role 
in PDAC tissues. Understanding the function of this lymphoid subsets in PDAC tissues 
may be instrumental to manipulating the immune system in favour of PDAC 
treatment. NQO1 was not immunoreactive to lymphoid cells. 
 We have also shown in that UHRF1 was localized to a histologically defined zone 
within the intestinal epithelium, we sought to determine if this relationship was 
maintained for NQO1 in matched normal intestinal epithelium of duodenum and 
colon; interestingly, an inverse relationship was observe but no immediate 
explanation could be advanced for this difference other than they are not pancreatic 
in origin. To confirm these observations, larger number of benign samples will be 
required. As mentioned previously, the duodenum and colon were not the focus of 
my thesis but I reasoned it was good practice to mention these observations as they 
were present as orientation cores on the PDAC TMAs stained for UHRF1 and NQO1. 
Taken together, the results of this chapter indicate that NQO1 is not an independent 
predictive biomarker in pancreatic cancer patients receiving adjuvant gemcitabine 
and may therefore not suitable as a biomarker for guiding patient treatment 
stratification.   
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6 OVERALL DISCUSSION 
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The overall aims of my thesis were to elucidate the role of UHRF1 on Nrf2 function in 
(I) pancreatic cancer cells (II) pancreatic stellate cells (PSCSs) and (III) to identify 
potentially predictive antioxidant enzyme biomarkers that can inform patient 
stratification for personalised pancreatic cancer treatment.  
UHRF1 was observed to be expressed in up to 90% of the PDAC tissues examined and 
contributed to PDAC tumourigenesis since its depletion was associated with 
pancreatic cancer cell growth inhibition, cell cycle arrest, Nrf2 downregulation and 
increased oxidative stress80. The transcriptional evidence for the regulation of Keap1 
mRNA by UHRF1 presented in this thesis suggests the possibility that UHRF1, in 
cooperation with other factors or regulators, may be required to effectively maintain 
inhibition of Keap1 transcription. Furthermore, UHRF1 may be involved with 
transcriptional regulation of Nrf2 but more studies will be helpful to confirm this 
regulatory pathway. 
Our intention to investigate the role of UHRF1 in the redox response in PSCs isolated 
from Nrf2-null mice was hampered by our finding that Nrf2-null PSCs could not 
survive in culture. Nevertheless, we successfully examined the expression of UHRF1 
in human PDAC cell lines, pancreatic stellate cells (PSCs) and in situ in human PDAC 
tissue samples. Interestingly, UHRF1 was not globally expressed in PSCs but only 
present in a small subset of PSCs and lymphoid cells indicating the possibility that 
UHRF1 may be most relevant in these subsets. Further work will be required to 
delineate the functional role of these subsets of UHRF1 positive cells.  
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Nrf2 is a master regulator of the antioxidant system that protects cells from oxidative, 
xenobiotic and electrophilic stress243. In cancers, including pancreatic cancer, the 
Nrf2 cytoprotective function is not only hijacked but it is constitutively expressed at 
higher levels to favour tumour progression and resistance to chemo-radiotherapy99. 
A greater understanding of how Nrf2 and its downstream targets such as NQO1 are 
relevant to cancer treatment needs to be explored.   
The NQO1 (rs1800566) SNP may be prognostic of overall survival in advanced 
pancreatic cancer patients receiving gemcitabine-based therapies but the SRXN1 
(rs6053666) SNP and the NRF2 (rs2886162) SNP were not associated with overall 
survival. A combination of NQO1 (rs1800566) and SRXN1 (rs6053666) SNPs was 
however associated with greater overall survival than observed for either NQO1 or 
SRXN1 SNPs alone, suggesting the potential for combining SNPs as prognostic 
biomarkers. 
The effect of single nucleotide polymorphisms (SNPs) involving oxidative stress and 
drug metabolising enzymes on predicting response to chemotherapy in pancreatic 
cancer may be achieved by association studies164,244 (such as genome-wide 
association studies, GWAS, where candidate SNPs can be interrogated in respect to 
their association with response to therapy), proteomic and functional studies. It is 
also important to appreciate that the effect of SNPs on response to therapy in cancers 
may be the contributing effect of multiple SNPs or environmental factors164.  
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The functional effect of NQO1 rs1800566 SNP are well established169; NQO1 CC wild-
type is a functionally active enzyme, CT is only partially functional and TT has very 
reduced or no activity. In our study, we could not fully understand or explain the 
reason(s) for the differences in survival between germline (blood cell-derived) NQO1 
CC genotype which was found to be associated with poor survival in the combined 
retrospective ViP and TeloVac trial data and high pancreatic cancer tissue NQO1 
protein levels which was found to be associated with better survival in retrospective 
ESPAC-1 and ESPAC-3 adjuvant trial data. Given that wild-type NQO1 CC genotype is 
known to be fully functional (active and strongly expressed protein)171, it was our 
expectation that the survival outcomes would be identical between CC NQO1 
genotypes in the combined ViP and TeloVac trials and high NQO1 protein expression 
in ESPAC-1 and ESPAC-3 trials. The patient cohorts in the TeloVac and ViP trials had 
advanced PDAC and were therefore not suitable for surgical resection while the 
ESPAC patients had surgical resection; we can only speculate that these are possible 
reasons for the observed differences in survival. Secondly, it has been reported that 
there is a high degree of concordance between germline (inherited) DNA SNPs and 
somatic (acquired tumour DNA SNPs) suggesting the same genotype SNPs in germline 
DNA also exists in tumour DNA245. In our study however, germline DNA SNPs and 
tumour DNA SNPs were not compared. Future studies will be important to determine 
the concordance between germline DNA SNPs and tumour DNA SNPs in PDAC. 
Ideally, cancer cells would be separated from stromal cells which may interfere with 
the interpretation of tumour DNA SNP analysis if homogenous cell populations are 
not used. 
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The survival of patients with pancreatic cancer may be improved by using biomarkers 
capable of predicting response to therapy146,246. To conclude, biomarkers are sorely 
needed to predict (I) patients mostly likely to respond to current therapies and (II) 
patients that will perform better on novel therapies. 
6.1 Future directions 
 
Potentially interesting areas for future research arising from this thesis include the 
following: 
Given the role elucidated for UHRF1 in regulating the Keap1-Nrf2 pathway (Keap1 
repression leading to the activation of Nrf2) in pancreatic cancer cell lines, it will be 
important to determine the methylation status of KEAP1 promoter in PDAC tissue 
samples. This will help confirm if this is the mechanism for Keap1 repression in 
pancreatic cancer. 
In this thesis, although there was no strong evidence for a down-regulation of Nrf2 
mRNA following 72 h of UHRF1 knockdown, a marginal decrease in Nrf2 mRNA was 
observed at 72 h time point. In order to investigate this further and exclude a 
transcriptional regulation of Nrf2 by UHRF1, additional analysis such as examination 
of the effects of UHRF1 knockdown on Nrf2-null cells, chromatin 
immunoprecipitation (ChIP) experiments and examination of the effects of UHRF1 
depletion or overexpression on Nrf2 in Keap1-null cells will be helpful.  
The observation that a subset PSCs and lymphoid cells expressed UHRF1 may indicate 
a special functional role for these subsets of cells or a cell cycle effect as pancreatic 
cancer cells have been reported to have a peak in UHRF1 expression at G2M phase of 
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the cell cycle80. To investigate further, Ki-67 protein expression (a cellular marker of 
proliferation) and stem cell markers may be assessed in these UHRF1 positive subsets 
of PSCs and lymphoid cells. Additionally, the cytotoxicity status of UHRF1 positive 
lymphoid cells may also be assessed for granzyme B or perforin expression. 
 We also made an interesting observation on a limited number of normal intestinal 
tissues. The restricted expression of UHRF1 to the basal crypts of the normal 
duodenum and colonic epithelium suggests the possibility of a stem cell-like role in 
this basal layer of the intestinal epithelium. To determine if this pattern of expression 
is a recurring theme in normal colon and duodenum, larger numbers of these normal 
intestinal tissues will need to be stained and examined for UHRF1. 
The observation that Nrf2-null mice develop early signs of pancreatitis suggest a 
protective role for Nrf2 in preventing pancreatitis. This Nrf2-null mice may potentially 
be used as a model for pancreatitis research. 
Finally, the NQO1 CC genotype has been reported to translate into a functionally 
active NQO1 protein compared with CT with reduced activity and TT with little or no 
activity169. We reported that patients with germline CC NQO1 SNP C609T 
polymorphism were associated with poor survival in advanced pancreatic cancer 
patients whereas in adjuvant chemotherapy treated pancreatic cancer patients, we 
reported that high tumour tissue NQO1 protein expression was associated with 
better survival. Determining the genotype status between NQO1 germline SNP and 
NQO1 tumour SNP as well as the NQO1 tumour tissue protein expression will further 
illuminate the concordance between these 3 levels of translational interest. 
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7 APPENDICES 
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Appendix 1. Pyrogram report for KEAP1a primers 
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Appendix 2. Pyrogram report for KEAP1a primers 
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Appendix 3. Pyrogram report for KEAP1b primers 
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Appendix 4. Pyrogram report for KEAP1b primers 
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                                            Appendix 5. Table A1 – Summary statistics and results of univariate models for NRF2/NQO1/SRXN1 ViP data 
 Overall Gemcitabine Gemcitabine + Vandetanib 
Prognostic 
Variable 
No 
patients 
(deaths) 
Median OS (95% 
CI) 
HR P No 
patients 
(deaths) 
Median OS (95% 
CI) 
HR P No 
patients 
(deaths) 
Median OS (95% 
CI) 
HR P 
NRF2 
 AA 
 AG 
 GG 
 
18(16) 
49(48) 
30(29) 
 
12.11(4.84, 
17.86) 
8.95 (7.70,11.02) 
9.24 (7.73,11.48) 
 
 
1.66(0.93,2.95) 
1.26(0.68,2.33) 
0.174 
(0.144 AG 
and GG 
consolidated) 
 
8(7) 
21(20) 
17(16) 
 
12.70(3.59,23.02) 
8.16(4.01,10.86) 
10.86(4.74-
16.32) 
 
 
1.96(0.82,4.68) 
1.36(0.56,3.30) 
0.258 
(0.218 AG 
and GG 
consolidated) 
 
10(9) 
28(28) 
13(13) 
 
4.87(1.55,17.86) 
9.97(7.70,11.48) 
8.22(3.19,13.03) 
 
 
 
1.34(0.63,2.85) 
1.22(0.51,2.92) 
0.747 
(0.470 AG 
and GG 
consolidated) 
NQO1  
 CT&TT 
 CC 
 
36(33) 
61(60) 
 
11.02(6.35,11.15) 
8.91(6.35,11.15) 
 
0.68(0.44,1.06) 
0.084  
17(15) 
29(28) 
 
8.95(4.74,16.32) 
9.37(5.00,11.87) 
 
0.79(0.42,1.49) 
0.465 
 
 
19(18) 
32(32) 
 
8.32(4.21,12.43) 
11.41(7.73,11.48) 
 
0.60(0.32,1.13) 
0.105 
SRXN1 
 CC 
 CT 
 TT 
 
6(6) 
58(56) 
33(31) 
 
13.03(1.87,NK) 
10.20(6.55,12.80) 
8.16(5.00,11.48) 
 
 
1.20(0.51,2.78) 
1.45(0.60,3.51) 
0.583  
2(2) 
25(24) 
19(17) 
 
1.87(1.87,NK) 
10.86(6.35,15.56) 
8.16(4.87,12.7) 
 
 
0.84(0.20,3.59) 
0.81(0.18,3.58) 
0.965  
4(4) 
33(32) 
14(14) 
 
13.03(7.40,NK) 
10.20(4.84,12.80) 
7.82(3.39,11.15) 
 
 
1.42(0.50,4.05) 
2.86(0.90,9.05) 
0.091 
 
Table A2 – p-values for NRF2/NQO1/SRXN1 when fitted to multivariate model for ViP patients 
 Multivariate model 
Prognostic Variable No patients (deaths) HR p 
NRF2 
 AA 
 AG 
 GG 
 
18(16) 
49(48) 
30(29) 
 0.117 
NQO1 
 CT&TT 
 CC 
 
36(33) 
61(60) 
 0.294 
SRXN1 
 CC 
 CT 
 TT 
 
6(6) 
58(56) 
33(31) 
 0.723 
 
 
226 
 
                                                       Appendix 6. Table A3– Summary statistics and results of univariate models for NRF2/NQO1/SRXN1 TeloVac data 
 Overall Arm 1 Arm 2 Arm 3 
Prognostic 
Variable 
No 
patients 
(deaths) 
Median OS (95% 
CI) 
HR (95% CI) P No 
patients 
(deaths) 
Median OS 
(95% CI) 
HR (95% CI) P No 
patients 
(deaths) 
Median OS (95% 
CI) 
HR P No 
patients 
(deaths) 
Median OS 
(95% CI) 
HR P 
Nrf2 
 AA 
 AG 
 GG 
 
12 (7) 
26 (14) 
5 (2) 
 
5.19(0.92,NK) 
9.73(4.01,14.37) 
8.98(3.22,NK) 
 
 
0.69(0.28,1.72) 
0.54(0.11,2.61) 
 
 
 
0.648  
(0.294 AG 
and GG 
consolidated) 
 
8(4) 
12(7) 
4(1) 
 
4.77(0.92,NK) 
6.01(1.81,NK) 
NK(3.22,NK) 
 
 
0.55(0.14,2.11) 
0.31(0.04,2.92) 
 
 
 
0.504 
(0.294 AG 
and GG 
consolidated) 
 
4(3) 
5(2) 
1(1) 
 
5.19(0.82,NK) 
11.77(2.20,NK) 
NK 
 
 
0.53(0.09,3.23) 
1.53(0.14,16.52) 
 
 
 
0.667 (0.641 
AG and GG 
consolidated) 
 
0(0) 
9(5) 
0(0) 
 
- 
8.94(1.32,NK) 
- 
 
- 
NA 
- 
 
 
 
NA 
NQO1 
 TT 
 CT 
 CC 
 
0(0) 
19(7) 
24(16) 
 
- 
11.34(8.94,NK) 
5.19(3.22,11.77) 
 
 
 
2.49(1.01,6.15) 
 
 
 
0.038 
 
0(0) 
8 (2) 
16 (10) 
 
- 
14.37(1.74,NK) 
4.80(1.71, NK) 
 
 
 
6.41(0.82,50.2) 
 
 
 
0.025 
 
0(0) 
7(3) 
3(3) 
 
- 
11.34(0.82,NK) 
5.19(2.20,NK) 
 
 
 
2.48(0.49,12.48) 
 
 
 
0.278 
 
0(0) 
4(2) 
5(3) 
 
 
8.94(8.94,NK) 
5.33(1.32,NK) 
 
 
 
1.27(0.20,8.02) 
 
 
 
0.798 
SRXN1 
 CC 
 CT 
 TT 
 
6(4) 
17(8) 
20(11) 
 
2.20(0.92,NK) 
11.34(4.01,NK) 
8.94(1.81,NK) 
 
1.45(0.45,4.64) 
0.71(0.28,1.77) 
 
 
 
0.498 
 
4(2) 
9(4) 
11(6) 
 
1.71(0.92,NK) 
12.23(3.22,NK) 
6.01(1.35,NK) 
 
1.27(0.24,6.77) 
0.71(0.19,2.65) 
 
 
 
0.775 
 
2(2) 
4(2) 
4(2) 
 
2.20(2.20,NK) 
11.34(5.19,NK) 
8.98(0.82,NK) 
 
1.61 (0.22,11.69) 
0.90(0.13,6.44) 
 
 
 
 
0.838 
 
0(0) 
4(2) 
5(3) 
 
- 
9.73(4.01,NK) 
5.33(1.32,NK) 
 
 
0.82 (0.14,5.00) 
 
 
 
0.832 
Arm1-Gemcitabine + Capecitabine alone (chemotherapy); Arm2-Chemotherapy + sequential immunotherapy; Arm3-Chemotherapy + concurrent immunotherapy 
 
Table A4 – p-values for NRF2/NQO1/SRXN1 when fitted to multivariate model – TeloVac patients 
 Multivariate Model 
Prognostic Variable No patients (deaths) HR (95% CI) P 
NRF2 
 AA 
 AG 
 GG 
 
12 (7) 
26 (14) 
5 (2) 
 0.385 
NQO1 
 TT 
 CT 
 CC 
 
0(0) 
19(7) 
24(16) 
 
 
 
2.46 (0.99,6.10) 
0.053 
SRXN1 
 CC 
 CT 
 TT 
 
6(4) 
17(8) 
20(11) 
 0.490 
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Appendix 7. Table A5. ViP data patient demographics and multivariate models 
without NRF2/NQO1/SRXN1 
 
 
 
 
 
 
 
 
Prognostic Variable No patients 
(deaths) 
Median (IQR) HR P (multivariate 
model) 
Treatment 
 Gem+Vandetanib 
 Gem+Placebo 
 
 
51(5) 
46(43) 
  0.263 
Histology 
 Pancreatic ductal 
adenocarcinoma 
 Undifferentiated carcinoma 
of the pancreas  
 
85(81) 
12(12) 
  0.269 
ECOG 
 Fully active 
 Ambulatory (work able) 
 Ambulatory (not work able) 
 
28(26) 
58(56) 
11(11) 
  
0.29 (0.13,0.67) 
0.46 (0.21,0.96) 
 
<0.001 
Stage 
 Locally advanced 
 Metastatic 
 
31(29) 
66(64) 
  0.233 
Tumour Site 
 Pancreas – head 
 Pancreas – tail 
 Pancreas – uncinate  
 Pancreas - body 
 
51(48) 
13(13) 
7(7) 
26(25) 
  0.170 
Differentiation Status 
 Undifferentiated 
 Poor 
 Moderate 
 Well 
 Not Known 
 
3 (3) 
17 (16) 
17 (16) 
8 (8) 
52 (51) 
 
 
 
7.14 (1.59,32.07) 
2.99 (1.14,7.83) 
1.83 (0.70,4.77) 
 
2.88 (1.22,6.83) 
0.027 (but 
excluded from 
AIC model) 
Sex 
 Female 
 Male 
 
43 (42) 
54 (51) 
  0.240 
Age 97(93) 67(61,73)  0.358 
 
Log CA19-9 93(89) 6.9(5.4,8.5) 1.18 (1.07,1.30) 0.008 
 
228 
 
 
Appendix 8. Table A6. TeloVac data patient demographics and multivariate models 
without NRF2/NQO1/SRXN1 
 
Prognostic Variable No 
patients 
(deaths) 
Median (IQR) HR P (multivariate 
model) 
Treatment 
 Gem+Vandetanib 
 Gem+Placebo 
 
    
Histology 
 Pancreatic ductal adenocarcinoma 
 Undifferentiated carcinoma of the pancreas  
    
ECOG 
 Fully active 
 Ambulatory (work able) 
 Ambulatory (not work able) 
    
Stage 
 Locally advanced 
 Metastatic 
    
Tumour Site 
 Pancreas – head 
 Pancreas – tail 
 Pancreas – uncinate  
 Pancreas - body 
    
Differentiation Status 
 Undifferentiated 
 Poor 
 Moderate 
 Well 
 Not Known 
    
Sex 
 Female 
 Male 
 
23(11) 
20(12) 
  0.471 
Age     
Log CA19-9 42(23) 6.90(5.16,8.92) 1.25(1.05,1.47) 0.007 
Stratum (consolidation of Stage and ECOG) 
 1 
 2 
 3 
 4 
 5 
 6 
 
5(4) 
7(4) 
1(0) 
8(4) 
18(7) 
4(4) 
  0.320 
Arm 
 Arm 1 
 Arm 2 
 Arm 3 
 
24(12) 
10(6) 
9(5) 
  0.353 
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Appendix 9. Table A7. Combined data patient demographics and multivariate 
models without NRF2/NQO1/SRXN1 
Prognostic Variable No 
patients 
(deaths) 
Median (IQR) HR P (multivariate 
model) 
Treatment 
 Gem+Vandetanib 
 Gem+Placebo 
 
    
Histology 
 Pancreatic ductal adenocarcinoma 
 Undifferentiated carcinoma of the pancreas  
    
ECOG 
 Fully active 
 Ambulatory (work able) 
 Ambulatory (not work able) 
    
Stage 
 Locally advanced 
 Metastatic 
    
Tumour Site 
 Pancreas – head 
 Pancreas – tail 
 Pancreas – uncinate  
 Pancreas - body 
    
Differentiation Status 
 Undifferentiated 
 Poor 
 Moderate 
 Well 
 Not Known 
    
Sex 
 Female 
 Male 
 
66(53) 
74(63) 
  0.871 
Age     
Log CA19-9 135(112) 6.91(5.31,8.67) 1.23(1.12,1.34) <0.001 
Stratum (consolidation of Stage and ECOG) 
 1 
 2 
 3 
 4 
 5 
 6 
    
Arm 
 Arm 1 
 Arm 2 
 Arm 3 
    
 
 
Table A8 – p-values for treatment interactions by trial 
Study p-value for treatment interaction 
VIP 
 NRF2 
 NQO1 
 SRXN1 
 
0.702 (0.634 AG and GG consolidated) 
0.614 
0.296 
TeloVac 
 NRF2 
 NQO1 
 SRXN1 
 
0.584 (0.690 AG and GG consolidated) 
0.371 
0.913 
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Appendix 10. Predictive effect of individual SNPs on treatment 
 
Effects of NRF2 SNPs on treatment 
 
Covariates 
 
HR (95% CI) 
 
P  
ECOG 1.75 (1.195, 2.571) 0.004 
NRF2 AG 2.29 (0.957, 5.474) 0.063 
NRF2 GG 1.14 (0.463, 2.789) 0.781  
NRF2 AA: Arm Vandetanib 1.07 (0.389, 2.949) 0.894  
NRF2 AG: Arm Vandetanib 0.78 (0.434, 1.408) 0.413 
NRF2 GG: Arm Vandetanib 1.46 (0.683, 3.105) 0.33 
 
 
 Effects of NQO1 SNPs on treatment 
 
Covariates 
 
HR (95% CI) 
 
P  
ECOG 1.45 (0.996, 2.116) 0.053 
NQO1 TT/CT 0.75 (0.399, 1.416) 0.378 
NQO1 CC: Arm Vandetanib 1.11 (0.653, 1.879) 0.704  
NQO1 TT/CT: Arm Vandetanib 1.1 (0.548, 2.224) 0.782 
 
 
 Effects of SRXN1 SNPs on treatment 
 
Covariates 
 
HR (95% CI) 
 
P  
ECOG 1.55 (1.091, 2.214) 0.015 
SRXN1 TT 0.87 (0.468, 1.619) 0.661 
SRXN1 CC/CT: Arm Vandetanib 0.89 (0.534, 1.493) 0.665 
SRXN1 TT: Arm Vandetanib 2.02 (0.97, 4.206) 0.06 
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Appendix 11. Predictive effect of combined SRXN1 and NQO1 SNPs on treatment 
 
Effects of combined SRXN1 and NQO1 SNPs on treatment 
 
Covariates 
 
HR (95% CI) 
 
P  
SRXN1_NQO1 group 2 &3 0.83 (0.403, 1.701) 0.607 
SRXN1_NQO1 group 4 0.80 ( 0.331, 1.933) 0.62 
SRXN1_NQO1 group 1: Arm 
Vandetanib 
1.69 (0.711, 4.038) 0.234 
SRXN1_NQO1 group 2& 3: Arm 
Vandetanib 
1.36 (0.77, 2.408) 0.288 
SRXN1_NQO1 group 4: Arm 
Vandetanib 
0.79 (0.335, 1.851) 0.584 
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Appendix 12. Matched UHRF1 and NQO1 expression in PDAC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Micrograph of adjacent normal ducts from PDAC patients. In the left column, normal 
adjacent ducts (A, B and C – red arrows) do not express UHRF1. Matched adjacent normal 
ducts for NQO1 (A and B [red arrow and black circle]) stain weakly and (C) strongly for NQO1. 
Scale bar = 50 µm 
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Appendix 13. Matched UHRF1 and variants NQO1 expression in PDAC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Micrograph of matched UHRF1 and NQO1 expression in PDAC patients. With patient 
stratification into high and low for UHRF1 and NQO1, A and B are both high-high for UHRF1 
and NQO1; C and D are high-low for UHRF1 and NQO1 respectively; E and F are both high-
high for UHRF1 and NQO1 and G and H are low-high for UHRF1 and NQO1 respectively. Scale 
bar = 200 µm 
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Appendix 14. Matched UHRF1 and NQO1 expression in PDAC continued  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Micrograph of matched UHRF1 and NQO1 expression in PDAC patients. For matched comparison, 
patients are stratified into high or low for either UHRF1 or NQO1: (A) and (B) are both low-low 
for UHRF1 and NQO1; (C) and (D) are low-low for UHRF1 and NQO1; E and F are high-low for 
UHRF1 and NQO1 respectively and (G) and (H) are both low-low for UHRF1 and NQO1. Endothelial 
cells (blood vessels) are immunoreactive for NQO1, red arrows in (B) and in (C) some 
inflammatory/immune cells in the stroma are UHRF1 positive. Scale bar = 200 µm. 
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Appendix 15. Definiens analysis UHRF1 setting 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter Value
Action General Settings
    Magnification 20
    µm/pixel 0.504
    Use metadata from file TRUE
    Stain Combination IHC Brown chromogen (e.g. DAB)
    IHC Marker Nuclear
    Production Mode FALSE
Action Initialize Cellular Analysis
    Activate Random Sampling FALSE
    Magnification 10
Action Nucleus Detection
    Hematoxylin Threshold 0.2
    IHC Threshold 0.5
    Typical Nucleus Size (µm²) 75
Action Marker Area Detection
    Threshold Marker 0.48
    Minimum Area (µm²) 40
Action Marker Area Classification
    Select Feature IHC Marker Intensity
    Threshold Low/Medium 0.6
    Threshold Medium/High 1.1
    Use Condition FALSE
    Remove Excluded Areas FALSE
Action Default Export
    ROI Statistics TRUE
    Cellular Analysis: Screenshot 1 Original
    Cellular Analysis: Screenshot 2 Overlay with Outlines
    Cellular Analysis Statistics TRUE
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Parameter Value
Action General Settings
    Magnification 20
    µm/pixel 0.504
    Use metadata from file TRUE
    Stain Combination IHC Brown chromogen (e.g. DAB)
    IHC Marker Cytoplasm
    Production Mode FALSE
Action Initialize Cellular Analysis
    Activate Random Sampling FALSE
    Magnification 10
Action Marker Area Detection
    Threshold Hematoxylin 0.2
    Threshold Marker 0.25
    Minimum Area (µm²) 200
Action Marker Area Classification
    Select Feature IHC Marker Intensity
    Threshold Low/Medium 0.6
    Threshold Medium/High 1.1
    Use Condition FALSE
    Remove Excluded Areas FALSE
Action Default Export
    ROI Statistics TRUE
    Cellular Analysis: Screenshot 1 Original
    Cellular Analysis: Screenshot 2 Overlay with Outlines
    Cellular Analysis Statistics TRUE
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